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Abstract
Gastro-retentive drug delivery systems (GRDDS) can improve the
erratic drug absorption of certain drugs, for example, theophylline. The
formulation design of floating pellets is of a particular interest, due to the
minimised risk of complete emptying into the intestine and the minimised
gastro-intestinal tract (GIT) irritation. Core pellets are usually prepared
by extrusion and spheronisation (E/S) processes, and are usually 
coated with more than one film before capsule filling or tableting
processes. This research increased the understanding in the
pharmaceutical floating pellets systems. The main aim of this research
study was to develop novel gastro-retentive floating pellets, using the
E/S processes with a new spheronisation aid not used before (Avicel
HFE 102; co-processed microcrystalline cellulose with ~10% mannitol) 
and the use of 10% ethanol as a liquid binder for obtaining high
sphericity (target: Aspect ratio; AR <1.2). Avicel HFE 102 was also used
as a cushioning aid in the form of powder or pellets, to allow the 
compression of coated pellets into tablets whilst maintaining sufficiently 
sustained drug release and floating properties. In addition, the use of a
single and thin film coat (made by Eudragit NE15 diluted by 25%
ethanol) was studied to produce pellets with properties of sustained drug
release (preferable target: 12-24 hours) and floating (preferable target:
6-12 hours, >90% floated, <15 minutes lag time). Mainly, the size and
shape analysis of the core pellets was determined. The drug release
and floating properties of the coated pellets were determined. The core
pellets studies prior the enhancement of the single-coating (where the
10% ethanol was used as a liquid binder) showed that they exhibited
spherical shape AR<1.2. In either 0.1N HCl medium or distilled water 
medium, the enhanced and novel single-coated floating pellets (where
the film made by the Eudragit NE15 dispersion -diluted with 100% 
ethanol, to obtain 25 w/w% ethanol containing dispersion-) showed that
they exhibited drug release for 24 hours or more. And, >98% of the latter 
pellets floated on surface, for at least 12 hours, with a lag time of 10-15 




       
        
          
           
       
        
         
       
       
      
            
         
          
         












compressed along with the cushioning powder. Upon tablets 
disintegration in 0.1N HCl medium, the single-coated floating pellets 
showed sustained drug release for up to 8 hours or more, and the
floating was at least for 24 hours. That is, the compression of the
enhanced single-coated pellets into tablets still produced useful pellets.
To sum the main points, core pellets were successfully made regarding
shape properties, using the new spheronisation aid (Avicel HFE102).
And, the single-coated floating pellets were successfully made and
intensively investigated for properties, like shape, drug release, and
floating properties. The success of the latter pellets is mainly attributed
to the use of ethanol in the liquid binder and the coating dispersion,
respective to the enhanced core pellets and the enhanced single-coated
pellets. The spherical core pellets and the single thin layer of only ~6.5%
weight gain were obtained. The latter coating layer had the enhanced
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Abbreviations
AUP: Area under the Peak. An area in the DSC thermogram.
AR: Aspect Ratio. A shape factor. It is the ratio of the maximum Feret
diameter (FDmax) to the minimum Feret diameter (FDmin). The AR maybe
used outside the pharmaceutical pellets field as FDmin/FDmax.
A (mm2): Area. It is the number of square units inside a two dimensional
shape, like a circle, where A=pi*r2. The Greek letter of Pi is the
circumference: diameter ratio. While, the surface area is the area or the
number of square units inside a three dimensional shape, like a sphere,
where A=4*pi*r2.
CPPs: Critical Process Parameters, or can be used for the Critical
Product Parameters
CQAs: Critical Quality Attributes, which is also called Critical Product
Attributes (CPAs). However, CPAs may also be used for the process 
parameters. Therefore, the critical process parameters and the critical
product parameters will be abbreviated here as CProcPs and CProdPs,
respectively
Cros-PVP: Cros-Povidone. It is a cross-linked vinyl polymer, and a
hydrophobic one. The cros-PVP is a semi-crystalline polymer, due to the
increased order induced by cros-linking.
DoE (Statistical): Statistical Design of Experiment. A tool in the ‘risk 
evaluation’ stage of the risk assessment category per QbD.
DSC: Differential Scanning Calorimetry. A calorimetric technique that is 
commonly used for thermal testing. It provides thermochemical
information, like the melting point, and the change in enthalpy (∆H) 
(joule/kg). The latter is a component in the Gibbs free energy (G) 
equation; ∆G= ∆H- T ∆S, where T is the Kelvin temperature, and ∆S is 
the change in entropy.
F-Circle (mm): Circularity. A shape factor. It is the largest circle
diameter inside the circle or inside the imperfect circle. Hence, it is either 




          
       
         
           
         
         
  
           
  
          
         
     
        
         
 
     
 
      
     
  
       
          
        
   
      
         
         
 
    
      
   
      
     
where A is the area and P is the perimeter of the sphere. Pi equals to
3.14. This can be directly measured by an imaging software.
FD: Feret's Diameter. A shape factor. It is defined by (Taylor, 2018) as 
“the mean value of the distance between pairs of parallel tangents to the
projected outline of the particle. This can be considered as the boundary 
separating equal particle areas”. This diameter can be calculated be an
imaging software.
FMEA: Failure Mode Effect Analysis. A tool in the ‘risk analysis’ of the
risk assessment category per QbD.
FR: Feret’s Ratio. A shape factor. Like circularity, it ranges from 0 to 1,
the closer to one the higher is the sphericity of the core pellets.
GIT: Gastro Intestinal Tract. A physiological organ.
GRDDS: Gastro-Retentive Drug Delivery Systems. One of the sustained
drug release system (SDRS). Hence, it is a Modified Release (MR) Drug
Delivery System.
HBS: Hydro-Dynamically Balanced System, it implies the Floating 
Systems
HPMC: Hydroxy Propyl Methyl Cellulose. A cellulosic polymer.
ICH: International Conference of Harmonisation. A quality guidelines 
authority in pharmaceuticals.
IQR: Inter-Quartile Range. A parameter for assessing the particle size
distribution variability, based on two quartiles. It equals to Q3-Q1, where
Q3 is the diameter (mm) at 75% cumulative undersize percentage, and
Q1 is at 25%.
KgF: Kilogram-Force or Kilopond (kp) is a gravitational metric unit of
force applied by a one kilogram of mass. 1KgF=9.80665 Kg-m/s² or
Newton. The unit can be used for quantifying the applied force on the 
sample.
MCC: Micro-Crystalline-Cellulose. A Cellulosic Polymer.
MMC: Myo-Electric Complex, happens during the gastric emptying in
the fasted state
MP: Melting Point in Celsius temperature. An endothermic peak for a 




           
        
        
         
  
     
        
         
          
     
          
   
       
     
    
       
        
       
        
          
       
        
         
      
       
     
         
    
       
  
          
     
MPa: Mega Pascal. 1 MPa= 1 million N/m2. A unit of Force, which can
be used for the surface tensile strength of tablets.
MSI: Mechanical Strength Index. A percentage used in the friability 
study, to measure the strength of tablets, especially the exterior strength
of tablets.
mupFDDS: Multiple Units of Pellets Floating Drug Delivery Systems 
(Floating Pellets). A specific oral solid and a specific GRDDS design.
N: Newton. A unit of Force. kN is particularly easier to use when
quantifying the force applied on a sample during tabletting for instance.
PAT: Process Analytical Technology. Various analytical tools used in-
process during the drug product manufacturing. It is one area in the risk 
control category of QbD
Perimeter (mm): Circumference. A shape factor. It equals to C=2*pi*r.
PMAs: Poly-Meth-Acrylates. They are acrylic co-polymers. These are
semi-crystalline co-polymers, or sometimes referred to as amorphous 
co-polymers, owing to their high amorphousity. These copolymers can
be anionic, cationic, or neutral. The common derivatives of PMAs are
the amino-alkyl (immediate release), carboxylic acid (delayed release),
ester or ammonio-alkyl (time-controlled release). Eudragit RL, RS, NE,
and NM are time-controlled release PMAs, which are all insoluble and
have pH-independent swelling. However, only RS grade is of high
permeability, and only NE and NM grades are highly flexible, that do not
require plasticiser. Though all of the copolymers are insoluble, they have
varied permeability. RL and RS grade are quaternary ammonium 
derivatives of PMAs, while NE and NM are ester derivatives of PMAs
(Evonik, 2017) and (Thakral, et al., 2013).
PVP: Poly-Vinyl-Pyrrolidone (Povidone). It is a vinyl polymer, and a
hydrophilic one. The PVP is an amorphous polymer.
QbD: Quality by Design. It is a quality management methodology in the
pharmaceutical industry.
QTPP: Quality Target Product Profile. It is one of the initial work required




         
            
      
     
        
       
       
        
          
          
      
         
      
        
    
        
      
        
 
    









R: Coefficient of Determination. It is a parameter that measure the
goodness of data fit in the ‘regression’ line. It is used to measure the
linearity of data fitted between specific x-axis and y-axis components.
RPN: Risk Priority Number. It is a number calculated semi-quantitatively 
from the multiplication of the severity, impact, and detectability values of
each risk factors. This number is a threshold risk score, above which,
risk factors are considered to be high risk factors.
RSD: Relative Standard Deviation. It is a parameter to measure
variation in data, in particular, it measures precision. It equal to SD of 
values divided by the average of values. The RSD times 100 gives the
RSD%, which is more numerically representative than RSD.
SA:V ratio: Surface area to volume ratio, where both of the latter  
calculated from the diameter values, which was calculated from the
perimeter values. Surface Area of sphere (SA)= 4*pi*r2, Volume of  
sphere= (4/3)*pi*r3. Hence, SA/V=3/r.
SD: Standard Deviation. It is a parameter to measure variation
(dispersion) of the sample values from the mean value.
SEM: Scanning Electron Microscopy. It is an advanced imaging
technique.
STS: Surface Tensile Strength. 






























     
       
        
          
        
       
        
        
          
   
      
      
        
    
         
    
       
        
          
     
    
 
        
       
         
        
          
           
        
         
      
1.1. Introduction
Pharmaceutics is a voyage of multi-disciplinary collections of theories
and technologies that mainly focus on the physical chemistry and design
of dosage forms of drug products, and accompanying methods of
preparation and testing. In this project, the dosage form of interest is the
one that contains pellets. The specific designs of interest are the double-
coated floating pellets design and the single-coated floating pellets 
design, such pellets can be compressed into tablets.
Pellets can be defined as oral solid intermediate formulations, spherical
in shape, relatively small in size, and made by a pelletisation technique,
usually by extrusion and spheronisation techniques with a 
spheronisation aid, the latter method is to obtain dense agglomerates of
pellets. Floating pellets achieve floating as they contain floating agents 
and retard polymeric agents, usually through the application of coating
layer/s.
The pellets can be made to act as a gastro-retentive drug delivery 
system (GRDDS), the floating pellets system as an example. The 
gastro-retentive term, is derived from its ability to achieve retention of
the dosage form in the stomach. Unlike the other GRDDS, floating
systems are currently available on the market, like the floating liquid of
alginates (Gaviscon®), and these systems avoid irritation to the 
epithelium of the gastro-intestinal tract (GIT). The latter is especially 
advantageous when the floating system utilise pellets, owing to the high 
distribution of the dose in the pellets, which further reduces dose
localisation. Unlike the floating tablet, the floating MUPS tablet/capsule
lack the "all or none" risk of emptying into the small intestine. This is 
because that the dose is distributed usually in few hundreds of units 
instead of being placed in one unit only. That is, unlike the single-unit 
system, if only one pellet sink, a negligible dose will escape the gastro-
retention. Therefore, the floating pellets system is said to be one of the
most preferred approaches in the GRDDS (Singh & Kim, 2000) and




      
      
   
           
 
       
        
         
     
          
        
        
     
        
       
 
    
           
      
         
       
        
          
        
            
         
         
           
         
         
        
The floating pellets system is of a particular interest for drugs with
narrow absorption windows or of erratic absorption, such as 
theophylline. The erratic absorption means non-uniformity drug
absorption in the GIT, resulting in a variable drug bioavailability (Kang
and Lee, 2009). 
The factors that affect the drug absorption are numerous including the 
drug product and the physiological factors, which subsequently affect
drug bioavailability. All of these factors may cause variable absorption
in the gastro-intestinal tract (GIT) for drugs, like theophylline; and this
can result in unfavourable fluctuated plasma drug levels. However, the
risk of attaining a toxic dose or not attaining the efficacious dose
becomes more pronounced when such drugs also have a narrow
therapeutic window. Hence, the floating pellets system is expected to
ensure the consistency of the bioavailability of the drug, by the gastro-
retention and the sustained drug release properties.
1.2. Pharmaceutical Oral Solids
1.2.1. Oral Solid Dosage forms
Designing a dosage form for the oral route is a very common path for 
formulating drugs into medicine. This topic is introduced in several
sources, including one of the most popular, concise, comprehensive,
and sufficiently detailed book; the Aulton’s pharmaceutics, where a clear 
introduction to the oral route is briefly articulated by (York, 2013).
Unlike other routes of drug delivery, the oral route is considered one of
the most important in drug delivery, owing to its superiority for reasons, 
like being a non-invasive and the safest in drug delivery, comparing to
the invasiveness and increased toxicity of the parenteral route of drug
delivery. Moreover, the oral route is the most common and convenient 
in drug delivery. All of latter advantages resulted in an improved patient
compliance. For the manufacturing point of view, the oral products are
easier, more agile and versatile to manufacturers, resulting in a superior 




          
     
        
          
        
       
        
      
          
        
         
    
         
            
      
          
      
        
         
       
       
      
       
      
         
         
    
         
        
      
          
      
forms of the various formulation designs can be related to drug stability 
in GIT, erratic absorption, and subsequent poor bioavailability profiles 
(York, 2013). Oral dosage forms can have various forms, such as the 
oral solids, the most common example is tablets, also, hard and soft
capsules, pellets, and less commonly oral films. The second common
form of oral products is the oral liquids, for example, solutions,
suspensions, and emulsions. The oral gas products, such as nebuliser, 
are also fairly common in the market. 
In particular, the oral solid dosage forms are the most common amongst
all other oral dosage forms, owing to their additional superiority when
compared to other forms of oral and non-oral delivery. Oral solid
products advantages include the convenience for the patient self-
monitoring and administration; with the possibility of handling the pills in
a pillbox. Then, that can result in an increased patient compliance. Also,
the chemical stability, the physical stability, and the microbiological
stability of the oral solids are higher when compared to the oral liquids, 
resulting in a higher and less variable shelf life. For the manufacturing
point of view, oral solids are particularly convenient to handle during
production, with high versatility and flexibility in fabricating the dosage
form design for their intended use and delivery. Moreover, oral solids,
especially the conventional tablets, have a well-developed know-how by
manufacturers, with relatively cheap and controlled mass. Hence, this 
was owing to the robust preparation procedures that provide accurate
drug dosing, as stated by (Alderborn, 2013). This high manufacturability
of the oral solids results in a superior advantage for the scale up
planning and troubleshooting. Hence, it will result in a higher possibility 
to deploy innovative products that offer long-term cost-effectiveness.
Most oral solids can be classified into two broad categories based on 
their mean diameter size, the single unit systems (SUS), such as tablets 
of 6-12 mm. Secondly, the multiple units of particulates systems 
(MUPS), such as mini-tablets of 1-6 mm, pellets of 0.5-2 mm (typically 




         
  
        
      
      
       
       
   
    
          
      
   
     
     
       
   
         
        
  
      
      
           
          
           
           
     
        
        
       
           
      
dosage forms are easier to coat when compared to other MUPS and to
other larger tablets (Porter, 2013). 
Additionally, mini-tablets have the least variable size, shape, and
surface roughness when compared to other MUPS forms. MUPS can
also be obtained from drug crystals (except elongated and acicular 
crystals), and also from irregular granules, which have the disadvantage
of angular nature, resulting in batch-to-batch variation, owing to thier
poor coating uniformity (Porter, 2013).
1.2.2. Multiple-units of particulates systems (MUPS)
This section will focus on the pellets as a type of MUPS. Based on
Ghebre-Sellassie (1989) definition, the word pellet is described as “a 
variety of systematically produced, geometrically defined agglomerates 
obtained from diverse starting materials utilising different processing
conditions.” The pellets products can include fertilisers, animal feeds,
iron ores, confectioneries, or pharmaceutical dosage forms. Pellets are
known for their inherently high flowability and compatibility (Ghebre-
Sellassie, 1989). As stated by Nokhodchi, et al (2010), other oral solid
formulations can also have high flowability and compatibility, such as the
liqui-solid formulations.
The dosage form containing pellets is particularly attractive when 
compared to mini-tablets and larger non-disintegrating tablets, because
pellets are smaller in size (< 2 mm). The latter size will have a similar 
gastric emptying to the liquid, resulting in more uniform distribution in the
GIT as it has more consistent emptying into the typical absorption site
of the small intestine (Davis, 2005) and (Kallakunta, et al., 2017). Pellets 
are less commonly called beads or spheroids dosage form. The 
uncoated form also known as core pellets, matrix pellets, or naked
pellets. Inert sugar/starch spheres are also called nonpareil beads, or 
starter pellets/cores. The MUPSs are superior when compared to the
single unit systems, owing to the small size and rounded shape of MUPS




       
        
         
       
      
         
        
         
          
        
            
     
    
        
         
      
          
          
       
         
        
      
          
       
           
         
       
         
          
          
             
              
         
During MUPS manufacturing, additional flexibility in fabrication can be
obtained for a broader range of drug formulation designs. These
features will ease the coating and better control the liquid diffusion
through the coating layer, and subsequently improve drug bioavailability. 
This flexibility allows for the co-delivery of the incompatible drugs (fixed-
dose combination), or for the delivery of the same drug but co-delivered
in two different release profiles units (pulsatile release). This co-delivery 
is possible as the two different combinations can be made in separate
batches of pellets and can be coated separately, and then mixed in one
dosage form (Caleva, 2015). The MUPS can be more uniformly coated,
owing to their size and shape. In a smaller scale, the single unit system
may have a superior coating uniformity over MUPS. Moreover, coating
uniformity depends on other process and formulation factors as well.
The MUPS can be uniformly packed, owing to their spherical shape
units, results in an inevitable excellent flowability. The MUPS have an
increased resistance toward the external environmental effects of
moisture, air, and light, especially when a hydrophobic coating is applied
(Kallakunta, et al., 2017) and (Reddy, et al., 2011). This protection is 
particularly important if those coated units were intended for capsule
filling, which will more likely reserve the water content in the hard
gelatine capsule, ensuring higher product stability. Here, the protective
coating of conventional tablets can be equally advantageous.
Gastrointestinal tract (GIT) irritation can be reduced using these dosage
forms, due to the higher surface area of the dosage units that results in
an even dose distribution in the GIT. The dose is being in multiple units
that are readily dispersible in the GIT, this results in a decreased
unfavourable drug localisation, and this then impact on GIT irritation. 
The MUPS have reduced the amount and impact of dose dumping,
owing to the fact that the dose is distributed in many sub-units, usually 
a few hundred of pellets contribute to a single dose. Thus any coating
defect in one pellet will cause a sudden drug release in a very small
fraction of the dose (~0.5 to 2% of the overall dose). As a result, the risk




           
      
          
      
        
      
          
       
          
        
     
         
         
    
      
        
          
     
         
       
           
     
       
          
         
      
  
    
   
          
       
       
drug release profiles, owing to their high surface area and the more
uniform coating that results in less variability in the water permeation
mechanisms into the drug formulation. And, this will also result in
decreased impact if poor coating uniformity obtained, reduces the
impact of batch-to-batch variation. Moreover, the coating processes of
pellets are renowned for their better spreading and uniformity of coating.
Each pellet controls its drug release rate, which is if assumed that no
clumping of pellets occurred during coating, storing, and/or during
immersion in the gastric fluids. The latter results in an absorption with
lowered inter-subject variation and intra-subject variation. This reduced
variation is especially important for the narrow therapeutic drugs, such
as theophylline. That will minimise the variable drug plasma
concentration, which may result in a reduced occurrence of adverse
effects in the central nervous system (CNS), and for maintaining an 
effective concentration for the therapeutics site. Hence, the reduced
variability can result in a higher reproducibility of the drug plasma levels,
owing to the more consistent absorption (Abdul, et al., 2010). Based on
the European Medicines Evaluation Agency (EMEA), the pellets have
more predictable residence time and in general longer residence time
than the non-disintegrating tablet (Caleva, 2015). The latter will provide
more time to allow for a complete drug release before the dosage form 
escape the site/s of drug absorption.
The physiological advantages of MUPS tablet/capsule will make the
option for the modified drug release to be more favourable, when
compared to the conventional tablet, for instance (Caleva, 2015). More
discussion regarding the MUPS tablets and MUPS capsules is in the
following section.
1.2.3. Tablet of the multiple-units of pellets system (MUPS 
tablet)
The capsule filling of pellets is more common than the compaction of
pellets, owing to the complexity added by the compaction/compression




   
    
       
       
         
    
      
      
          
       
     
          
       
         
       
       
       
       
     
         
         
       
       
          
          
          
        
          
    
          
      
           
Nevertheless, the MUPS tablets have many superior advantages over 
MUPS capsules (Abdul, et al., 2010). 
During the MUPS tablet manufacturing, faster and lower cost of
production costs are obtained, owing to three reasons, the capsule-filling 
is slower, the capsules’ shells themselves add more cost, and the control
of capsule integrity after filling is considered expensive as well. In 
addition, tabletting does not require a complicated process control when 
compared with the capsule-filling for pellets. Hence, the MUPS tablets
will have simpler, cheaper, and more efficient method of preparation.
However, the drug formulation optimisation of MUPS tablet is 
considered more challenging due to the particular impact of
compression force in the quality of the coated pellets. The MUPS tablet
can have a higher dose loaded in the tablet, but that depend on the 
amount of the other excipients added to cushion the coated pellets. The 
MUPS tablet tolerates scoring without losing the modified release
properties, resulting in flexibility for identifying the modified release
tablets. The MUPS tablet provides the chance for understanding the
complication of the compaction process of pellets.
In addition, MUPS tablets will have a decreased tampering/counterfeit
risk, owing to the difficulty of mimicking the internal components (the
coated pellets) of the tablet; this requires equipment to make the pellets,
coating of pellets, and compression of pellets, which are challenges for 
the counterfeit production (Wagner, 2015). Upon the MUPS capsule
patent expiry, a change to MUPS tablet will bring new patency to the
coated pellets. The design complexity and flexibility to change can also
result in an extension of the patent lifecycle that maintains the
competitive advantage of the product. However, a change from MUPS 
capsule to MUPS tablet need to be risk mitigated by ensuring that the
bioequivalence study was sufficiently comparable (Wagner, 2015). After 
the patent expiry of the MUPS tablet, the tablet will be harder to match
by a generic competitor when compared to a MUPS capsule. An 




     
       
      
       
   
          
       
     
       
            
           
         
         
          
      
            
       
       
         
          
       
       
        
          
         
          
      
     
        
       
        
       
expiry, it finally had one generic competitor LEK, from Novartis in 2005/6 
(Wagner, 2015). The MUPS tablets ensures a lower risk of copying the
technology process by a competing manufacturer. Hence, this is owing 
to the innovative complexity of MUPS tablet when compared to the 
MUPS capsules and conventional tablets.
For the patient use, the MUPS tablet is also more favourable than the
MUPS capsule. It has better patient compliance owing to the better 
swallowing, due to two reasons as follows (FDA-CDER, 2015). Upon 
swallowing, the tablet has less tendency to adhere to the oesophagus 
wall when compared to the hard-gelatine capsule of the same dose.
Also, compacted tablet will be smaller than the capsule-size of the same
dose. The latter reason is particularly important when a high dose is 
required for low potency drugs. The size of the dosage form is also
dependent on the amount of the binder and the cushioning excipients.
The MUPS divisibility is another advantage, because the capsule cannot
be divided into two halves, while the tablet can be divided. For the
modified drug release system, dividing MUPS tablet is safer than
dividing conventional tablet. The latter is regardless of the conventional
tablet being of a matrix or a reservoir type. Because, the coated pellets 
are numerous individual units, and a coating damage in some pellets will
not impact the other coated pellets performance (FDA-CDER, 2015).
Therefore, the compression of pellets into tablets is considered more
technologically modern and more ideal than the hard-gelatine capsule
filling process. Though that should be considered based on the desires 
of maintaining patency of the drug formulation and the dosage form. 
Moreover, unlike the tabletting of powder, the process to make the
MUPS tablet reduces the dust formation. However, this is also
dependent on the binder form and cushioning form used. In conclusion,
when compared to the tablets and capsules, the pellets and especially 
the tableted pellets can be claimed to have ideal characteristics to be 
selected as a superior dosage form in the pharmaceutical oral solids.




      
    
         
        
        
     
         
        
       
      
         





         
      
      
       
          
          
           
        
        
        
      
          
       
         
      
      
functionalised with one or more coating layers, or less commonly 
functionalised without coating.
The coated pellets either finalised by filling into a hard gelatine capsule
or compressed into a tablet, the compressed pellets are usually called
MUPS tablet, ensemble pellets, or tableted pellets. The resulted capsule
or tablet is ready for the patient administration for a specific therapeutic 
indication. See the final dosage form illustration of pellets in Figure 1.1, 
where the naming of the floating property is indicated. For details about
the pellets made by extrusion and spheronisation method and other 
preparation processes, see sections 1.8.2 and 1.8.3. The following 
section will address the modified drug release systems, where the
sustained drug release systems are of major concern in this project.
Figure 1.1: A simple schematic diagram that illustrates the final product appearance
in either a capsule filled by medicated pellets (left), or a tablet contains the compressed
medicated pellets and cushioning pellets (right), the diagrams drawn by the author.
1.2.4. Modified release (MR) drug delivery systems
Oral solids can be classified based on the drug release mechanism/s in
the drug formulation design. Broadly, these are 1) immediate release
drug formulations, where most of the drug is expected to be released
into a liquid medium within one to two hours. 2) Modified release drug
formulations, where the drug release profile is extended, delayed, or 
pulsatile. This approach have an initial high cost, owing to its
technological complexity that requires an additional product and process 
optimisation and scale-up loads (Allen, et al., 2005), i.e. it is costly for a
short term. However, this approach is considered superior to the
immediate release system, owing to the reduced dosage regimen,
increased safety, increased efficacy, and long-term cost-effectiveness




          
           
        
         
         
        
      
         
         
       
      
        
           
          
      
        
        
        
     
         
     
    
     
        
        
   
        
           
        
          
         
      
By controlling the drug release profile from the dosage form, you can
better ensure the plasma concentration to be in a steady state within the
safe therapeutic window. This control can reduce and maintain the peak 
plasma concentration (Cmax) and the time at which the peak plasma
concentration is reached (Tmax). Hence this control will reduce the curve
fluctuations, where the over-dose or the under-dose incidents can be
minimised, especially for the narrow therapeutic window drugs, such as 
theophylline. Also, modified release systems can reduce the cost for the 
long-term manufacturing and for the end user, the patients.
The reduction in the long-term cost was due to many aspects, profits 
obtained by the patentability. And by being more competitively 
advantageous in offering a dosage regimen that is more convenient,
effective, safer, and cheaper for the patient to take for a long period of
time. The latter advantage is owing to the less dose waste as the patient
does not require frequent multiple drug loadings into the blood 
circulation, to re-gain effective drug concentration. The latter aspect is 
beneficial to patients as the total dose per day will be reduced (patients 
are less apt to neglect the regimen, increasing patient compliance), 
become less frequently taken, and less fluctuated in the plasma. 
That is expected to result in minimising the over-dose and the under-
dose events, and subsequently fewer hospitalisation events. That
means fewer emergency loads, fewer nursing loads in administering
drugs and for monitoring patients, and fewer dispensing loads regarding
prescriptions. These long term benefits are expected to overweigh the 
initial higher cost of manufacturing the modified release system for the
manufacturer and the patients alike.
The modified drug release systems can be broadly categorised into two 
systems, based on the formulation design that affect the drug release
profiles. The first is the matrix system, which is also called the monolithic 
system, where the sustained release agent is mixed thoroughly with the
active and the other inactive components of the drug formulation. The




       
     
      
        
      
  
        
      
       
           
      
         
    
    
        
     
     
       
         
         
             
              
        
           
          
          
         
     
   
          
       
        
matrix systems, which are swellable systems that can be erodible as 
well, and 2) insoluble polymer matrix systems, which are intact systems
based on pores formation and matrix tortuosity (McConnell & Basit,
2013). These systems are known to show inadequate or lack of in-vitro
in-vivo correlation (IVIVC) when compared to membrane systems (Das 
& Das, 2003). 
The second broad category is the membrane systems, also called the 
reservoir systems, where the sustained release agent is a semi-
permeable membrane film, which allows the active component to move
from the inner core or the sub-coat layer to the surrounding liquid, in a
controlled fashion. The membrane used can be porous or non-porous. 
This approach can be modified to obtain the osmotic release systems 
(McConnell & Basit, 2013). The diffusion-controlled system is of
particular interest in this project.
Similar to the matrix system, the membrane system can have drug
release in a dissolution-controlled mechanism, or a diffusion-controlled
mechanism. The dissolution is commonly controlled by diffusion. The 
diffusion is limited by the concentration gradient, membrane thickness,
the drug solubility in the membrane, and the coefficient of permeability 
in the membrane (Porter, 2013). If the matrix system was used, the drug
on the surface of the core will release at zero-order rate. Once the drug
there is released, the drug in the centre of the core will start to migrate
and at longer distances that takes more time to release the drug from 
the core. The latter drug release will not be in a zero-order rate. On the
other hand, if the membrane system was used, the drug release will be
at a constant gradient, where a zero-order rate can be obtained (Sinko,
2017). More mechanisms of the drug release can be applied including
the dialysis-controlled, mechanical-controlled, and bio-responsive
mechanisms (Sinko, 2017).
Modified drug release oral solid systems can be named based on their
location of the drug release in the GIT (McConnell & Basit, 2013). 




      
          
       
        
       
      
      
          
           
          
          
          






          
      
        
        
           
         
       
         
      
       
      
          
        
 






The gastro-retentive drug delivery systems (GRDDS) target the stomach
for drug release, floating systems are one example of such a system, as 
seen in Figure 1.2. In this system, the drug formulation is actively 
retained in the stomach by its design performance. The GRDDS is a
class of a sustained drug release systems (SDRS). The SDRS may also
called extended drug release systems (EDRS) or prolonged drug
release systems (PDRS). The SDRS is a broad category that mainly 
concerned with sustaining the drug release over time, with or without
targeting a location of the drug release. Notably, the sustained drug
release pellets are being discussed as an ideal dosage form of oral
solids, owing to its large surface area, where the complete dissolution
and absorption of the loaded drug can be more consistently achievable









Figure 1.2: For illustration, this image shows pellets floating in the stomach.
1.2.5. Gastro retentive drug delivery systems (GRDDS)
The GRDDS are modified release systems that intended to remain in 
the stomach for a prolonged time. The floating drug delivery systems 
(FDDS) are a type of GRDDS, and they are well established in research,
patent research and in the market for decades, see the marketed 
products in section 1.9. The distinctive feature of GRDDS lay in their 
design flexibility, where the candidate drugs and drug classes can be
efficiently delivered, to provide an optimum bioavailability. After a
specific time elapse, the GRDDS formulations are expected to get easily 
metabolised in the body. Hence, after the drug release, prolonged
retention of the dosage form in stomach should be avoided during




       
      
          
     
           
           
     
          
         
           
        
         
       
 
        
          
      
         
        
       
        
         
       
        
       
          
    
         
       
              
         
           
as theophylline that has an erratic absorption, and absorbed mainly at
the upper part of the small intestine, the duodenum, with good 
absorption in the colon. Gastro-retention is also desired when the drug,
such as alginates for heartburn are therapeutically acting on the 
stomach. It is also desired for diazepam, which is insoluble at high pH,
and when the drug, such as captopril and ranitidine are degraded at high
pH (Singh and Kim, 2000).
The erratic absorption of certain drugs can lead to variable absorption in
the GI tract that results in variable plasma drug levels. However, the risk 
of not obtaining the required dose in the blood circulation becomes more
pronounced when the drug molecules also having a narrow therapeutic 
window, like theophylline (Kang and Lee, 2009). This limited surface for 
absorption urges the consideration for more targetable delivery of such
drugs.
In Figure 1.3, a variety of approaches can be taken for GRDDS (Singh
& Kim, 2000) and (Lopes, et al., 2016), and are summarised as follows.
Low-density or floating system (FDDS), it is the drug formulation design
intended to be floated on the liquid surface of the stomach. A detailed
literature review will be presented shortly for the types of floating
systems and specifically, the floating pellets systems (mupFDDS), in the
upcoming section. High-density system, it is the drug formulation design
intended to sink into the stomach’s groove, namely, to sink into the
pyloric antrum groove, which located just before the pyloric sphincter.
Bio-adhesive or muco-adhesive system, it is the drug formulation design
intended to stick to the stomach’s epithelium for a sufficient time. This 
system type can be co-designed with an effervescent floating system.
Swellable plug, super-porous hydrogel or largely swelling system, it is 
the drug formulation design intended to swell sufficiently enough, to be
plugged away by the stomach’s pylorus, and then eroded after sufficient
time elapsed. It has an average pore size of more than 100 µm, to allow
reaching the swelling equilibrium in one minute (Pawar, et al., 2011). 




       
        
         
        
        
         
         
          
     
      
      
 
       
   
  
 
name; non-effervescent floating system is implying that as well. Modified
shape or expandable system, it is the drug formulation design intended 
to unfold into a specified geometry of different shapes and sizes, where 
the peripheral parts of the system are erodible after sufficient time
elapsed, that eases the elimination of the system. Magnetic system, it is 
the drug formulation design intended to be magnetically attracted to an
object located outside of the body, near the stomach. Indigestible feed 
system, it is the drug formulation design intended to be co-administered
with indigestible polymers and/or fatty salts to mimic the fed condition, 
which subsequently delays the gastric emptying time (Singh & Kim,
2000) and (Lopes, et al., 2016).
Figure 1.3: Illustrates most of the gastro-retentive systems. Apart from the high-
density systems, the systems shown here are designed or can be designed to float.




     
      
         
        
       
          
          
     
      
     
        
     
         
          
        
     
       
       
       
         
     
        
       
          
     
       
        
         
     
       
            
         
     
Interestingly, the specific FDDS reviews (at least 23) outnumber the
GRDDS reviews (at least 15). The following reviews were consistently 
stating the pharmaceutical and the physiological aspects regarding the
GRDDS designs (Chawla, et al., 2003), (Streubel, et al., 2006), (Garg & 
Gupta, 2008), (Bhardwaj, et al., 2011), (Mathur, et al., 2011), (Pandey,
et al., 2012), (Siraj, et al., 2013), (Pant, et al., 2016) and (Tripathi, et al., 
2019). Also, a recent and more focused review on the GRDDS in-vivo
success brought by (Mandal, et al., 2016). Another GRDDS review was 
more focused on the applications against the Helicobacter pylori-
induced ulcer by (Bardonnet, et al., 2006). Unique reviews for the
expandable GRDDS was provided by (Klausner, et al., 2003) and for the
super porous hydrogel GRDDS was provided by (Mayur, et al., 2012). A 
GRDDS review that was more focused on the FDDS, and where
marketed GRDDS presented can be seen by (Pawar, et al., 2011). More
presentation for the marketed products can be seen by (Chhetri & 
Thapa, 2014), (Lopes, et al., 2016). The latter is particularly 
recommended for a concise, comprehensive and recent update.
The following reviews were consistently stating the pharmaceutical and
the physiological aspects regarding the FDDS designs (Singh & Kim,
2000), (Shaha, et al., 2009), (Hardenia, et al., 2011), (Chandel, et al.,
2012), (Mukesh, et al., 2012), (Bhardwaj & Harikumar, 2013), 
(Meenakshi, et al., 2014), (Pooja, et al., 2015), and (Ishak, 2015). Other 
reviews that additionally presented the marketed FDDS products can be
seen by (Arora, et al., 2005), (Patil, et al., 2006), (Narang, 2011), (Kaur,
et al., 2013), (Patil & Saptarshi, 2013), (Kandwal, et al., 2014), 
(Sarawade, et al., 2014), (Gupta & Kothiyal, 2015) and (Rewar & 
Shakya, 2015). The (Goyal & Sharma, 2014) was focused more on the
effervescent FDDS designs. (Avinash, et al., 2012) focused on the
FDDS designs for drugs used in the cardiovascular diseases. (Solanki,
et al., 2017) focused on the FDDS for Histamine 2 receptor antagonists,
to relieve heartburn. (Prajapati, et al., 2013) focused on the raft forming
FDDS designs, while (Foster, et al., 2013) focused on the





   
      
   
         
        
        
   
       
      
          
      
    
        
       
        
       
           
        
       
          
    
         
      
         
         
 
          
     
    
         
1.3. Floating Drug Delivery Systems (FDDS)
1.3.1. Floating drug delivery systems (FDDS)
The low density or floating drug delivery system (FDDS) is also known
as the hydro-dynamically balanced system (HBS). Davis initially 
discussed such systems in 1968. Since then, the literature has heavily 
focussed on the single-unit floating systems, while the multiple-units 
floating systems like pellets have been discussed to a lesser extent. 
Regardless whether single or multiple units, or whether matrix or 
membrane/coated systems being used, floating has been achieved via
effervescent floating or non-effervescent floating systems. However,
sometimes, mixed systems have been used and shown to be more
reliable, as they provide synergistic floating mechanisms (Singh & Kim,
2000). For example, a muco-adhesion mechanism and/or swelling
mechanism can be added to substitute the effervescent mechanism, to
allow for more advanced gastro-retention functionality in the FDDS
(Singh & Kim, 2000), see Figure 1.4. Unlike other GRDDS, floating
systems do not affect gastrointestinal tract (GIT) motility/transit, resulting
in no alteration of the gastric emptying rate. Also, as stated earlier, unlike
other GRDDS, they have a well-established presence in the market, like 
Madopar® HPS, a single-unit capsule system that swells to float.
Therefore, they were said to be one the most preferred approaches of
GRDDS (Nadigoti, et al., 2011). 
Tens of articles were seen during the last decade studying the single-
unit floating systems (su-FDDS), primarily tablets. A relatively recent
example can be seen by (Abdel Rahim, et al., 2015). Other examples 
are (Strübing, et al., 2008), (Sungthongjeen, et al., 2008) and (Guguloth, 
et al., 2011).
In addition to the advantages stated in MUPS section 1.2.2, the multiple-
units FDDS (mu-FDDS) will have additional superiority to the single-
units FDDS (su-FDDS) (Hendeles & Weinberger, 1983), (Shargel, et al.,




     
       
       
       
      
       
  
       
       
        
         
        
        
         
        
      
         
 
        
     
          
   
   
  
    
         
          
        
       
     
        
et al., 2011). Floating MUPS (also abbreviated as mupFDDS)
tablets/capsules have a higher flexibility in regulation, as they are more
likely to have consistent in-vitro in-vivo correlation (IVIVC). This is 
particularly evident when considering the overall advantages of the 
consistency of the sustained drug release and floating. The latter are
owing to the small size and spherical shape properties of pellets (Singh
& Kim, 2000).
Non-effervescent floating approach are better than the effervescent one. 
The latter approach may have premature CO2 generation during
processing and storage. This risk can increase if a citric acid co-exists 
in the formulation for the intention to provide a micro-acidic environment
upon hydration. Premature CO2 generation can impair the floating
capacity of the design. Also, the effervescent system is a pH-dependent
system, where a low pH medium is required to generate the gas to be
entrapped for lowering the pellets density to float. The fasted stomach
is a necessity if a micro-acidic agent is not used. These reasons may 
affect the IVIVC within the different systems of the floating pellets (mu-
FDDS).
The following sections will discuss the fabrication and the development
challenges of different FDDS approaches, followed by appropriate
literature comparisons. An overview for the floating systems can be seen
in Figure 1.4.
1.3.2. Effervescent floating drug delivery systems 
(effervescent-FDDS)
The effervescent FDDS is less preferred over the non-effervescent
FDDS, due to that the former is a pH dependent system. Nevertheless,
the effervescent FDDS is still being the most common approach seen in
the literature and the market. The effervescent FDDS is primarily a gas 
generating system, which utilises a foaming agent or more commonly a 
gas-generating agent, such as the widely used sodium bicarbonate that 




        
           
       
         
     
           
      
     
   
         
        
     
         
        
         
    
     
        
            
         
 
reduce the density of the dosage form, causing it to float. Its frequent
use in formulation design is perhaps due to the prevailing view that the
floating may not be readily achievable otherwise (Singh & Kim, 2000). 
The latter argument will be investigated in this project, to clarify this 
rationale for such carbonate salt.
Moreover, the CO2 can do more than just floating to achieve optimum 
mechanism of gastro-retention. It creates an initial alkaline
microenvironment that accelerates hydration. The latter aids the
initiation of a bio-adhesive hydrogel structure (polymer gelation) that will 
be based on the adjacent constituents as well (Singh & Kim, 2000). The 
effervescent FDDS are listed below (Singh & Kim, 2000) (Gupta & 
Kothiyal, 2015) and (Ishak, 2015):
Foaming systems, where the formulation has an effervescent agent, like
sodium bicarbonate, with or without an acidifying agent, like citric acid
or tartaric acid. And with a hydrocolloid gelling agent, like the specific 
cellulosic polymers such as hydroxyl-propyl methylcellulose (HPMC),
the polysaccharides such as chitosan, and the sodium alginate. The 
foaming system is also called swollen pills system, referring to floating
tablets, here, the swollen word can be related to the swelling induced by 






            
  
  
        
       
      
      
          
           
          







































Figure 1.4: Technological approaches used in literature for single and multiple units
floating systems, Mixed-systems being increasingly studied in literature. More details 
are seen in sections 1.3.2-3.
The dosage form is fabricated in a way that allows for controlled CO2
generation and liberation. The typical final forms of FDDS are tablets,
tableted pellets, or pellets in capsules. In this section, the details of
specific layered pellets of interest, and the fabrications of materials 
involved will be addressed. Also, more information on the designs of
interest in this project, see section 1.3.4. And more details on the floating
mechanisms of floating pellets can be seen in section 1.4. It is good to




             
  
         
        
        
        
        
          
        
          
       
     
       
           
           
           
     
         
         
       
         
        
        
         
    
        
   
  
      
             
also have the potential to float without a gas-generating agent, i.e. to be
as fully non-effervescent FDDS systems.
Ion Exchange Resin Foaming System, where the resin beads/pellets
formulation was loaded with an effervescent agent and attached to a
drug of a negative charge, then encapsulated by semi-permeable or 
retard membrane that controls CO2 liberation. Upon exposure to gastric 
content, bicarbonate ions get exchanged with the chloride ions of gastric 
fluids, results in partial liberation of CO2, as the membrane trap the
released CO2. This controlled CO2 release allows for the formation of the
floating resin beads as a layer/seal (Atyabi, et al., 1996). The system is 
not widely used, time-consuming, and very expensive to formulate, as 
stated by (Prajapati, et al., 2013).
Raft-Forming or In-Situ Gelling Foaming System, where a thick liquid
formulation that upon contact with gastric fluid will gel instantly, and that
form a raft on the liquid surface as a barrier foam, that was along the
use of bicarbonate salt to ease raft floating, a famous example of this 
type is the suspension of Gaviscon.
Expandable and Osmotic Foaming System, where a folded device in a
capsule formulation that consists of a hollow deformable unit can
convert from collapsed to an expanded position. Then after sufficient
time, it returns to the collapsed position again. One chamber contains a
drug, while the other contains a cyclo-pentane or ether, these are
gassing/vaporising agents that are sensitive to the body temperature.
The second chamber has a bio-erodible plug to allow the vapour to
escape after time. The system is apparently complex and has safety 
issues, and these gases are of particular concern to smokers.
1.3.3. Non-effervescent floating drug delivery systems 
(non-effervescent FDDS)
Many of the non-effervescent floating systems involve swelling, which




        
      
           
        
       
      
        
            
          
        
         
        
           
      
        
         
      
    
        
       
       
      
        
         
        
      
           
      
       
      
       
explained shortly. Similar to the effervescent FDDS, these formulation
designs here varied in their technological concepts.
These systems are summarised in the following papers (Ichikawa, et al.,
1991), (Iannuccelli, et al., 1998), (Singh & Kim, 2000), (Waterman,
2007), (Hung, et al., 2014), and (Awasthi & Kulkarni, 2014):
Super Porous Hydrogel Swelling, Super Swollen Pill, Eroding Gel, or 
Plug System, which is obtained using super-gelling/swelling agent, such
as purified shellac, with a channelling agent, and with or without the use
of an effervescent agent. The pill size enlarges quickly to be plugged
away by the pylorus sphincter and then to become floated as well. It is 
more applicable to large unit systems, like tablets or capsules, while
pellets are not applicable as they will rupture upon vast expansion, and
will not reach the desired size to be plugged away the pyloric sphincter.
Plug systems can be designed as non-floated GRDDS as well.
Hydrocolloid Gel Swelling or Swollen Pill System, which is obtained 
using a gel-forming hydrocolloid, like HPMC, which creates a receding
boundary upon hydration, induces surface gelation, followed by a
gelatinous barrier that controls the diffusion process. A popular system 
was the floating capsule as su-FDDS obtained by Roche, in the brand
name of Medopar HBSTM. Hence, the name hydro-dynamically balanced
system (HBS) was first used in the market (Singh & Kim, 2000).
Air Compartment, Balloon or Hollow/Shell System, with or without
Swelling, which can be obtained using calcium alginate and poly-vinyl
acetate (PVA). The PVA is acting like a channelling agent that increases 
membrane permeability and prevent the compartment collapse. It can
be obtained using poly-styrene, ethanol and/or dichloromethane, to 
make the hollow globular shell in the core of the dosage form system.
This system was reported to be prepared by ionotropic gelation, solvent
evaporation or by the emulsion solvent diffusion methods. The term 
micro-balloons can be referred to the swollen micro-pellets/spheres 




        
          
        
            
        
        
           
         
     
        
      
        
       
      
    




















   
  
 







   
  






















     
  
 






can also be generally referred to as swollen pills systems. The term 
balloon sometimes can be referred to the swollen systems that have the
potential to float. Moreover, balloons also may mean the largely swelling
systems that cannot float or can float, like the plug and the floating plug
systems, respectively. These terms, like the term air compartment, can
also be referred for preformed low-density systems, i.e. during the
manufacturing process, a gassing agent reacting to an acid, and the gas 
generated will provide air in the cores, resulting in low-density dosage
form prior administration, like the pellets made by (Iannuccelli, et al., 
1998). Those pellets floated immediately for more than 24 hours in the
artificial gastric fluids, regardless of the pH. Laminated Film System, 
which is obtained through film overlaying, the resulting films provide
small air pockets entrapment, which causes the films to float (Singh & 
Kim, 2000). More examples for non-effervescent floating systems are
listed in Table 1.1.
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(Singh & Agar molds Agar 2% or more, The oil prevent entrapped air
Kim, 2000) with mineral oil from escaping, which avoided 
the bias of compaction
1.3.4. Effervescent and non-effervescent multiple units of
pellets floating drug delivery systems (mupFDDS)
The effervescent and non-effervescent floating drug delivery systems of
multiple units of pellets (mupFDDS) designs can vary significantly based
on the methods of preparation, the number of coating layers, the
intended floating mechanism/s, and the drug release profile. The design
of floating pellets made using the extrusion and spheronisation method
is of particular importance in this project. Previous work done in the 
literature regarding floating pellets designs that no coating or up to
quadruple-coated pellets. This summarised below, and more
information given in Tables 1.2 and 1.3 (Sinko, 2017).
Core Matrix Design, which may consist of drug-loaded pellets, with or 
without bicarbonate. The design is usually considered challenging,
owing to many reasons, namely, the difficulty of processing the fully 
functional core pellets, and the difficulty of obtaining quality attributes 
within specifications. Single Layer Design, which may consist of cores 
loaded with drug and bicarbonate, with a single multi-functional
polymeric layer, the layer is of gas-retard and drug-retard functions.
Although this design is simpler than the designs below, it is more
challenging to optimise floating and sustained drug release properties.
As the following mechanisms become more difficult to optimise; the gas-
generation from the cores, the gas-entrapment and gas-release by the
single layer, and the drug-release by the single layer. Double Layer 
Design, which may consist of drug-loaded cores, with an inner sub-coat
layer, of gas-generating function, followed by an outer polymeric layer,
of gas-retard and drug-retard functions. Triple Layer Design, which may
consist of drug-loaded cores, with an inner sub-coat layer, of a drug-
retard function, followed by a second inner sub-coat layer, of gas-
generating function, and finally, an outer polymeric layer, of a gas-retard




        
       
        
        
      
       
       
        
         
       
   
           
      
         
      
        
       
      
         
      
           
      
       
       
      
         
       
         
        
          
        
          
    
cores for swelling and void formation, with an inner sub-coat layer of
swelling-retard function, followed by a second inner sub-coat layer of
drug and hydrocolloid function, followed by a third inner sub-coat layer 
of hydrocolloid function, and finally, an outer polymeric layer of drug-
retard function. Although multi-layered designs may have more
distinctive and predicted functionality, they are less cost-effective and
more-time consuming when compared to the less layered designs. 
Therefore, the less-layered design can reduce the excipients where the
remained layers have to do more functions. In this project, the latter is 
desired though it requires more optimisation work to obtain multi-
functionality by the reduced-layer design. Upon layer reduction from 
triple to double layered design, the optimisation of the retard coating
layer becomes more demanding. Because the former design has two
retarding layers, one for retarding drug release and other for retarding
gas release. While the later design has only one retard layer that retard
both drug and gas release. The floating requires more water-soluble
retard polymer, where the sustained drug release requires less water-
soluble polymer. The optimisation work also depends on other various 
factors, such as the drug solubility, the compositions of the coating
dispersion, and the coating process variables. Upon layer reduction from 
double to single layered design, the optimisation of the retard coating
layer remained as demanding. However, the optimisation of the core
pellets become more demanding. The latter because the additional 
addition of NaHCO3 or other agent that reduce density in the core pellets. 
Hence, the powder sensitivity to the granulating liquid volume is 
expected to be increased during the wet massing process. Upon layer 
reduction from single layered to matrix design, the optimisation of all 
materials will be more demanding. Moreover, the drug release of the 
matrix system is often more variable than the coated/membrane system,
as explained in earlier. An illustration in Figure 1.5 shows the layout of
the single-coated floating pellets. The following section will further 
elaborate on the concepts of floating, with more reflection on the




                  
   
   
 
 










      
   
  
   
       
  
       
      
       
  








    
   
   
    
    
   
   
     
  
 
      
        
     
   
     
     
 
     
  
     
  
 
     
   
    
     
  





     
     
   
   
  
      
     
  
     
      
     
      
  
  
    
  
    
   
   
      
   
      
Table 1.2: The effervescent and non-effervescent mupFDDS designs made by the extrusion/spheronisation method. This table has an exclusive list so far,













(Shang Yuh Machine), 
rotor FB coater (GPCG-1 
Glatt)
Cores: 25% Drug, 55% MCC, and
20% NaHCO3. Coating layer: was
of different GIT-soluble and GIT-
insoluble polymers combinations.
A mixture of 5% Kollicoat SR and 5% PEG
600, where a 20% coating gain provide 
floating lag time of 15 minutes and maintained
buoyancy for over 12 hours. And all of the drug
released in 3 hrs, or it was delayed for >2 hrs
to start sustaining the drug release for 6 hrs.
All coating efficiencies are over
90%.
(Hung, et Losartan Single layer, RB extruder, Cores: MCC of Avicel® PH102, RS:RL 1:1 with 15% DEP can show potentially The NE30D grade results stated
al., 2014) potassium 
, freely
soluble
and spheroniser of Shang 
Yuh®
NaHCO3 and L-HPC and fixed
drug level. Coating layer:
Eudragit® RL30D, RS30D, or
NE30D, with di-ethyl phthalate
(DEP) or tri-ethyl citrate (TEC), or 
Surelease® 25% with HPMC.
good SR and floating if the drug used was 
slightly soluble in water.
Batches showed either >80% DR in 2 hrs, or 
SR for 4 hrs followed by an only ~10%DR for 
the next 20 hrs, or it will be delayed for >4-8 
hrs to start the release that is sustained for
40%DR at 24 hrs. All batches showed >80%
floating and remained floated for 24 hrs, lag 
time: ~5-30 min.
and analysed clearly in the surface
tension study in the enhancment
chapter, with an improved
functionality.
In the screening work for the
single-coated pellets, use of PVP
or cros-PVP instead of L-HPC.
This reference was shown that L-
HPC has superiority over MCC, 
regarding water absorption and
swelling tendency.





effervescent via swelling. 
Wet massing by 80 mesh
sieve, RS extruder of 0.4
mm (JBZ-300), blow dryer,
FB coater (Werner Glatt),
flat-faced single
Powder mix of drug, MCC of Avicel
PH101 and stearyl alcohol as low-
density agent (1:1:10). Kneaded 
with 5% PVP k30 liquid binder.
The tableted floating pellets were floated
immediately for more than 12 hours for non-
compressed and compressed coated pellets 
(% of floating not stated) and SR was for up to
8 hours, though DR reach 80% in 4 hours (for 
both non-compressed and compressed 
coated pellets and comparable to PK data of
The enhanced formulations in this
project are noticeably different in 
two means: (1) No combination of
Eudragit RL30D and RS30D was
used, (2) No alcoholic PVP as the 
liquid binder was used, instead an
ethanol liquid binder was used.





   
   
 










   
 
   
  
  
    
    
   
    
    
       
        
        
         
     
    
  
      
 
     
 
   
 
     
     
   
 






    
     
   
    
   
  
        
     
    
     
    
    
  
 




   
 
  
   
  
 
    
 
   
       
  
     
  
 
      
  
   
     
punch/press (Shanghai
Pharm Machinery Factory)
absorbed drug in animals). The medium used
for drug release is not stated.
get wet without soaking or
dissolving, which decreases the 
risk of no re-swellability.
(Sungthon Anhydrou Double layer, TM of Cores: MCC of Avicel® PH101. Only RL30D grade allowed floating. Higuchi is This is seen as the least
gjeen, et s Rotomixer Foster®, MWM, Sub-coat: NaHCO3 and HPMC of the best fit: linear with the squared root of time challenging mupFDDS design in 
al., 2006) theophylli 
ne, slightly 
soluble
RB extruder of Caleva® 25 
and RPRCHGS of
Caleva® 250
Methocel® E15LV and PEG6000.
Retard coat: Eudragit® RL30D,
RS30D or NE30D, with DEP.
for 12 hrs (with low variation). The floating was
less than 0.5 hr for the high concentration of
NaHCO3 batches, while, it was >24hrs for the 
low NaHCO3 batches. (floating profiles of 24 
hrs were not shown)
literature, as the number of layers 
provides distinctive and sufficient
functionality, yet it is more time
consuming than single-coated 
designs. In double-coated chapter, 
the double coated pellets mimic
this design, and with the use of 




Ofloxacin Triple layer, 80 mesh dry 
sieve, Extruder and 
Spheroniser (WL350,
Wenzhou®), FB coater 
(FD-MP-01, Powrex®)
(1) Avicel PH105 and drug-loaded
cores, (2) EC (10cp) strength of
3% w/v, with PVP k30 as pore 
forming and plasticiser, in 4:1 ratio,
dissolved in 95% alcohol, (3)
sodium bicarbonate with HPMC
E5 (ratios of 1:4, 1:2, 1:1, 2:1, and
4:1) with PEG 6000 (in 10% w/w of
HPMC solids). The weight gain
was 12% w/w, (4) Eudragit RL30D 
plasticised by DEP (20% of RL30D
solids). Weight gain was 15% w/w.
Successfully sustained the drug release. The 
floating was for at least 6 hours in vivo.
The design here is more
complicated and more time-
consuming. Therefore, the 








sifting, RMG of HSMG10 
Levin Process®, Extruder 
20 and Spheroniser 250 of
Caleva®, FB coater of 
(1) MCC of Avicel® PH102, ultra
micronised cros-PVP of poly-
plasdone® XL10 and drug-loaded 
cores, (2) 8% wt gain of EC (7cp)
dispersed in IPA, hydromellose of
Similar to Sungthongjeen, only the RS30D
grade was shown successful floating, and with 
6 hours floating in-vivo.
Similar to Hung, the Katakam work
has no factors layout for the cores 
to allow further optimisation.






    
      
    
     
    
     
   







   
   
 
 
   
   
   
    
  
      








   
 
 
    
  
  
    
   
 
   
 
   
   
    
       
  
   





   
 
    
 
   
  
  
     
     










       
      
      
GPCG Pamm Glatt® 1.1 
Wruster.
Methocel® E5-LV Premium, (3)
12% wt gain of NaHCO3 with the
use of Methocel® E15-LV (in 2:8,
5:5, and 8:2 ratios) (4) 5, 10 or
15% weight gain of Eudragit®
RL30D, RS30D, or NE30D, with
DEP or TEC 20%
Katakam’s design is complex as
well.
(Setthache Tetrahydr Matrix-non effervescent THC-SEDDS solution of four Floating and drug release properties achieved They used ten polymers to achieve 
ewakul, et o- via self-emulsifying. polymers, as a liquid binder, after from the self-emulsified matrix, and no coating that, which is a bit of high cost, and





developed in-site using 2 
mm pore size screen.
pouring 5ml of water in the dried 
powder of other five polymers,
including MCC.
applied. complexity here arise from the 
potentially unfavourable hidden 
interactions.
(Biswas, et Metronida Matrix-non effervescent Cores that have HPMC (as One formulation has the best fit in Higuchi The ratios tested cannot be a full
al., 2012) zole via swelling. Pellets made 
by the extrusion method.
hydrocolloid agent) in different
grades (K4M premium, and 
L100LV premium) in ratios of 2:1,
1:2, and 1.5:1.5. Where sodium
alginate (as mucoadhesive) was 
used in 3.5g, 5.25g, and 7g,
respectively. 
drug release model (r=0.994). Floating data
not obtained due to lack of full access.
representation of factors' levels, 
yet full access is needed to confirm
whether this was considered.
(Hwang, et Cilostazol, Matrix-non-effervescent Cores have Cilostazol, glyceryl The resulted porous structure offers The lyophilisation along with 
al., 2016 ) a 
hydrophob 
ic drug
via air compartment. The
pellets were lyophilised as 
well.
behenate as a matrix former and 
floating aid, hydroxyethyl cellulose
as an additional floating aid,
camphor as a sublimating agent.
immediate floating. The HEC addition
increase the floating duration for an
acceptable time. The hydrophobicity of the 
drug allows for an erosion-mechanism 
sustained release profile.
excipient use is stated as a way to 
provide highly porous system for
non-effervescent floating.
Lyophilisation was not used in this 
project.
No full access obtained; the % and
duration of floating is not known.















   
  
    
    
  
      
    
     
 
         
   
  
     
  
 







    
    
    
    
   
 
     
   
     
     
    
     
 
      
   
     
  
    
    
    
  
      
  





                
 
                      





(He, et al., Bolo leaf Matrix-non effervescent Cores have Bolo leaf phenols Floated immediately for >12 hrs, SR for >6 hrs The chitosan bio-adhesion is 
2017) phenols via bio-adhesion and (BLP) and chitosan as a bio- and followed Higuchi model. ~73% adhesivity responsible for gastro-retention. 
(BLPs) potential air compartment adhesive. to the gastric tissue and >40% retention rate But not known what is causing an
and/or swelling. No full access obtained; not known
whether the chitosan his
responsible for the floating and the
SR effects.
in rats after 6 hrs. immediate floating.
Bio-adhesion was not used in this 
project.
(Li, et al., Dypridam Quadruple (1) Water soluble excipients like Unlike other designs, the NE30D grade was The NE30D grade was selected
2014) ole layer-non-effervescent via 
air compartment, WM by
80-mesh sieve, FB coater
mannitol, and Avicel® PH101in 4:1, 
(2) EC (10cp) and PVP k30,
dissolved in alcohol/water (80:20 
v/v), immersed in water for 12
hours to allow water channelling,
then dried to allow voids formation, 
(3) drug, HPMC E5 and PEG 6000
(10% of latter), (4) HPMC and PEG
6000 (10% of latter), (5) Eudragit®
NE30D.
shown successful floating. based on this paper success, and 
PVP 44,000 g/mol selected as
well. Although NE30D grade was
not successful in other studies,
but, owing to its neutral solubility in 
water, it is expected to allow for
fine-tuning the balance between 
floating and SR profiles. As floating
need hydrophilicity while SR
needs hydrophobicity in the 
retarding polymer. Also, the paper 
gives insights for the fed state 
testing.
*References were ordered based on the number of layers in the studied design and the date of publication, followed by the type of floating system regarding the effervescent
presence.
** The equipment model configuration or the brand name is specified where possible. Abbreviations: FB: fluid bed, TM: tumbling mixer, MWM: manual wet mixing, RB: radial-






                











     
    
      
   
 
   
  
    
  
 
     
  
    
    
   
    
   
    
      
 
    
  
    
    













    
 
   
 
   
 




    
    
     
    
   
    




    
   
  
 
       
        




   
     
    
  
    
      
  
   
   
    
 
         
  
   
      
  
Table 1.3: Some of the effervescent and non-effervescent mupFDDS designs made by methods other than the extrusion/spheronisation method. Some more






Design and Method** Compositions Floating and SR Profiles Comments
(Sawicki & Verapamil Matrix, wet granulation followed by Cores were having drug 20.0%, The most appropriate tablet It is an example of tableted coated pellets.
Łunio, hydrochlori direct spheronisation: moist mass sodium hydrocarbonate 20.0%, mass for floating pellets was The Kollidon CL is used in this project (In ch.
2005) de made rubbed through a metal sieve
(Retsch®, Hann) of 1.25 mm mesh
diameter.
Spheroniser Caleva®
120. Spheroniser shield rotation 
speed measured by a Caleva
tachometer. A blow-dryer was used 
as well.
Avicel® PH101 10.0%, Arbocel®
P290 33.4%, lactose 12.3%,
Povidone K-30 4.3%. Kollicoat®
SR 30 D. Plasticisers were 10%
propylene glycol, 10% triethyl
citrate or 10% dibuthyl sebecate.
The films’ thickness for SR was
70 mm.
Avicel PH102, mannitol and
Kollidon CL (as swelling
agent). SR of tableted 
pellets was identical to non-
compressed pellets, where 
nearly 70% of the drug was 
released in 6 hours.
5) to compare with the enhanced PVP 
batches.
(Amrutkar, zolpidem Triple layer, liquid layering method, Cores were non-peril sugar Floated completely within 5 It describes that the gas generation inducing 
et al., tartrate a drug containing solution with pellets, drug layered, min and for over 10 hours. balloon or swollen pellets, owing to the gas 
2012) various excipients, to be layered into 
non-peril sugar pellets/starter
pellets, using bottom-spray fluidised 
bed coater (Pam Glatt®).
effervescent sub-coating layer;
sodium bicarbonate, followed by
a MR layer; Eudragit® NE 30D.
Drug release was either
zero-order or Higuchi’s, and 
for up to 10 hours, but with
initial burst, and with some
fluctuations.
generation rather than the effect of other
swelling polymers. SEM shows that the 
smoothest surface was obtained by the 2nd
layer.
The Eudragit NE30D here is showing effects,
which is showing some similarity to the effects





Matrix, hot-melt extrusion: powders
sifted by sieve 40, wet massing by
manual mixing in a poly-ethylene 
bag, then extruded by HME
(Thermo® Pharma 11 twin-screw
A molten mix of the drug, sodium
bicarbonate, glycerol
monostearate as the thermal
lubricant, polyethylene oxide
Floating and SR achieved
for up to 12 hours.
This method is the most current in research for
developing novel mupFDDS designs with 
claims to be a superior method over other
methods, in particular, it was claimed to be a





      
     
 









   
    
   
     
  
     
   
    
  
      
      
   
    
  




    
 
 




   
 
   
   
    
  
  
     
       
 
            
 
                   
                
       
extruder), extrudates segmented in 
5 mm length using a cutting blade.
(PEO) or Eudragit® RS PO with
HPMC.
method, as HME have easier processing
features and less time-consuming.
(Kumaran, Mosapride Matrix, Ionotropic gelation, non- (1) Drug, sodium alginate and lations were All formu After pellets formation, stirring will be
et al., effervescent: mechanical stirrer, de- HPMC (9:1 ratio), and KHCO3 floated completely in both continued, to improve pellets’ mechanical




(2) 1% w/v CaCl and 10%w/v
glacial acetic acid, then beads 
will form in a solution.
simulated gastric fluid, and
in pH1.2 media, for 24 hours
strength, and to allow sufficient time for
completing CO2 generation inside the beads.
HPLC testing of drug release, and swelling
from such systems is explained.
(Vidyadha Stavudine Matrix micro-pellets/ micro-balloons, Micro-pellets made by HMPC E5, SR profile was shown the Among process factors, the stirring speed was
ra, et al., emulsion solvent diffusion and drug, and IPA as liquid binder. first-order release over 12 found to be critical.
2015) evaporation, non-effervescent: 
sonicator, mechanical stirrer,
filtration, and desiccator for drying at 
room temperature for 24 hours.
Micro-encapsulated by the 
emulsion evaporation, the 
emulsion is EC 7cps, Eudragit® S 
100, and 1% PEG400.
hours, with as low floating 
lag time as 1 minute.
*References were ordered based on the number of layers in the studied design and the date of publication, followed by the type of floating system regarding the effervescent
presence.
**Other recent studies used for these methods were as follows: the ionic gelation method by (Bera, et al., 2015), hot-melt extrusion by (Vo, et al., 2016). Moreover, the liquid layering
method where the Celphere®; MCC starter pellets were used by (Pagariya & Patil, 2013). Also, the emulsion solvent diffusion and evaporation by (Kumar, et al., 2017) where a


















           
   
     
 
         
        
         
     
      
    
          
       
          
          
        
       
        
   






   
  








   
   
Floating agent, Plasticiser and 
Hydrocolloid Containing Sub-coating
Drug,
Drug and Layer Reduction Spheronisation Aid,
Spheronisation and Floating
Aid Containing Agent/s Containing
Cores Cores
Sustained Release
Agent and Emulsifier Agent and Emulsifier
Containing Retard Layer Containing Retard Layer
Sustained Release
Figure 1.5: Schematic diagrams of mupFDDS used, where components of each stage
of formulation preparation are identified.
1.4. Floating Mechanisms of the Floating Pellets
1.4.1. Floating mechanisms
When a floating dosage form is immersed in the dissolution medium, a
lag time before the floating takes place is typically seen, this is followed
by continual floating on the surface of the liquid, resulting in a 
hydrodynamically balanced system (HBS). In the effervescent floating 
system of pellets or tablets, gas generation and entrapment is vital
(Solanki, et al., 2017). 
Also, the floating mechanism of effervescent system can be elaborated
as follows (Singh & Kim, 2000), (Sungthongjeen, et al., 2006) and 
(Solanki, et al., 2017). Specifically, the CO2 generated leak into the
existing pores in either the sub-coat layer or in the core pellets. The CO2
entrapped by the retard-coat layer. This lowers the density of the overall
dosage form system. Effective gas-retard agent, include the commonly 
used Eudragit RL30D. The latter is usually applied in an outer coating




      
       
      
       
       
        
        
      
   
          
           
          
           
            
      
       
        
       
   
      
            
         
        
        
        
       
        
          
     
          
        
       
In the non-effervescent floating system of pellets and of some tablets 
designs, the mechanism of floating can include swelling and/or muco-
adhesion. The muco-adhesion mechanisms are based on numerous 
theories, include wettability, electronic, fracture, adsorption, and
diffusion inter-locking theories. The muco-adhesion mechanism and its
theories are beyond the scope of this project, nevertheless, the
mechanisms involved in each theory are listed by (Lopes, et al., 2016). 
In this project, the focus was on the swelling mechanism for the non-
effervescent floating.
After liquid uptake by the coated pellets in such systems, gradual
relaxation of the cros-linked polymers will occur in the core pellets and
the coating layer, resulting in a volume increase that supersedes the
weight increase. The latter will result in a reduced density of the coated
pellets. The time needed to achieve the latter can be called the lag time
needed to initiate floating before the controlled swelling takes place. The 
flexibility of the polymer relaxation is controlled by the plasticiser.
Controlled swelling is critical to avoid the excessive swelling, as this may 
make the system heavier, causing it to sink.
1.4.2. Water uptake and floating strength
In these floating systems, understanding the mechanism of water uptake
is clearly important to understand both the floating profile, but also the
drug release profile. A correlation study by (Chen, et al., 2012) showed
that the water uptake of pellets explains their floating lag time and their 
drug release rate, while the tensile strength of pellets explains their 
floating duration. These findings were regardless of the coating level
applied for the making of the polymeric film/membrane. The film controls 
water permeation. To sum up, at different coating levels, the water 
uptake by the film will affect the floating lag time. Floating strength was 
studied through a customised equipment, noticeably by (Timmermans & 
Moes, 1990), (Strübing, et al., 2008), (Hung, et al., 2014) and reviewed
by (Solanki, et al., 2017). Their work provides additional, supportive, and




       
         
   
   
 
 
           
           
       
       
       
        
         
    
   
       
     
         
        
        
        
       
    
    
        
         
        
The following section will discuss where the gastro-retention is most
desired, based on some specifications that relate highly to the drug
substance of interest.
1.5. Drug Candidates' Requirements for the
GRDDS
1.5.1. General considerations in biopharmaceutics
There are several aspects of the drug substance need to be considered
before selecting the suitable candidate to be formulated into a drug
product. These considerations comply with the emphasis of the
International Conference of Harmonisation (ICH) on with the concepts 
of the pharmaceutical quality by design (QbD), regarding obtaining pre-
knowledge about the drug substance prior formulation. The drug
bioavailability can be affected by the drug product and the physiological
factors, see Figure 1.6
One of the important aspects is the “biopharmaceutics classification
system (BCS)”, which was first introduced by (Amidon, et al., 1995). It 
classifies drugs according to their dosage strength, solubility, and 
permeability, see Table 1.4. Class I drug (drug of high solubility and high 
permeability) is safer and easier to formulate into a modified release
(MR) drug delivery system than other BCS classes. However, if the drug
is poorly soluble but highly permeable (class 2 drug), as with most drugs,
the MR formulation success become more difficult. 
Another classification system was introduced by (Wu & Benet, 2005), 
the “biopharmaceutics drug disposition classification system (BDDCS)”,
where they found that the majority of high permeability drugs (class I
and II drugs) get eliminated by metabolism. Hence, the rate of





             
 
  
   
  






    
 
    
   
   






















sustained drug release 
agents) 
The Route of Drug 
Delivery (e.g. oral, and
parenteral routes) 
Dosage Form (e.g. oral
solid of MUPS tablet, and 
oral solid of conventional























         
          
           
        
          
  
      
      
       
    
          




    
     
  
  
      
 
     
   
         
        
     
           
       
          
       
          
          
        
        
          
       
      
Another aspect considering the drug substance is the Lipinski's rule of
five, to speculate drug permeability. This rule is used to predict the
passive drug absorption from the GIT and to predict the overall drug
properties. The state that a drug is more likely to show poor permeability 
through the bilayer membrane when the drug possess more than one of
the following (Loftsson, 2015).
(1) More than 5 Hydrogen-bond donors,
(2) More than 10 Hydrogen-bond acceptors,
(3) More than 500 g/mole molecular weight (M.wt), and
(4) More than 5 logPoctanol/water.
Table 1.4: The biopharmaceutics classification system (BCS), where drugs classified
based on their solubility and permeability, which related to their water and lipid 
solubility, respectively (Wu & Benet, 2005).
Solubility vs
Permeability
High Solubility Low Solubility
High Permeability Class 1 (Rapid
Dissolution, Biowaiver)
Class 2
Low Permeability Class 3 Class 4
1.5.2. Drug candidate requirements for the gastro-
retentive drug delivery systems (GRDDS)
As an addition to the previous section considerations, the formulation of
a drug as gastro-retentive system is encouraged when either of the
following is evident, the candidate drugs are listed in Table 1.5.
The drug is insoluble at higher pH values, like the pH of the intestine
(pH~ 5.7-7.4), which is evident for some acidic and basic drugs, such as 
diazepam, where GRDDS can minimise the drug precipitation in the
intestine. Unstable drugs at high pH, such as captopril and ranitidine
degrade at high pH, where the GRDD can minimise the drug
degradation in the intestine. Drugs with an absorption window in the
stomach or in the upper small intestine, drugs can have erratic
absorption, which are good candidates for GRDDS, like theophylline.
Drugs acting locally in the stomach diseases: a common product in mind
is the floating liquid alginates (Gaviscon®), which relieve heartburn for 




          
   
    
           
          
           
         
        
          
         
          
           
        
         
     
        
      
        
         
           
         
       
       
         
          
        
        
        
           
     
      
       
(Hamman, et al., 2007). The following characteristics are the drug
candidate requirements for drugs that sustained-release products 
(SRDDS), including GRDDS.
The rate of the drug absorption and excretion should be neither too high 
nor too low, which means at least two hours half-life is required.
Because, a very high dose will be necessary if the drug has shorter than
that half-life. And, also means that not more than six hours half-life is 
required. Because, an inherent sustained action over a long time can be
obtained if the drug has longer than that half-life (Allen, et al., 2005), 
(McConnell & Basit, 2013) and (Prescott & Nimmo, 1979). In a specific 
occasion, the SRDDS can be pursued even if the half-life of the drug is 
high. This is when the purpose of SRDDS is to reduce the adverse effect
of the drug. This is possible as the drug fraction absorbed is flattened, 
where a maintained efficacy within the safe therapeutic window can be
obtained. For example, the L-hyoscyamine causes dry mouth and
impaired vision as adverse effects, and it has a long half-life. The 
SRDDS pellets of L-hyoscyamine can be taken once daily, and it 
maintained the drug in the safe therapeutic window. The latter has 
reduced these adverse effects (Prescott & Nimmo, 1979).
The GIT absorption should be uniform. The varied absorption of drugs,
like theophylline, can be due to their erratic absorption. Therefore,
introducing GRDDS formulation will be necessary to resolve this issue.
The GRDDS is an excellent approach to tackle the bioavailability 
problem, owing to the inconsistent drug absorption. As it offers a great 
control over the dosage form, in terms of both controlling the location
and the timing of drug release (McConnell & Basit, 2013).
The drug should be administered in as relatively small dose formulation
as possible to ease swallowability. Otherwise, the sustained release
formulation will be too large to be easily swallowable, as the sustained
release formulation requires typically higher dose than immediate
release. Pellets, and specifically ensemble pellets are particularly is




     
          
       
          
         
        
             
        
    
therapeutic index (wide therapeutic window), which means that the
therapeutic response will be less sensitive to change with a changing
drug plasma level. Pellets are particularly advantageous when such a
drug need to be formulated as SRDDS, owing to their dose distribution
and uniform coating. The drug should be used for a chronic condition
rather than an acute condition. The acute conditions will usually require
a higher dose and resolved in a short term. Hence, it is not cost effective
to formulate SRDDS formulation for a drug that treat only acute




                 
   
     
 













    
  
  
   
   
      
 









    
  
  
   
  













    
  













     
  
 
Table 1.5: Examples of candidate drugs for GRDDS that have a problematic delivery for different reasons, resulting in their poor bioavailability profiles (Singh
& Kim, 2000) and (Lopes, et al., 2016)
Therapeutic Class Candidate Drug Therapeutic
indication
Reasons for GRDDS Resulting issues if taken in
a formulation other than
GRDDS





Theophylline Anti-COPD; a 
bronchodilator




from the stomach and
the upper part of the
small intestine
Large amount of the dose will
skip the absorption site, owing
to the limited and the variable
transit time in the stomach
Increase the overall drug
exposure to the site of
absorption and the 
bioavailability
Calcium channel Verapamil Anti-hypertensive, More soluble in the Large amount of the dose will Enhance the drug solubility 
blockers (CCBs) anti-angina fasted stomach pH; 
acidic pH media
skip the dissolution site, owing 
to the limited and the variable
transit time in the stomach
and the overall
bioavailability
Dopamine agonist + Bromocriptine Anti-parkinson + anti- Bromocriptine cause Large amount of the dose will Metoclopramide relieves
dopamine antagonist (BC) +
metoclopramide
emetic nausea, and the anti-
emetic acts in the 
stomach
skip the active site, owing to 
the limited and variable transit 
time in stomach
nausea, especially when 
floated in stomach, 








As above Provide high drug
concentration, sustained,
and localised in the 





    
      
     
        
     
          
          
   
     
        
        
        
         
      
     
      
         
          
           
           
        
        
        
        
       
         
      
         
          
        
          
1.5.3. Theophylline as a suitable candidate model drug
i. The therapeutic indications of the drug theophylline
Theophylline (1,3-Dimethylxanthine) drawn in Figure 1.7, is a well-
known bronchodilator. It belongs to the tea alkaloids group drugs and
acts as a nonselective phospho-di-esterase (PDE4) inhibitor. Also, it 
was shown to have a muscle relaxant effect, a cardiac stimulant effect,
and a diuretic effect. Hence, it is used to relieve asthma, chronic
obstructive pulmonary disease (COPD) and bronchopulmonary 
dysplasia (BPD) (Koda-Kimble, et al., 2007). 
ii. The drug theophylline as a GRDDS drug candidate
Table 1.6 is shown the descriptive terms of aqueous solubility, classified
based on the USP solubility criteria. The properties of theophylline are
appropriate for GRDDS, as shown in Table 1.7. Based on the USP 
solubility criteria, theophylline is slightly soluble in water (8.3 mg/ml) 
(BASF, 2009, and Sigma-Aldrich, 2014). 
Based on the biopharmaceutics classification system (BCS), the
maximum oral dose of theophylline in the market (600 mg) need to be 
considered as well. The latter dose need to be soluble in 250 ml or more
in aqueous media over a pH range of 1-8, for the drug to be as highly 
soluble. The 600 mg of theophylline requires only 72.3 ml of water to be
soluble. Moreover, theophylline dose need to have >90% absorption
through lipid bilayer membrane, to be considered as highly permeable
drug (Ashford, 2013). Theophylline did not violate any condition
regarding the rule of five. Therefore, it was considered as highly 
permeable. Hence, according to BCS, theophylline is considered highly 
soluble and highly permeable drug (class 1) (Vo, et al., 2016).
Theophylline (as a Bronsted-Lowry acid) is fully ionized at high pH
(≥10.81), based on its pKa value of 8.81. Theophylline (as a Bronsted-
Lowry base) is fully ionized at pH of -1.3 or lower, based on its pKa value
of 0.7. The latter situations will provide the maximum solubility of the




       
      
            
           
     
        
      
       
         
       
      
     
        
           
      
        
     
         
       
    
        
       
          
       
        
        
           
        
           
            
           
         
   
conditions, because the unionization is desired for the permeability of
the drug. That’s why the drug (as a Bronsted-Lowry base) is partially 
unionized and only slightly soluble at a pH of 1.2 (when the 0.1 HCl is 
used). While the distilled water pH of 5.8 indicates that the drug (as a
Bronsted-Lowry acid) is completely unionized (Aulton, 2013), indicating
a further decrease in solubility. The latter may render the 1.2 pH medium 
to show better dissolution profiles for the drug theophylline, when 
compared to the 5.8 pH medium.
It has rapid absorption orally, and high bioavailability if taken after food.
Hence, food delays gastric transit, resulting in a food-induced gastro-
retention. This food-induced retention is favourable for the drugs of
erratic absorption, such as theophylline, to improve its bioavailability 
profile. Nevertheless, It has an erratic absorption from the duodenum
(Kadono, et al., 2002) and from colon (Mura, et al., 2003), it. It has a
narrow therapeutic window. Sustained release pellets formulation will
significantly reduce the risk of dose dumping. It has no receptor 
desensitisation by its prolonged exposure when used for controlling 
asthma or COPD conditions. The floating system will ensure most of the
drug released to be consistently and primarily absorbed by the
duodenum, to ensure consistent bioavailability.
Drug absorption and bioavailability of drugs, including theophylline, will
also be affected by various physiological and formulation factors, as 
summarised in Figure 1.6. The order of drug release from the dosage
form, like pellets, affect the pattern/mechanism of drug absorption. 
Usually, it can be in either a zero-order rate or first-order rate, according
to the administered dose (Ashford, 2013). The former is concentration
in-dependant owing to the fact that the concentration is dependent on a
retard polymer, while the latter is concentration dependant. The rate of
drug escaping the stomach toward the small intestine will be dependent
on the drug release rate of the GRDDS formulation. The surface area of
the absorption site will affect the drug absorption as well. The common
site, the small intestine, has a high surface area that is desired for 




         
       
      
        
       
 
          
        
 
       




   
  
   
  
 
    
    
   
    
    
     














All of these characteristics of theophylline make it as suitable candidate
model in optimising the floating pellets formulations. Theophylline
properties can be highly suitable regarding the many advantages of
floating pellets. The following section will address the physiological
challenges that are facing the GRDDS, particularly the FDDS.
Figure 1.7: The chemical structure of anhydrous theophylline (empirical formula:
C7H8N4O2, the chemical name: 1,3-Dimethylxanthine, molecular weight 180.16). The
compound is drawn by the ChemDraw.
Table 1.6: The water solubility table, where part per part (ppp) concentration unit 







Solubility range (mg 
ml-1)
Very soluble Less than 1 ≥1000
Freely soluble 1-10 100-1000
Soluble 10-30 33-100
Sparingly soluble 30-100 10-33
Slightly soluble 100-1000 1-10
Very slightly soluble 1000-10000 0.1-1




       
    
       
 
 













   
  
 
       
 
  
   
  
 
    
  
 







   
 
 
   
 













     
  




   
      
  
 











Table 1.7: the drug theophylline properties that impact its bioavailability. 
Property Value Comments Reference
pKa 8.81 it act as both Bronsted
acid and Bronsted base,
that means, it has













7.36 mg/ml in water, 
at 25 Co
Slightly soluble.




















and ~6 mg/ml of
hydrous/stable form
Anhydrous form act as a 
pseudo-polymorph. A 
super-saturated 
solubility, also called 
meta-stable or kinetic 
solubility will last for less 
than a minute, and it is
not likely to affect the 







-0.02 The latter value is










180.164 g/mol It has less than 500 M.wt 
chemical structure.





1 H-bond donor Less than 5 H-donors.





3 H-bond acceptors Less than 5 H-






2 sites of absorption Duodenum (mainly),
and colon (partly). It has
an erratic absorption 
and claimed to have a 
(Kadono, et 
al., 2002), 












    
   
 






   
 
 
    
  




    
 
   



















   
 
   
  




      
    
     
   
          
        
          
         
        








0.45 L/kg in adults 
and 1.0 L/kg in 
neonates lipid 
tissues
It has a low Vd. The
lower the half-life,
because a low Vd 
means the drug is
expected to stay for a 





Protein binding 50-65% in adults,
and 45-50% in 
neonates
The protein binding is
considered moderate. It





Half Life (t half) 6-12 hours in adults 
and 20-60 hours in 
neonates.





Therapeutic 10-20 mg/L The dose regimen (Barnes, 
Range should provide a plasma 
drug profile within this
range
2010)
Dose tolerance Not observed It has no dose
tolerance/dose
desensitisation if used 




Food Effect on Protein-rich diet and Reduced half-life from (Shargel, et 
the Half Life low-carbohydrate,
and charcoal made 
beef.






1.6. Physiological Challenges for the GRDDS in
the Gastro-Intestinal Tract (GIT), with Focus on
the Considerations of Floating Systems
1.6.1. General considerations in biopharmaceutics
For the erratic absorption drugs, the control of the dosage form transit is 
critical, as the dosage form is desired to stay in the stomach for longer 
hours. To achieve that, a gastro retentive formulation design is needed.
However, to avoid foreseeable risks in the formulation design, it is 
important first to identify what can possibly happen to this formulation




           
     
           
           
     
           
       
        
             
         
         
       
      
        
            
            
       
          
        
         
      
 
        
       
          
         
             
        
         
       
have sufficient retention time in the stomach and should overcome the
gastric motility problems. A common problem is the short mean gastric 
residence time (GRT) of 2-3 hours. Hence, the latter short GRT will not
provide the sufficient time to allow for the drug to experience sufficient
duodenum exposure, the desired absorption site for theophylline. That 
will result in a variable absorption, and subsequently, in a variable
bioavailability. The gastric emptying time (GET), the gastric resident
time (GRT), and the gastric emptying rate (GER) are all synonyms for 
the resident time of the dosage time in the stomach (Singh & Kim, 2000).
Moreover, the GRT can be largely varied with many co-occurring factors.
For instance, the occurrence of the fasted state and/or the diseased
state may largely increase the GRT. Hence, this will provide
unpredictable gastric emptying times that vary from few minutes to 12
hours. Therefore, the introduction of a GRDDS formulation design will
control the transit time of the drug product, and subsequently, the transit
of the drug substance. That will control the drug release in terms of
location and timing. The poor bioavailability risk related to the latter 
problem can be tackled and mitigated (Pawar, et al., 2011). Hence, the 
FDDS dosage form should be floated within 15 minutes, and optimally 
within 3 minutes, and should be reached the expansion equilibrium 
within 1 hour (Hung, et al., 2014). 
1.6.2. Gastric emptying process
The gastric emptying time (GET) is highly variable, which is owing to the
following reasons (Ashford, 2013). The various anatomy of the tissue
walls throughout the GIT: the different level of blood supply, types and
level of pores/channels/transporters, and the presence of microvilli, will
all affect the extent and the rate of absorption. Based on the drug
substance, the absorption is dictated by either the passive or the active
permeability mechanisms, according to the transport type that the drug




     
   
      
          
        
          
          
         
        
       
           
        
          
     
          
      
      
            
      
           
              
            
       
          
            
            
        
          
     
 
 
mechanisms with the basic pharmacokinetics involved are detailed
sufficiently by (Loftsson, 2015).
The various chemical and the microbiological constituents throughout 
the GIT. The different concentration of surfactants, acids, enzymes, and
microflora in different locations, will affect the solubility and/or the
degradation of the drug prior absorption. For instance, the presence of
the CYP3A4 enzyme in the gut wall is considered an issue that affects
some drugs, like docetaxel, where the drugs' stability can be highly 
affected prior absorption in the GIT (Thummel, 2007). The fed/fast state
effects (more details are below), the disease state, the genetic make-
up, and gender, will also have an effect on the drug absorption in many 
ways. Also, the difference in the formulation design, dosage form, the 
excipients, will all affect the dosage form emptying, and the subsequent
drug dissolution, and drug permeation/absorption.
In the fasted state, the stomach will follow the inter-digestive myoelectric 
cycle, which is more commonly called the migrating myoelectric complex 
(MMC), which consists of four phases that altogether takes about 1.5-2 
hours to complete, see Table 1.8. In the fed state, the pattern of gastric 
motility differs significantly during the emptying of the gastric contents.
It is due to that MMC phases will no longer be relevant, as the stomach
will not be emptied in the fed state to allow the digestion of its contents.
The housekeeping wave in the MMC cycle will take ~1.5-2 hours to be
reached. However, this housekeeping wave will be delayed in the fed 
state until the food digested are emptied as liquid or semi-solids. That
is, the housekeeping wave will be delayed for 4-10 hours, based on the
meal contents, where a fat meat will delays the wave the most (Singh & 
Kim, 2000) and (Ashford, 2013). Moreover, the ionic content of the GIT
can has an effect on the drug release in either fasted or fed conditions 




      
  
    
   
 
   






    
     
    












   
 
    
  







          
     
           
    
        
   
          
          
       
           
         
       
         
           
         
          
         
             
        
          
       
           
         
Table 1.8: Migrating myo-electric complex (MMC) phases and the GIT in different
states.
MMC phases Stomach transit time
in the fasted state 
(pH 1-2)*
Stomach transit time in the






Optimally, pellets should remain
floated in the stomach for >4 hours. 
i.e. Meanwhile, these MMC phases 
in the fasted state are expected to













Optimally, more than two
housekeeping waves will occur in 
the fasted state without sweeping
off the floated pellets.
4. Transitional
period
A brief period occurs 
between phase 3 and 
1
-
*The total transit time in the stomach is approximately 1.5-2 hour (fasted state),
approximately 4-10 hours (fed state; pH 4-7), and >4 hours for the floating pellets.
The total transit time in the whole gastro-intestinal tract (GIT) is approximately 8-12 
hours (fasted state), approximately 16-24 hours (fed state), and an estimated 16 
hours for the floating pellets mimicking the fed state transit time.
1.6.3. Food-induced variability in gastric emptying
As evident in the previous section, the food is considered to be a major 
factor in delaying the GRT and could be even more detrimental than the 
floatability of the formulation and its gastro-retention. Unlike floating
tablets, the floating pellets, once sink, they will escape to the small
intestine when the stomach is under the inter-digestive state; the fed
state. The latter is because that the pylorus sphincter opening will be
smaller in the fed state, but not entirely closed, allowing for the small
units of <2 mm to escape as the liquid transit (Padfield, 1989) and
(Davis, 2005). Therefore, the emptying of pellets from the stomach is 
not seemed to be affected by the fed/fasted state. In conclusion, the
pellets will allow the dosage form to have a superior self-control on its 
transit, and the emptying will not be limited by the fed state presence.
Also, the latter advantage of pellets is more of particular importance to
the enteric delivery of a drug, to avoid the premature drug release as the 
dosage form is interacting with the less acidic medium of the food
(Padfield, 1989). Food can also interfere indirectly, raising the pH of the




        
       
          
        
   
          
           
            
     
        
       
         
         
        
          
         
        
        
      
  
      
          
          
        
       
      
       
        
     
       
      
       
(2) the effervescence reaction of FDDS. These problems can be
mitigated by incorporating an acidifying agent. Alternatively, starter inert
core pellets of citric acid or tartaric acid can be used instead of the sugar-
pellets. These options will provide an acidic microenvironment inside the
dosage form.
Moreover, if the floating formulation is of non-effervescent type, then it
will have food independent property. It will allow the dosage form to float
in the stomach in either the fed state or fasted state. That will improve
the patient compliance, especially for patients with irregular eating
habits. Therefore, in this regard, the effervescent mupFDDS design will
be compared to the non-effervescent mupFDDS design, using acidic-pH 
and water-pH media as seen in this project. The food also delays the
onset of peristaltic contraction in the stomach, ensuring that there is a 
no-premature emptying of floating pellets. That is because the nervous 
system has an effect on the stomach emptying process, based on the
fast/fed state (Singh & Kim, 2000) and (Ashford, 2013), as seen by the
MMC phases in Table 1.8. The following section will address the
materials used in the project for composing the floating pellets.
1.7. Introduction to Materials as the Excipients in 
Floating Pellets
Microcrystalline cellulose (MCC) is a non-disintegrating excipient that is 
commonly used to produce pellets. During the wet mixing, the MCC
polymer can enhance the water distribution in the moist mass, that result
in a consistent wet mixing process (DFE-Pharma, 2011). The water 
distribution enhancement is due to many desirable properties that MCC
possess; namely, it induces consistent cohesiveness, water retention,
and water release. That is favourable for high binding property that
allows for high drug loading. Also, that makes it a water retentive
material that tolerates various stresses of processes after the wet
massing and/or granulation step. That is, it provides sufficient
rheological properties like plasticity, which allow for consistent re-




         
        
        
          
        
          
        
         
          
        
         
       
          
       
          
      
         
       
         
        
            
          
     
          
       
       
     
        
           
        
          
          
         
process, such as extrusion and spheronisation processes (Jain, et al.,
2010). Although MCC is still considered the most desired spheronisation 
aid, it has some limitations, thus other alternative aids like the co-
processed MCC and cros-PVP are used. The limitations claimed are the
adsorption of drugs, deactivation of drugs like ranitidine, and may incur 
long dissolution time (Jain, et al., 2010). Most drugs have the ability to
be loaded in MCC at a loading of 40-60%. To justify the MCC use as a
cushioning material, the literature stated that the lyophilised pellets of
high MCC content were shown to be protective, inert, and highly 
compressible cushioning aid (Habib, et al., 2002). Also, blending an
organic solvent with an aqueous solvent, such as ethanol with water, to
be used as a liquid binder was previously shown to form MCC granules 
that cushion and better protect the coated pellets (Vladyka, et al., 2005).
In hydroxyl propyl methyl cellulose (HPMC) polymers, a low molecular 
weight HPMC can be used in coating solutions as a binder. It ensures 
the deposition of other accompanied and functional molecules is 
achieved. For instance, it allows the deposition of drug molecules on the
surface of the solid agglomerates or compacts (Sungthongjeen, et al.,
2006). On the other hand, the high molecular weight HPMC, which is a
highly cros-linked polymer, tends to be more viscous and less soluble in
water. In this project, it is used in the swelling system as a hydrocolloid
swelling agent. During wet massing, it ensures that the cores can have
a higher swelling capacity that may potentially provide a non-
effervescent floating aid (Sungthongjeen, et al., 2006). Also, it is known
that as its viscosity increase, the gel-forming ability increase, resulting
in more prolonged drug release (Kadajji & Betageri, 2011). The poly-
ethylene-glycol (PEG) polymers are used for various functions, and 
some were used for advanced purposes, like the so-called
PEGylayation, which was first proposed in the late 1970s, to improve the
selectivity of the drug to the desired physiological receptors (Kadajji & 
Betageri, 2011). The one of interest here for floating pellets is PEG 6000
polymer, which was prepared with the HPMC polymer, to improve the




           
         
        
          
            
        
             
          
     
      
        
        
         
          
          
          
         
            
     
         
    
       
       
      
        
       
            
        
     
withstand the volume expansion upon fluid absorption. That is, it is used
as a plasticiser in the coating solution (Sungthongjeen, et al., 2006).
Sodium bicarbonate (NaHCO3) is a carbonate salt, which upon exposure
to an acidic medium, will undergo a neutralisation reaction, results in the
generation of a gas, the carbon dioxide (CO2). Hence, it is used as a
gas-generating agent, where it first mixed with a non-acidic coating 
solution, then sprayed on the surface of the core pellets, to make a sub-
coat layer. Alternatively, it can be wet-mixed in a non-acidic wet massing
liquid along with other powders to make the core pellets 
(Sungthongjeen, et al., 2006). The low molecular weight poly-vinyl
pyrrolidone (PVP) is commonly used in the wet granulating liquid as a
binder for the powder bed, or in the coating solution for the coating
materials (Kadajji & Betageri, 2011). It is also used in the wet massing
liquid as a liquid binder (Qi, et al., 2015). In this project, a low molecular 
weight grade has been used, the 44,000 g/mole, to potentially allow for 
the PVP swelling to occur in the core pellets. The crospovidone (cros-
PVP) is used as a super-disintegrant to allow for a fast disintegration of
a tablet. Also, it is used as a solubiliser, a swelling agent, an alternative
spheronisation aid, and many other functions (Jain, et al., 2010). Here,
it is used as a swelling agent, to examine whether there are any 
differences in the resulting pellets quality.
The poly-meth-acrylates (PMAs) is a polymer can be made in a wide
range of grades of different quaternary ammonium groups, which will
allow for different water permeability. There are closely related
derivatives of polymers that have different properties, like the different
pH-dependant solubility, that can allow for an enteric drug delivery 
(Evonik, 2017). It is used here to restrict the gas release and the drug
release, to allow for gastro-retention and sustained drug release,




   
  
      
          
          
         
           
       
       
        
          
 
         
          
     
        
     
    
         
       
         
           
      
         
        
        
       
         
   
 
1.8. Introduction to Preparation Processes of 
Floating Pellets
The techniques have various technological concepts, many of which
were long used in literature and the pharmaceutical industry. The aim 
here is only to shed light for some of the conventional and available
pelletisation techniques. An overview for the processes involved is seen
in Figure 1.8. The several aspects of some of these methods on the
floating pellets systems will be elaborated in the results chapters. As 
with many other dosage forms, during the floating pellets development,
the drug dissolution is considered a major characterisation process. The
dissolution science itself has an origin since the late 19th century.
1.8.1. The related granulation techniques
Granulation processes are divided into two main categories, dry and wet
granulations. The wet granulation is also sub-classified into fluid bed and
shear granulations. Moreover, the shear granulations are either high or 
low shear granulation methods. The interest in this project is the low-
shear granulation method, as seen next page.
i. Wet granulation processes
The wet granulation processes are classified into two main categories,
as follows. Fluid bed granulation, is where the mechanism of granulation
is through the nucleation and granule growth. The viscosity of liquid
binder should be low and thus more fluid is needed, due to the spraying
requirements. Shear granulation, is where the mechanism of granulation
is through wet massing and granule growth. The viscosity of liquid binder 
should be higher and thus less fluid is needed. The high viscosity liquid
increases the shear stress during wet massing, to improve granule
properties and powder mixture homogeneity. It can be regarded as 
either high or low shear granulation, based on the mixing speed applied




                                    
 
                      
 
 
                                        
 
 
     
     
            
       
         





      
       
 
  
           
Planetary Mixer (Kenwood) Radial Extruder (Caleva)
Oven Drying
Top-Bench Spheroniser (Caleva) Top-Spray Mini Coater/Drier (Caleva) 
Oven Drying 
Single-Punch Tabletting Machine (Manesty) Filling into Gelatine Shell Capsule*
Figure 1.8: summarises the steps that conducted in this project for the overall process 
of making the coated pellets, where the pellets will be either filled into a capsule or
compressed into a tablet. The shown images are similar to the equipment used in this
project. *The scale-up of the capsule filling should consider the pellets feeder attached 
to the capsule filling machine. (Images were taken from the respective companies, 
except that the tabletting machine image is taken from the gracesguide.co.uk, and the




    
       
           
         
            
      
          
          
     
         
  
        
         
      
     
      
        
          
   
          
             
        
         
       
          
     
     
          
  
ii. Low shear wet granulation process
The low shear granulation process consists of two main mechanisms,
as follows. The ‘wet massing’ is where the moist-sand wet bed will be
formed. The wet mass can be produced using mixers with kneeling
ability. That is, it can be obtained by a mixer of a convective mechanism,
such mixers are the planetary, ribbon, screw, or paddle mixers. The 
‘densification and granulation’ are where the agglomeration will result in
the granule growth. The granules can be produced using an oscillating
granulator or gear role granulator. Granules are slightly elongated in
shape with a smooth, but porous surface (Aulton & Summers, 2013).
1.8.2. The pelletisation techniques
Pelletisation process can be considered as a specialised wet granulation
technique. The word pelletisation in the context of the pharmaceutical
manufacturing was defined by (Ghebre-Sellassie, 1989) as follows: “It is 
an agglomeration process that converts fine powders or granules of bulk 
drugs and excipients into small, free-flowing, spherical or semi-spherical
units, referred to as pellets”. Historically, the interest in pelletisation or 
spheronisation for the pharmaceutical use can be traced back to the late
9th century.
However, in the late 19th century, the advent of tablets and capsules 
supersedes the spheres making to a great extent. In the mid of the 20th
century, the spheres become an interest again for the pharmaceutical
use. Although the extrusion and spheronisation method was used in
other industries, the pharmaceutical industry took time to apply it. The
interest in pelletisation re-emerged in 20th century due to the increasing
demands for efficient sustained drug release systems (Ghebre-
Sellassie, 1989). The pelletisation mechanisms including relevant






     
   
    
       
     
         
         
       
           
        
    
         
       
         
     
        
        
        
        
        
         













































Figure 1.9: shows the pelletisation mechanisms (like compaction) and the relevant 
techniques (like compression).
The used pelletisation techniques or methods for making the
pharmaceutical floating pellets, are described below, but not necessarily 
limited to the following (Kumari, et al., 2013).
i. Extrusion and spheronisation: this is where the wet mass will be
extruded, then extrudates will be spheronised. It is the most popular and
well-established method for making the pharmaceutical pellets, and
arguably, one of the most desired methods. It is widely used in industry,
as it simplifies plant procedures and reduces cost (Caleva, 2015). In this 
method, the optimisation of the liquid binder is considered highly 
challenging (Chu & Chaw, 2012), (Puah, et al., 2013) and (Garekani, et
al., 2013). This method is used in this project. Therefore, more details 
about this method will be seen in the upcoming section.
ii. Direct spheronisation or high-shear granulation: this is where
agglomerates are formed from the wet powder through the use of rotary 
fluidised bed granulator, or formed from a suspension by a spray dryer.
Then, followed by a subsequent size enlargement until these
agglomerates reach the size range of a micro-pellet (<500µm) or a milli-
pellet (0.71-1.18 mm) (Aoki, et al., 2015) and (Srivastava & Mishra,




       
 
         
         
           
       
         
          
          
        
        
            
     
        
        
    
     
    
       
           
         
      
            
 
      
      
         
        
          
        
granules in a spheroniser, skipping the extrusion process (Sawicki & 
Łunio, 2005).
iii. Hot melt screw extrusion: this is where powders are melted and mixed 
gradually with the use of a screw, then the homogeneous melt is 
extruded as a thin and long thread-like melt. A cutter is used to chop the
melt into spherical pellets. This method is increasingly common in the 
research, as it claims easier processing (Vo, et al., 2017), which will
ease the pilot scale formulation development (Hossain, et al., 2017).
iv. Inert sphere layering: this is where inert starter pellets, which are the
commercially pre-made pellets, will be used for drug and functional
coatings. The formulator here will only focus on optimising the coating
of these pellets. Because the drug has to be layered on these inert
cores, this method usually requires at least double-layers design,
regardless of the drug delivery system required. It is also considered a
common method of pelletisation (Pagariya & Patil, 2013), (Amrutkar, et
al., 2012) and (Hosseini, et al., 2013).
v. Emulsion-solvent diffusion and evaporation: this is usually by 
evaporating solvent from either emulsion/suspension of microparticles 
or soaked microparticles (Streubel, et al., 2006). It is usually by forming
an oil in water (o/w) emulsion, then forming a shell through the rapid out-
diffusion of ethanol, followed by generating a gas phase through the
diffusion and evaporation of dichloromethane. Finally, micro-balloons 
will be formed because of the hollow sphere formation (Streubel, et al.,
2006).
vi. Cross-linking, ionic gelation or coacervation, with or without
lyophilisation: this it is where a heterogeneous polymeric solution and
drug solution were mixed, then poured in a drop-wise manner into a 
cross-linking solution of, e.g. calcium hydroxide, resulting in the
formation of the wet matrix pellets. Those pellets can be frozen, then




        
     
 
   
        
         
            
         
        
        
        
         
         
          
        
     
        
        
       
         
     
       
     
          
       
    
 
 
into the sublimation phase, resulting in the lyophilised pellets (Murphy,
et al., 2012) and (Thomas, et al., 2012).
1.8.3. The extrusion and spheronisation
i. Packability of particles
In the extrusion and spheronisation process, water/liquid binder uptake
by the powder during the wet massing is known to be critical. A study by 
(Sarkar, et al., 2013) showed that during the wet massing process, a
critical factor was found to be evident, the particles packability, which is 
the arrangement of particles components. Packing was correlated to the
cohesive strength of the agglomerates. As the shear forces applied to
the wet mass, the coalesced particles integrity and re-shaping ability can
be determined. Packability was found to be affected by and affected on
the spheronisation of the extrudates into pellets. Hence, it affects the 
production yield of the narrow size distribution of pellets.
ii. Growth mechanisms of pellets by the high shear wet granulation
There are different proposed mechanisms for pellets growth/formation,
some of which can happen simultaneously. The mechanisms involved
in the high shear granulation methods are of some to little relevance to 
the other methods of palletisation, like the extrusion and spheronisation
method. Nevertheless, the latest view for the high shear granulation
proposes several steps for pellets formation, which are nucleation,
coalescence, layering, and abrasion/mass transfer. In contrast, the
pellets size reduction mechanisms include attrition, breakage, and/or 
shatter (Muley, et al., 2016), see Figure 1.10. The size reduction in
pellets should not exceeds the pellets growth, to allow for producing





           
       
    
       
         
          
     
        
        
            
      
        
        






           
        
      
     
         
  
  
Pellets Growth Pellets Breakage
Figure 1.10: Pellets formation mechanisms (a. nucleation, b. coalescence, c. layering,
d. abrasion transfer) and size reduction mechanisms (e. attrition, f. breakage, g.
shatter) from the high-shear granulation methods (Muley, et al., 2016). 
iii. Wet massing (a low shear wet granulation process)
The wet massing was undertaken by the use of a planetary mixer, or 
less commonly by the use of a screw mixer (Puah, et al., 2013) and (Chu
& Chaw, 2012). The phases of wet massing involve the solid-liquid 
interactions, namely, the pendular, funicular, capillary, and droplet
phases, see Figure 1.11. The pendular phase has the lowest spreading 
of liquid binder, while the droplet phase has the highest (Sakr, et al.,
2012). The capillary phase is considered the optimum phase for a
consistent wet mass (Muley, et al., 2016). The wet mass consistency 
can be measured qualitatively by the hand squeeze method, and 
quantitatively by the powder torque rheometer.
Under wetting Desired wetting Over wetting
Solid molecule
Liquid molecule
Figure 1.11: The solid-liquid phases during wet massing, prior extrusion and
spheronisation. Left to right: pendular, funicular, capillary, and droplet phases. The 




       
     
          
     
        
         
   
         
        
        
     
       
        
         
           
           
     
        
       
       
           
      
      
          





iv. Extrusion (a special type of wet granulation)
The pharmaceutical extruders come with different configurations that
can have different effects on the intermediate and the final product
attributes. Figure 1.12 summarises the common extruder configurations.  
Main configurations are listed, but not necessarily limited to the following  
(Muley, et al., 2016), (Aulton & Summers, 2013), (Mehta, et al., 2005)
and (Ghebre-Sellassie, 1989).
Basket or gravity-feed extruders, where the wet mass is fed into rotating
roll or radial arm, which compresses the bed against an oscillating
cylinder roll, gear roll, or a ring screen that configured for a specific 
perforations size. The gravity-feed rotating radial arm extruder of two 
oscillating rolls was used in this project. The two oscillating rolls oscillate
against the perforated ring screen. The screen comes with or without a 
cutter, to cut extrudates into even lengths. Radial extruder may be seen
as a sieve extruder, owing to the specific and even dimeter of the screen
openings. In addition to the gravity-feed design, a radial extruder can be
also configured as a screw-feed design.
Screw-feed extruders, where the powder is mixed with a liquid binder,
then the wet mass was forced by a single- or twin- screws against
uniform openings. It comes with different designs like the axial, the 
dome, and the radial designs. It also comes with different blades, axial
blades like the non-continuous and continuous blades. And radial blades 
like the conical-blade and the intermeshing-blade. Ram or piston-feed 
extruders, where the wet mass is fed into a piston inside a cylinder or 





    
      























Figure 1.12: The extruder configurations used in the extrusion/spheronisation method. 
Gravity-feed radial configuration was used in this project. The one shown here has 
some differences from the actual one used, the latter stated in the text. The image





        
            
          
        
       
      
     
       
          
          
         
      
     
            
        
  
         
       
      
      
      
      
         
     
       
      
        
v. Spheronisation (a special type of wet granulation)
The typical pellets size is 0.71-1.4 mm. A disc/plate with a rotating drive
shaft is used. It can be called as round, spinning, or friction plate. It spins
at a high speed in the bottom of a cylindrical bowl. The plate has grooves  
from its cross-hatched (waffle iron) or radial designs of different sizes.
These grooves allow for an increasing friction against the extrudates,  
where the spheronisation occurs (Caleva, 2015), (Aulton & Summers,
2013) and (Ghebre-Sellassie, 1989), see Figures 1.13-14.
The rod-like extrudates (maybe also called as granules, or cylinders)
were placed on the plate, and cut into segments as the plate spins. Then 
the segments collide with the bowl wall and then thrown back to the
centre. Hence, the latter movement will likely result in the rope-like
motion along the bowl wall. The segments will be gradually rounded by 
the collisions with the bowl wall and the plate, and of each other (Caleva,
2015). The rope-like motion around the edge of the bowl is needed to
facilitate the friction, which is required for the spheronisation to occur 
(Caleva, 2015).
The extrudates are expected to be plastic enough to allow the
deformation into spheres. The extrudates deformation is expected to
occur upon the impact and collisions they receive during spheronisation. 
Powdering or dusting can occur if extrudates were too plastic, while 
sticking and dumbelling can occur if extrudates were not plastic enough. 
The mixer torque rheometer can easily, accurately, and quickly measure
and optimise the plasticity of the wet mass prior extrusion and
spheronisation (Caleva, 2015). The spheronisation mechanism of
extrudates was proposed with different variations, where the common
phases are the cylinder, dumbbell, and spheres formations (Muley, et





     
              
 
 
       
  
 
Figure 1.13: The sphernisation plates used in the extrusion/spheronisation method.
Waffle iron pattern was used in this project. The image obtained from (Caleva, 2015).






          
       
   
 
        
          
  
       
      
         
        
       
        
        
          
        
          
        
        
     
        
       
       
Figure 1.15: The spheronisation mechanism of extrudates, where shape evolution into
pellets is illustrated. (A) proposed by (Rowe, 1985), while (B) proposed by (Baert &
Remon, 1993).
1.8.4. The coating techniques
Different coating techniques are available for coating pellets, they are
listed, but not limited to the following (Srivastava & Mishra, 2010):
i. Fluidised bed (FB) coating
The fluidised bed coaters can come with different spray configurations 
that greatly dictate the coating process efficiency. The most commonly 
known configurations are as follows. Top spray, using, e.g. Caleva mini
coater/dryer, which is used in this project. Among other variables, the
variables involved in the top-spray FB coating process were of high
importance in obtaining fully functional pellets. Most factors involved in
the top-spray fluidised bed coating process are important to the coating
efficiency as well as to the function of the floating pellets. To examine
the importance of the coating process factors and all the other factors 
involved in the making of the floating pellets, see the risk analysis 
section 3.2 in chapter 3. Bottom spray, also called Wurster spray, it is 
where the first film-coated tablet was made. Wurster is the configuration
of choice for pellets coating, using, e.g. a Glatt Wurster HS coater, or 
Precision and Supercell™ coater of GEA. The third configuration of FB 
coater is the tangential spray. The FB coating is more relevant for the 




        
       
      
  
            
     
      
         
         
      
       
         
       
      
          
   
 
          
       
      
        
          
         
      
        
   
       
       
         
          
       
          
advantageous in terms of providing a discrete coating. The latter can
decrease the agglomeration risk and provide a uniform deposition of the 
droplets on the pellets' surfaces (Porter, 2013).
ii. Pan coating
Similar to the fluid bed coaters, the pan coaters can come with different
spray configurations that greatly dictate the coating process efficiency.
The most commonly known configurations are as follows. Tapered
cylindrical pan, where spray guns are mounted in the front opening,
while the drying and exhaust air are from the rear opening, using, e.g. 
Pellegrini coater. This type suffers from poor thermal contact and poor 
coating finish (Cole, et al., 2002). Perforated rotary or side-vented rotary 
pan, where both spraying and aeration are from the same opening,
which provides better heat and mass transfer, and better coating finish,
using, e.g. Manesty Accelacota, Driam Driacoater, and a Glatt coater 
(Cole, et al., 2002). Also, another example in the market is the Premier 
500 coater of Bosch.
iii. Dry powder coating
This will eliminate or largely eliminate the need for the liquid in coating,
resulting in reduced operational cost, safer processing for the moisture-
sensitive materials like the amorphous solids, and allow for better 
identification of counterfeit medicine (Sauer, et al., 2013). Recent
advances in this field are evident, as the introduction of the novel one-
step micro/nano-particle coating technology, which is now in the market
by (Smith, et al., 2016). Several types belong to the dry powder coating
category (Sauer, et al., 2013), such as liquid-assisted coating, thermal-
adhesion coating, and electrostatic coating.
Different coating techniques and configurations, along with other coating
process factors and coating solution factors, can greatly affect the
tendency toward coating defects. Defects can be in the form of blisters,
flakes, cracks, and pinholes. The coating defects can result in pre-
mature/sudden drug release from the cores upon exposure to the 




           
        
        
         
  
  
      
         
     
          
         
      
        
         
           
       
       
        
           
        
      
     
    
           
           
        
          
         
          
          
          
       
be at high risk when such defects present in the coated dosage form.
The thermal effects of the curing process are controversial, as some
studies showed that curing of coated dosage form might increase,
decrease, or have no effect on the drug release profiles (Bhattacharjya
& Wurster, 2008).
1.8.5. The tabletting techniques
Different tabletting techniques are available for tabletting the coated
pellets. They are listed, but not necessarily limited to the following
(Alderborn, 2013). Eccentric tabletting, where a single-punch press is 
used, and has one die and one pair of punches. It is used during the 
formulation development and for the clinical trials production, with up to
~200 tablets per minute when automated. This method was of particular 
interest, as this project involve using small samples, which justify its use
in this project. The compression force is considered the most important
factor in the tabletting of the floating pellets. The compression force in
the tabletting process is considered an essential process variable that
can significantly affect the quality attributes of the final formulation
(Alderborn, 2013). Rotary tabletting, where a rotary press, which is also
called a multi-station press. It is used during the scale up with as 
minimum presses as three, and used during the large production with
as many presses as 60 or more, with over 10,000 tablets per minute. It
results in fast and cost-effective production.
Hydraulic tabletting, where a computerised hydraulic press is used, 
which is also called a compaction simulator. It is used in the research,
where it can mimic the loading pattern of the production presses. Hence,
it will further facilitate the tabletting scale-up for proactive risk mitigation.
Hand-held tabletting, where a hand-size press is used. It can be used in
the early risk assessment stage, but, there is no evidence yet for its use
as a reliable and an accurate method of prediction. The method lack 
control on the compression force, as it only relies on the hand strength.
Example is the Vice handheld press (LFA, 2017). The following section




    
   
        
         
           
      
     
         
   
       
         
       
        
        
      
     
       
1.9. The Marketed GRDDS, MUPS Tablets, and
MUPS Capsules
There are several marketed gastro-retentive systems, and more
noticeably, the floating systems. Most of the floating systems on the 
market are based on the presence of an effervescent, see Table 1.9. 
Also, other marketed gastro-retentive systems and pellets systems are
seen in Tables 1.10-11, respectively. 
As seen in Tables 1.9-10, there is no clear statement that these dosage
form contains pellets intended for floating or for any other gastro-
retentive mechanism. Moreover, there is no marketed gastro-retentive
dosage form for the drug theophylline in the market. As seen in Table
1.11, there are dosage forms that contain pellets for the drug
theophylline, which are filled into capsules or compressed into tablets.
However, the manufacturers of the latter dosage forms did not clearly 
state whether these pellets are intended for gastro-retention or not.
Examples of the marketed products of theophylline loaded pellets 





     
     
 
   
           
            
    
  
        
  
 
       
 
    
           
           
            
       
 
     
 
   
   
  
 
   
   
 
     
   
  
 









   
   
  
 
           
   








   
   
             
    
 
        
 
    
   
              
Table 1.9: Marketed floating systems.
Brand name Generic name Therapeutic
indication
Formulation design Manufacturer Reference
Zanocin OD Ofloxacin Infections Effervescent floating system Ranbaxy, India (Pawar, et al., 2011)
Riomet OD Metformine HCl Diabetes Effervescent floating system Ranbaxy, India (Pawar, et al., 2011)
Cifran OD Ciprofloxacin
Ranbaxy India
Infections Effervescent floating Form Ranbaxy India (Pawar, et al., 2011)
Prazopress XL Prazosin HCl Hypertension Effervescent and swelling-based
floating system
Sun Pharma, Japan (Pawar, et al., 2011)
Metformin HCl LP Metformin HCl Diabetes Minextab Floating® Galenix, France (Pawar, et al., 2011)
Cafeclor LP Cefaclor Infections Minextab Floating® Galenix, France (Pawar, et al., 2011)
Tramadol LP Tramadol Severe pain Minextab Floating® Galenix, France (Pawar, et al., 2011)
Baclofen GRS Baclofen Sun Muscles
Relaxant
Coated multi-layer floating & swelling
system





Floating, CR capsule. Its advantage: 
reduce motor fluctuations.
Roche, UK (Singh & Kim, 2000), (Pawar, 
et al., 2011)




Effervescent floating liquid alginate 




(Singh & Kim, 2000), (Pawar, 
et al., 2011)
Valrelease Diazepam Anxiety Floating capsule Roche, UK (Singh & Kim, 2000), (Pawar, 
et al., 2011)








(Singh & Kim, 2000), (Pawar, 
et al., 2011)
Conviron Ferrous sulfate Iron deficiency Colloidal gel forming FDDS Ranbaxy, India (Pawar, et al., 2011)
Almagate Flatcoat Aluminum
magnesium 
Heart burn Floating liquid form. Its active act as a 
floating agent.
- (Singh & Kim, 2000), (Pawar, 
et al., 2011)





        
        
   
 
    









     
   
 
     





        
            













Table 1.10: Marketed gastro-retentive systems other than or not clearly stated as floating systems (Pawar, et al., 2011).
Brand name Generic name Therapeutic indication Formulation design Manufacturer
Gabapentin GR Gabapentin neuropathy Polymer-based swelling technology:
AcuForm™ (In phase three clinical trial)
Depomed, USA
proQuin XR Ciprofloxacin Infections Polymer-based swelling technology:
AcuForm™
Depomed, USA
Glumetza Metformin HCl Diabetes Depomed, USA
Metformin GR™ Metformin HCl Diabetes Depomed, USA
Kadian Morphine sulfate Severe pain — Sumitomo Pharma, Japan
Cipro XR Ciprofloxacin hydrochloride
and betaine
Infections Erodible matrix based system Bayer, USA
Accordion Pill TM - - Expandable film filled in capsule Intec Pharma




         
         
   
 
   
 
       
   
 
       
         
        
           










          
       
       
 
 




       
  
    
 
   
 
        





     
   
  
      
  
 
            
 
                 
Table 1.11: Marketed pellets-containing tablet or capsule (MUPS tablets or MUPS capsules).
Brand name Generic name Therapeutic indication Formulation design Manufacturer Reference
Losec MUPS Omeprazole
magnesium
Peptic ulcer, gastro-esophageal reflux 
disease (GERD)
Enteric release tablet Astrazeneca (Tan & Hu, 2015)
and (Chen, et al., 
2017)Nexium Esomeprazole
magnesium
Peptic ulcer, GERD Enteric release tablet Astrazeneca
Prevacid Lansoprazole Peptic ulcer, GERD Enteric release tablet Takeda
Betaloc ZOK Metoprolol succinate Hypertension (HTN) tablet Astrazeneca
Harnal D Tamsulosine HCl Prostate hyperplasia and HTN - tablet Astellas




(Chen, et al., 2017)





Theo-Dur* Theophylline Asthma, bronchitis and emphysema - Key Pharmaceuticals
Liallda Mesalamine Ulcerative colitis - Shire
K-Dur Potassium Hypokalemia with or without metabolic
alkalosis in digitalis intoxication or in 
familial periodic paralysis




Peptic ulcer, GERD Pulsatile release tablet
Alvogen Malta
Operations Ltd





Peptic ulcer, GERD Delayed release tablet AstraZeneca





Nasal congestion Extended release tablet
Merck Sharp and
Dohme Corp
Oracea Doxycycline Infections Delayed release capsule
Galderma Laboratories
Lp
Elixophyline* Theophylline Asthma, bronchitis and emphysema Sustained release capsule Actavis plc (Hamman, et al., 
2017)





      
       
       
      
         
        
  
        
        
       
     
        
           
    
      
      
         
   
        
  
        
         
            
        
         
     
      
        
     
        
     
1.10. Pharmaceutical Quality by Design (QbD)
In this project, only the risk identification and the risk analysis (sub-
categories of the risk assessment) were conducted per QbD, where the
risk evaluation was based solely on the minimal approach of
development. Hence, no statistical design of experiments (DoE) studies 
were conducted in the thesis. For future remarks, the DoE section 1.10.3 
will serve as a guidance for the optimisation work during scaling-up 
manufacturing.
The total quality management (TQM) provides a plethora of concepts,
where the QbD is seen as a sub-topic. The TQM is noticeably resourced
by the collaborative approach of Six Sigma (6Q) movement, which is 
known for its business advantage across the various industries. One
useful resource that widely recommended for a brief understanding of
6Q is the pocketbook of (George, et al., 2005). For the QbD in pharma,
many resources are available from regulatory documents, quality books,
published quality papers, as well as from the advanced software
knowledge that applies the quality concepts and tools. A recent book 
that give a practical approach to the pharmaceutical QbD is 
(Schlindwein & Gibson, 2018).
1.10.1. An overview of the QbD approach for the
pharmaceutical development
Quality by design can be defined merely as a strategic approach to
quality, where a proactive thinking is paramount. Although the QbD
implementation will be of high cost initially, it is expected to reduce the
long-term costs, as the needs for the troubleshooting are expected to be
minimised (Zhang & Mao, 2017). Unlike end-testing the quality, the QbD
concerns with the continuous improvement, via a continuous and 
structured understanding of process attributes and product attributes.
This proactive quality work will provide the privilege of being more
informative about the unforeseeable risks (Zhang & Mao, 2017). In 
2003, the US Food and Drug Administration (FDA) launched the current




       
       
      
         
        
            
           
     
      
      
     
            
     
       
      
     
 
        
      
       
     
        
   
           
     
    
      
       
   
   
comparable version to the International Conference of Harmonisation 
Quality 6 document (ICH Q6). The cGMP launch along with other quality 
documents have increased the awareness toward obtaining the higher 
level of quality assurance in all stages, from the research and
development to the large-scale manufacturing. Some common and
some tailored tools can be used in accordance with the stage of the
product lifecycle (Zhang & Mao, 2017). After that, the ICH set up the so-
called the enhanced quality by design (QbD) approaches for the
pharmaceutical development and manufacturing. Where the ICH
encourages the adoption of the QbD approaches over the
minimal/traditional approaches, for the pharmaceutical development
(ICH, 2009), see Figure 1.16 The main documents of interest in the ICH
quality guidelines for the QbD initiative are as follows:
i. ICH Quality 8 (Q8): Pharmaceutical Development (PD) guidelines.
ii. ICH Quality 9 (Q9): Quality Risk Management (QRM) guidelines.
iii. ICH Quality 10 (Q10): Pharmaceutical Quality System (PQS) 
guidelines.
The QbD defined by the Q8 as "a systematic approach to development
that begins with predefined objectives and emphasizes product and
process understanding and process control, based on sound science
and quality risk management (QRM)". The detailed implementation of 
QbD was discussed by Q9 (ICH, 2005) and Q10 (ICH, 2008). The quality 
risk management process (QRMP) summarises the major umbrellas of
the QbD work, see Figure 1.17. The QRMP also involves the application
of the process analytical technology (PAT) tools. The QRMP categories
consists of the following:
i. The risk assessment: for the process and product development, which
is the main focus in the work of this project.
ii. The risk control: for the control strategy development.




        
        
         
    
       
    
        
       
        
      
      
        
      
          
          
        
         
        
        
         
           
      
         
      
         
         
         
       
          
       
       
The risk assessment defined by the Q9 as “an assessment that consists 
of the identification of hazards and the analysis and evaluation of risks 
associated with exposure to those hazards” (ICH, 2005). The risk 
assessment consists of the following:
i. Risk identification: for identifying all potential factors, using, for 
instance, the Fishbone diagram tool.
ii. Risk analysis: for analysing all potential factors, to select high-risk 
factors, using, for instance, the failure mode effect analysis (FMEA) tool.
iii. Risk evaluation: for evaluating the outcome of high-risk factors, using,
for instance, the design of experiment (DoE) tool.
The various process and formulation factors in the cores making,
coating and tabletting of floating pellets will urge the needs for risk 
assessment study per QbD, that will not only offer systematic 
understanding but also will ease the scale-up of the floating pellets for 
the pilot and production scales. The risk assessment will be based on 
the literature and the preliminary/screening experiments, in attempts to
select and initially assess the high risk factors. These factors to be
further tested in the enhancement and optimisation studies, where the 
updated risk assessments can be obtained (ICH, 2009). The aspects of
early on planning and the set-up of experiments in the risk assessment
stage are considered the backbone of the QbD. It is where the proper 
risk analysis can be ensured as viewed by many regulatory agencies,
like FDA and ICH, as the most important stage. Therefore, collecting
good data from pre-knowledge in literature and preliminary experiments 
is vital for obtaining a solid risk assessment (Hand, 2008) and (Eriksson,
et al., 2008). The risk analysis will allow the selection of best factors and
factors settings to build the DoE model. The DoE model will provide an
experimental worksheet, where then it allows for the results from these
experiments to fit in it, which provides a prediction for the design space
(DS). Here is where the risk evaluation leverages the risk analysis
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Figure 1.16: A comparison of the different pharmaceutical development approaches





            
       
              
        
      
 
       
      
           
         
      
       
         
        
           
      
 
































   
  








































































Figure 1.17: Quality risk management process (QRMP) that comprise most of the
quality by design concepts stated by ICH-Q8, Q9, and Q10 guidelines. *All of these 
risk identification tools are needed to be used in the QbD work, while other risk
assessment categories will require at least one tool per the category.
1.10.2. An overview of the failure mode effect analysis
(FMEA)
This tool requires that all factors be identified first prior its application.
Then all factors will be intensively investigated for their tendency toward
failure in the overall outcome of the product and/or the process.
The failure descriptors will be as follow: (1) failure severity, (2) failure
probability and (3) failure detectability. Semi-quantitatively, each of
these failure descriptors will be risk numbered as low risk/1, medium 
risk/2, high risk/3, or very high risk/4 against each factor. The risk 
numbering is based on the analyser/s pre-knowledge. After that, these
numbers of each factor will be multiplied by each other, to obtain the so-





          
      
      
        
      
     
        
        
         
      
     
      
 
        
        
       
          
       
    
       
      
          
         
      
      
      
          
      
            
        
   
    
A threshold RPN value will be set based on the pre-knowledge, the 
experimenter knowledge and the preliminary studies. Beyond that
threshold, the potential high-risk factors are identified. The pre-
knowledge is primarily from the literature and from the expertise of the
analyzer/s, while the preliminary studies are from the initial risk 
evaluation (Wang, et al., 2015). 
This knowledge will be updated and reviewed as the risk evaluation
advance, particularly, during the enhancement work. Hence, these
updates will allow the establishment of the risk control and the risk 
review. The latter two stages of QRMP are more relevant to the 
pharmaceutical industry (ICH, 2005) and (ICH, 2008).
1.10.3. An overview of the statistical design of
experiments (DoE)
During the last decade, the statistical DoE has increasing applications 
in the pharmaceutical sciences, like in (Qi, et al., 2015). The statistical
DoE science is counted as an established sub-field of statistics.
However, only some relevant information will be stated here. The QbD
initiative is using this science to meet the needs for the high-quality 
development of various pharmaceutical processes and products. The 
DoE is considered one of the well-known tools in the risk evaluation 
stage of the QbD. The record for early DoE usage was linked back to
the 18th century, where the physician James Lind used a form of DoE in
his clinical trials. Some of the known contributors to the modern DoE 
field in the 20th century and beyond are seen in four eras as follows 
(Montgomery, 2013): A) the agricultural DoE era, primarily by Ronald
Fisher contribution in the 1920s and early 1930s. B) The industrial DoE 
era, mostly by the input of Box and Welson in 1951, and Kiefer and
Wolfowitz in 1959. C) The discrete-parts industrial DoE era, primarily by 
Genichi Taguchi and Wu in 1980, Kackar in 1985, and Taguchi in 1987
and 1991. D) The modified Taguchi and computer-assisted DoE era, by 
various contributors worldwide, the work of Douglas Montgomery and 




       
            
        
       
        
     
     
          
      
     
        
       
        
         
        
         
         
          
          





         
          
           
     
The pharmaceutical scientists and the pharmaceutical industry will be
able, by the use of DoE, to define a robust region of operability in
preparing the floating systems. The DoE will allow the systematic 
screening of materials and/or processes factors, at different levels. Then
that will enable the systematic optimisation for the region of the best
factors levels’ combination. Hence, it potentially helps in producing 
robust and standardised specifications of mixture and/or process 
factors’ levels, to be used for such formulations. That is, the DoE 
consolidates the QbD concepts in the pharmaceutical formulation
development (Eriksson, et al., 2008).
To sum up, the DoE is an innovative approach for risk evaluation, as it
elucidates more information than the traditional/intuitive approach of one 
at a time experiments. It runs factors' levels simultaneously through a
mathematical model, usually through the use of statistical software. The
DoE designs are mainly classified into two distinctive categories, the full
factorial designs, and the fractional factorial designs (Zhang & Mao,
2017) and (Eriksson, et al., 2008), see Figure 1.18.
The DoE designs listed in Figure 1.19 are based on the DoE objective,
the design class, and design family. Also, the DoE use for either mixture
or process factors or both was noted there.
Figure 1.18: Showing diagrams for (A) the full factorial design; 23, and (B) the half 
fractional factorial design; 23-1. These designs are for 3 factors, 2 levels each, but the
second model is taking only the half of the experiments in the first model. The diagrams





            
     
         
 
         
         
       
     
    
          
        





    
   
  












































































    










Full Factorial Designs for
either Mixture or Process
type of factors: reasonably
applicable for up to four







































































































Full Factorial Designs for
either Mixture or Process
type of factors: reasonably
applicable for up to four




Figure 1.19: The DoE objectives and the statistical models involved as per objective
and as per the design category (Erikson, 2012).
1.10.4. The use of the QbD in the floating dosage forms
development
Although certain floating pellet systems have been proven to be
promising, they are yet complex and prone to high variability as seen in
the literature. That may discourage their transfer to the industry.
Additional scalability issues include the multiple stages of
manufacturing, the longer processing time, and the technically tedious 
processes that are prone to errors. Also, a skilled and knowledgeable





     
       
     
     
       
            
       
         
          
      
         
        
        
          











Therefore, quality by design (QbD) approach for the floating pellets 
development is largely needed. The use of DoE in floating systems 
(FDDS), including floating pellets systems (mupFDDS) and tableted
mupFDDS was evident by numerous studies. It is recently evident by 
those making the pellets using the extrusion and spheronisation 
processes, like (Li, et al., 2014) and (Qi, et al., 2015). A region constraint
(irregular region) can be tried for trouble-shooting using the D-Optimal
design. That can result from the use of largely different factors' ranges 
of mixture type. This issue was of relevance to this project, namely, for 
the core pellets (risk evaluation results per the statistical DoE are not
shown). Apart from the use of DoE, the other risk assessment tools were
not studied before for the floating pellets systems. Therefore, the aim 
here is to explore the benefit of the other risk assessment tools as well, 
like the use of cause and effect diagram (Fishbone diagram) and the





    
   
       
     
  
         
       
       
         
 
  
          
       
     
       
         
        
         
         
       
   
      
      
     
     
        
        
      
          
         
        
1.11. Aims and Objectives
i. Aims:
(1) Assess the feasibility of making “double-coated, then the single-
coated” floating pellets drug formulations, and assess their 
feasibility for tabletting.
(2) Obtain enhanced and novel floating pellets, which confirm the
suitability (in terms of floating and drug release) of a simplified
formulation (single coat as opposed to double coat) for product
design and development of modified release oral solid dosage
form.
ii. Objectives:
(1) Prepare core pellets, coated pellets, and ensemble pellets of the
double-coat and single-coat floating pellets designs. That using
the processes of extrusion and spheronisation, top-spray 
fluidised bed coating, and single-punch tabletting, respectively.
(2) After the making processes, analyse core pellets, coated pellets,
and ensemble pellets of the double-coat and single-coat designs.
That is mainly through image, drug release, and floating studies.
(3) Assess the feasibility of using a new spheronisation aid (Avicel
HFE 102) in the core pellets making of the double-coat floating 
pellets design.
(4) After the latter objective is confirmed, assess the feasibility of
incorporating various materials during the core pellets making of 
the single-coat floating pellets design, like incorportaing
povidone (PVP), and sodium bicarbonate (NaHCO3).
(5) Once the latter objective found feasible, enhance the core pellets 
and the film of the single-coat floating pellets design.
(6) For further processing, like pellets tabletting, use cushioning
excipient to protect the film integrity of pellets and to ensure a
sufficient binding to the coated pellets. That is to minimise film 































      
        
        
        
     
        
     
         
       
          
       
     
 
       
       
     
     
         
         
          
          
       






2.1. Materials used for the Production of Floating
Pellets
2.1.1. Excipients for the coated pellets (double-coated 
and single-coated pellets)
The chemicals (materials) used in this project, their roles, and suppliers 
are listed in the Table 2.1. For preparation of the double-coated pellets,
the core pellets were loaded with anhydrous theophylline, and with
Avicel PH101 or Avicel HFE102. Distilled water was the liquid binder.
The sub-coat or effervescent layer (inner layer) was made with either 
3.33 or 6.66 w/w% sodium bicarbonate, and with hydroxy propyl methyl
cellulose (HPMC) of 80-120 centimetre Poiseuille (cP) viscosity grade
The targeted coating weight gain is 11±1%. The retard coated layer 
(outer layer) was made of the polymethacrylates. The coating dispersion
was diluted to 15% strength. The targeted coating weight gain is 11±1%.
Eudragit NE30D is pre-plasticised by the manufacturer, and this grade
is a form of polymethacrylate dispersion that has pH-independent 
solubility.
For preparation of the single-coated pellets, materials were incorporated
the core pellets were loaded with anhydrous theophylline, Avicel
HFE102, sodium bicarbonate, polyvinylpyrrolidone (PVP) 40,000 g/mol,
and/or micronised crospovidone (Cros-PVP). Either distilled water or 10
w/w% ethanol was used as a liquid binder during the wet massing. The
ethanol containing liquid binder was used in the enhancment work. The
retard coat was also made of the Eudragit NE 30D. The dispersion was 
diluted to 15 w/w% strength. The targeted coating weight gain is 
15.6±1%. In the enhancment work, the total volume of dispersion





             
   
 
 
     
 
  
   
 




     
    
  









    
  
      
  
  
    
    
 


















    
        
        
         
            
          
  
     
    
     
        
      
 








(MCC); Brand name: Avicel PH
101
Spheronisation aid FMC BioPharma
Philadelphia, USA 
(gift)
MCC co-processed with 
mannitol content of ~10%;











Hydroxyl propyl methyl cellulose
(HPMC) of 80-120 centimetre 
Poiseuille (cP)
Floating aid and binder Sigma-Aldrich,
Gillingham, UK
Polymethacrylates; Brand
name: Eudragit NE 30D.
It contains 1.5% nonoxynol as
an emulsifier
A sustained drug release
agent, a gas retarding 












Brand name: Kollidon CL-M





2.1.2. Excipients for the ensemble pellets
The ensemble pellets were formed mainly by the compression of the
pre-prepared drug-loaded coated pellets, along with either cushioning
pellets or cushioning powder. The cushioning agent used was the Avicel
HFE102 grade only, with or without using a 10% ethanol during the wet
massing stage of pelletisation, more details will be in the preparation
section 2.2.
2.2. Preparation of the Floating Pellets
Table 2.2 summarises codes used for floating pellets batches. The 
preparation process parameters for the pelletisation, coating, and
tabletting were listed in Table 2.3-4. The process parameters during




       
      
 








       
 
       
  
       
 
       
 
       
 
       
 
      
 
        
 
     
     
     
 
 
   
   
   
   
   
     
     





     
     
 
     
   
    
  
     
 
 
      
 







     
     
     
     
     
    
     
Table 2.2: Codes used for floating pellets batches*
Batch Code** Key Differences in Compositions Location in 
Text









B2D-PH,40,3 Avicel PH101, 40% drug loading, 3.3%
NaHCO3
B3D-HFE,40,6 Avicel HFE102, 40% drug loading, 6.6%
NaHCO3
B4D-HFE,40,3 Avicel HFE102, 40% drug loading, 3.3%
NaHCO3,
B5D-PH,60,6 Avicel PH101, 60% drug loading, 6.6%
NaHCO3
B6D-PH,60,3 Avicel PH101, 60% drug loading, 3.3%
NaHCO3
B7D-HFE,60,6 Avicel HFE102, 60% drug loading, 6.6%
NaHCO3
B8D-HFE,60,3 Avicel HFE102, 60% drug loading, 3.3%
NaHCO3
B7D2-HFE,60,6, 15.3 Avicel HFE102, 60% drug loading, 6.6%
NaHCO3, 15.6% weight gain Eudragit 
NE15D
B7D2CPowder B7+ 47.3%**** cushioning powder
B7D2CPellets B7+ 47.3% cushioning pellets










B7S-12P,12N 12.5% PVP, 12.5% NaHCO3
B8S-11P,11N 11.25% PVP, 11.25% NaHCO3






B10S-12P,47HF,10E 12.5% PVP, 0% NaHCO3, 10% ethanol
B11S-12CP,47HF,10E 8.6% cros-PVP, 3.5% NaHCO3, 10%
ethanol
B12S-12P,47PH,10E 12.5% PVP, 0% NaHCO3, 47.5% Avicel
PH101, 10% ethanol
B13S-60DL,10E*** 0% PVP, 0% NaHCO3, 60% drug loading, 
10% ethanol
B14S-2P,17N,10E 2.5% PVP, 17.5% NaHCO3, 10% ethanol
B15-Cushioning
Pellets
100% Avicel HFE102 Chapters 3, 5
and 6








B10SLow B10S + 33.3% cushion powder
B11SLow B11S + 33.3% cushion powder
B12SLow B12S + 33.3% cushion powder
B12SHigh B12S + 66.6% cushion powder
B13SLow B13S + 10% cushion powder
B13SHigh B13S + 65% cushion powder




     
       
   
   
            
 
      
   
            
      
            
     
      
 
        
 
B14SHigh B14S + 66.6% cushion powder
*All compositions will be detailed in the following tables of this chapter. Hence, here
only the key compositions that help differentiating the batches were stated, to better
guide the reader throughout the results chapters.
**The number of all pellets and pellets containing batches made and analysed in
the thesis are 34 batches. 
***The strength of e.g. the NaHCO3 refers to the strength in the coating dispersion, 
where the actual amount of NaHCO3 can be known when correlating to the obtained 
weight gain of the films. Other main fixed components in the double-coated pellets:
62.5% distilled water, and Eudragit NE (0% ethanol).
The 0% ethanol in Eudragit is also used in the screening for the single-coated 
pellets. Another main fixed component in the enhanced single-coated pellets:
Eudragit NE (25% ethanol). The single-coated pellets have varied water content,
and that will be explained in the respective chapter.









       












   
   
 





     

















          
         
          
         
          
           





      
      
                    
      
                  
           
Table 2.3: Summary of the complete formulations’ compositions for the double coated floating pellets.
Batch code Core pellets compositions for the














































B2D-PH,40,3 Avicel PH101; 60% 40 62.5 3.33: 6.66 3.0
B3D-HFE,40,6 Avicel HFE102; 60% 40 62.5 6.66: 3.33 1.5
B4D-HFE,40,3 Avicel HFE102; 60% 40 62.5 3.33: 6.66 3.0
B5D-PH,60,6 Avicel PH101; 60% 60 62.5 6.66: 3.33 1.5
B6D-PH,60,3 Avicel PH101; 60% 60 62.5 3.33: 6.66 3.0
B7D-HFE,60,6*** Avicel HFE102; 60% 60 62.5 6.66: 3.33 1.5 47.3: 52.7





- 100 - - - -
*10g from the narrowed size of 1-1.18 mm core pellets were subjected to the coating process.
**All coating dispersions were freshly prepared in a total volume of 300ml prior the start of the coating process. Regarding the coating materials, the w/w
percentages represent the concentration in the coating dispersions. Hence, the coating solids in the coated layers of B1 are the coating gain solids.
Therefore, if 10% is the weight gain, and the core pellets intended for coating were 10g, then the coating solids are 1g.








         







   
 










     
   
  
 
       
   




       
       
       
       
       
       
       
 
 











      
  




    
 
 
       
 
      
 













compositions for 15.6±1% 
and 6±0.5% coating weight






















B2S-25N 00.00% 35.0% 25.00% 40% 43.75% -
B3S-20P 20.00% 40.0% 00.00% 40% 31.25% -
B4S-20N 00.00% 40.0% 20.00% 40% 50.00% -
B5S-22.5N 00.00% 37.5% 22.50% 40% 50.00% -
B6S-22.5P 22.50% 37.5% 00.00% 40% 25.00% -
B7S-12P,12N 12.50% 35.0% 12.50% 40% 43.75% -
B8S-11P,11N 11.25% 37.5% 11.25% 40% 43.75% -
Enhancment
phase
B9S-8P,3N,10E 08.60% 47.9% 03.50% 40% 37.50%
Eudragit NE30D (ethyl-
acrylate-methyl-meth-acrylate 
(EAMMA)) diluted to 15%




















00.00% 40.0% 00.00% 60% 62.50% 90:10, and 55:65
B14S-
2P,17N,10E







       
        
                  
  
            




00.00% 100% 00.00% 00% 100% Not Applicable
*5g from the narrowed size of 1-1.18 mm core pellets were subjected to the coating process.
**The cushioning powder ratios were selected to 1) allow for a sufficient binding and cushioning, 2) ensure that the drug-loaded pellets are meeting the required
dose loading in the tablet.
***B13S batch was of different cushioning powder ratio, due to that the medicated pellets were having higher drug loading (i.e. 60% instead of 40%). The 





























     
 
 













   
 
 






   
 
  





    
    
   
   
 
  
                    
               
                    
 
 






























125 g* Spheronisation 
load
~80 g* Coating load 6-10 g Tablet feed 
size
400mg
Mixing time 10 min Extrusion 
time
5 min Spheronisation 
time




































0.8 mm - -







*The extrusion load was divided into nearly 5 proportions of 25g -dependent on the liquid binder amount-, which were fed one at a time. The typical
spheronisation load is 100g for this disc diameter (120 mm), This load or less will provide a desired robe-like movement (Caleva, 2015).




     
       
     
             
        
      
       
      
         




            
  
     
      
       
    
     
   
         
     











   
2.2.1. Pelletisation/core pellets making process
The powder was wet mixed by a process called wet massing. The 
pelletisation process was conducted using the extrusion/spheronisation
method. The obtained wet core pellets were dried on the top of the oven
at a surface temperature of 52 °C. Dried core pellets were stored in glass 
jars ready for the core pellets analysis and the subsequent coating and 
tabletting processes. The pelletisation process is shown in Figure 2.1.
The process can be understood from (Sungthongjeen, et al., 2006), 
(Politis & Rekkas, 2011), (Korakianiti, et al., 2000), (Mehta, et al., 2005),
(Puah, et al., 2014), (Chu & Chaw, 2012), (Low & Chaw, 2012) and 















of Wet Pellets Pellets Drying 
Figure 2.1: A summary of the pelletisation method for the pharmaceutical core pellets
at a lab scale.
i. Weighing the raw powders
The powders for making the core pellets (for making the intra-granular
compsitions) were weight using Precisa analytical balance (four decimal
places). For de-clumping, pre-sieving theophylline powder in an 
appropriate sieve size was performed.
ii. Planetary mixing
After sieving the theophylline powder, all powders were transferred into
the planetary mixer (Kenwood Chef®; a simple 3-way-blade). The mixer 




      
          
      
           
        
          
        
       
    
         
   
      
         
            
            
      
       
      
            
            
     
         
         
    
  
       
        
        
        
    
 
(pre-mixing) and wet massing. The planetary mixer has a. Pre-mixing
was performed for 3 minutes at a speed setting of 3, then the wet 
mixing/granulation process was performed for 10 minutes at a speed
setting of 4 (Puah, et al., 2014). Liquid binder was added in 5ml fractions 
every 1-2 minutes, until the required wet mass consistency was reached
(Puah, et al., 2014). The consistency of the wet mass was checked using
the hand-squeeze test. It was checked prior and after the last liquid
binder additions, where the capillary state of the solid-liquid phase is 
expected to be near. The mixture's fluffiness was visually checked.
When pausing the mixer, the sticky clumps on blades were scratched.
iii. Radial extrusion
The wet mass was extruded straight after reaching the required
consistency, using Caleva® Extruder 20, with screen sizes of 1.2 mm or
1 mm. The run time was about 5 minutes, and the extrusion speed was 
set at a speed of 30 rpm, as recommended by Puah, et al., (2014). The 
extrudates size and structure was visually observed after the extrusion.
The extrudates were stored in a light-protective and air-tight 
container/jar for no more than 30 minutes prior the spheronisation
process (Puah, et al., 2014). It should be noted on the rollers of the
extruder, if a thick layer appeared, it would be an indication that the wet
mass was too wet. Upon spheronisation, that may form either dumbbells 
or enlarged pellets. On the other hand, if the wet mass was overly dry,
dry and porous extrudates will be produced. Upon spheronisation, that
may cause powdering (Caleva, 2015).
iv. Bench-top spheronisation
Extrudates were fed into the top-bench spheroniser of Caleva®
Spheroniser (Model 120). The speed set was high at 2500 rpm with 10 
minutes residence time. The latter was recommended by Pauh, et al.,
2014) to achieve AR values ≤1.2. The pellets size and roundness was 






     
           
        
       
        
        
    
   




       
  
    
         
      
 
      
           
       
          











After spheronisation, the product (pellets, or dumbbells, etc) was 
discharged into a collection tray. Then the product was oven dried at 52
°C for 2 hours until a constant weight was reached. The latter was 
determined by re-weighing (data not shown). The percentage yield was 
calculated after sieving, based on the weight before and after drying. 
The usable yields of pellets were stored in glass jars for later processing
(Puah, et al., 2014).
2.2.2. Coating of the core pellets

















Figure 2.2: A summary for the fluidised-bed coating method for the pharmaceutical
core pellets at a lab scale.
i. Coating liquids preparation
The compositions of all coating liquids used in this project are listed in 
Tables 2.2-3. The coating process parameters were listed in Tables 2.5-
7.
Hydroxyl propyl methyl cellulose (HPMC) dispersion:
HPMC solutions were prepared using the cold blending method in a low
shear paddle mixer (Heidolph RZR 2041). At RT, distilled water (of two 
third the targeted amount) was weighed and added to the intended glass 




          
         
         
          
          
          
        
  
       
    
        
       
           
   
     
     
        
          
       
           
           
       
         
           
            
           
        
      
         
          
    
duration of mixing is 2 hours. The smallest amount of powder was added
first to the liquid as follows, the polyethylene glycol (PEG) 6000
plasticiser, then sodium bicarbonate, then HPMC 80-120 cP. The HPMC
addition will need at least 10 minutes. A cautious and gradual addition
of HPMC into the liquid is needed, to ease de-clumping. During the
HPMC addition, the viscosity of coating liquid increases, thus the speed
of mixing was gradually increased from 300 to 600 rpm.
Poly-methacrylate dispersions:
The original Eudragit NE30D contains 30% poly-methacrylates. It was 
diluted to 15% poly-methacrylates prior its use. The dilution for less than
20% strength is recommended by (Evonik, 2016). The dilution liquid was 
either a distilled water only or a distilled water with 10 or 25% ethanol. 
That is, the final dispersion should be of 15 w/w% solids and 10 or 25 
w/w% ethanol content.
ii. The coating process
An overview of the coating process:
The coating procedure was adapted from (Evonik, 2016) as possible.
Depending on the design of the formulation made, the coating was 
performed for either one or two coating layers, using the top-spray 
fluidised bed coating of Caleva Mini Coater/Drier 2, see Figure 2.3. The
fluidisation should result in a ring-like movement of pellets that can be
checked visually. The coating process parameters were as seen in
Tables 2.6-8. The targeted weight gain in mg= (weight of batch size*
weight gain %)/ 100. The obtained coating weight gain %= (the obtained
weight gain in mg* targeted coating weight gain %)/ targeted weight gain
in mg). The WG was checked in 15-30 minutes intervals, to ensure that
the obtained WG is not largely varied from the targeted WG.
For the double-coated pellets system, two subsequent coating layers 
with an intermediate drying step of 30 minutes at 60oC were performed.
Then, the wet coated pellets dried at 52 °C for at least 2 hours, until a 




       
        
         
         
         
          
      
            
   
    
         
                
       
          
 
 





   
 
For the single-coated pellets system, one coating layer was made, then
finally dried at 52 °C for 2 hours, to obtain <5% liquid content. 
Additionally, the curing was performed for 22 hours at 52 °C. Hence, the 
drying was extended to include static curing for 24 hours in the single-
coated systems. The latter was because that the curing ensure complete
plasticisation of the retarding polymer, which will avoid changes in the
system’s functions with time upon storage. Besides, the additional 
curing time of 22 hours was not showing a difference in the drug release
and floating profiles.
Free films preparation
Approximately 10 ml of the pre-prepared coating solution was poured
into a flat glass dish, then placed on the top of the oven at 52 °C, for two
hours or until no change in weight loss was recoded. The film's thickness 
was 0.2 mm, using a micrometre of Moore and Wright Metrics (Sheffield,
UK)





Figure 2.3: A top view for the coater’s cone, where it shows the fluidised pellets




            


























      
  
   
 






   
 
      
       
               
               
  
                  
               
          


































RT 3.1 0.25-0.5 
bar****










RT 3.1 0.25-1 bar ~12 6-10 180.96-199.06 25 10-14.5 ~12
*A magnetic stirrer was used to ensure the liquid homogeneity during coating.
**The nozzle height was the measured distance between the pellets' bed and the nozzle's opening.
*** The pipe’s circular orifice diameter is 40 mm. Therefore, the air flow speed/velocity can be expressed from 108.58 m3/hr to 289.53 m3/hr, that correlates
to the range of 6 to 16 mm/sec air flow speed (Engineering.com, 2017).
****The pressure of 0.5 bar is the default one that usually used for this coater. The pressure unit of PSI stands for the pounds per square inch. 
Note: the full scales are as follows: 6-16 mm/s fan airflow, 10-25 Hz agitator frequency, 20-60 C heater, 1-4 RPM pump speed (peristaltic pump of 4 rolls),
0-2 bars (0-30 PSI) atomising air pressure. While the nozzle height against the product support mesh is typically 10-20 cm. The coating solution flow rate 




        


































   
 

































          















































































      
        
    
       
        
          
          
      
       
        
              
           
          
          
    
   
          
       
          
         
         
       
           
            
           
           
          
        
        
 
2.3. Preparation of the Ensemble Pellets
The ensemble pellets consisted of drug-loaded pellets, and cushioning
materials of either powder or pellets forms. The cushioning pellets 
consisted of Avicel HFE 102 (Microcrystalline cellulose; MCC, co-
processed with ~10% mannitol) were made as described in section
2.2.1, where 10% ethanol was used as liquid binder. The used size
fraction of the cushioning pellets was similar to the used size fraction of
the drug-loaded core pellets (1.0-1.18 mm). Each tablet’s components 
were weighed separately for each tablet. After which, the tablets were
made, using a single-punch tabletting machine (Manestry Type F3,
Liverpool, UK). Fitted with a flat-faced punch of 9.6 mm, to reach a target
mass of 400 mg with a tablet thickness of 4.65 mm and a diameter of
9.6 mm. The compression force was adjusted to achieve a targeted
crushing force of ~5 to 7 KgF (49.03-68.65 N).
2.4. Characterisation Methods for the Floating
Pellets and the Ensemble Pellets
All of the characterisation methods used in this study are listed in Figure
2.4. It summarises how the compositions of the floating pellets were
tested at all stages of perpetration (upon preparing raw materials, core
pellets, coated pellets, and ensemble pellets). Hence, the formulation
development will be started with the pre-formulation testing followed by 
the intermediate-product testing, and finally by the end-product testing.
It is important to state here that not all of the characterisation methods 
were used in all chapters. Also, to minimise repetitions, once a test is 
stated for the core analysis, it will not re-stated for the coated pellets and 
ensemble pellets analysis. Based on the literature and by the trial and
error, the preparation processes were analysed to a certain extent in this 
project (data not shown). All parameters of the characterisation

























































































































































   
        
    
         
         
         
      
         
        
        
     
     
       
       
        
    
   
       
       
       
          
       
         
     
     
    
         
             
          
         
        
2.4.1. Pre-formulation testing
The results of pre-formulation testing are included in chapter 5.
i. Differential scanning calorimetry (DSC)
The DSC was used to determine the thermal properties of used powders 
and free films made from the coating liquids. The DSC was succinctly 
defined by (Chiu & Prenner, 2011) as a technique that “measure the
specific heat capacity of thermally induced events as a function of
temperature”. The DSC is known to measure the melting (MP) and glass 
transition (Tg) of a polymeric sample upon melting and softening,
respectively. Although both of which are energy-absorbing processes,
the MP peak is an endothermic sharp peak that indicates crystal melting,
while the Tg step change is an endothermic step that indicates 
amorphous softening. Hence, on the other hand, crystallisation and
amorphosisation are exothermic processes that release energy. Crystal
melting peak can be seen in (Bhattacharjya & Wurster, 2008).
Sample preparation for DSC
An automatic thermal analyser system was used (TA instruments 
Q1000). Samples of 3-4mg were weighed by the Mettler MT5 micro-
balance of six decimal places (SNR-N86550). Samples were placed in
an aluminium pan with an aluminium lid (Hermetic pan type), which is
sealed by the pan press (Abdel Rahim, et al., 2015). Temperature
calibrations before and after sample runs were performed using the
indium standard. One emptied pan was sealed to be used as a
reference, for a simultaneous measurement with each sample’s 
measurement (Prasad, et al., 2013).
Software use for DSC
The refrigerated cooling system (RCS) was turned on. The mode of the
run was set to a standard type, and the test was set to a ramp type. The
run set to scan at 10 °C/min, from 0 to 300 °C. The latter range was 
selected based on the melting points of the materials tested (Abdel





      
         
        
    
       
          
  
          
      
       
      
    
       
    
       
       
        
           
      
       
           
      
           
           
        
        
   
      
         
       
        
       
mL/min), and s runtime of ~30 minutes for each sample (Mazurek-
Wadołkowska, et al., 2013). The generated graphs were analysed using
the Q1000 Analyser software (Abdel Rahim, et al., 2015).
Temperature calibration for DSC
The standard indium runs were performed before and after all samples 
runs to calibrate the temperature in the DSC equipment. The melting
points (Tm=157.43-157.86 °C for before and after measurements) 
obtained were close to the literature Tm of the indium (Tm=156 C°) (TA-
Instruments, 2009). The indium peak change after testing the film 
samples by 0.43 °C. The latter implies that the temperature of thermal
events in the thermograms of films can varies by ±0.43 °C. 
ii. Density of solids
The density of solids was obtained through the use of the multi-
pycnometer (Quantachrome Instruments, MVP-D160-E, Boynton
Beach, Florida, USA). This was used to derive the density values for 
powder materials, core pellets and coated pellets. The instrument was 
used to determine the pressure values required for calculating the
apparent volume (Vp). A fixed amount of sample, typically 2 to 4 g was 
weighed, using Precisa analytical balance (four decimal places). The 
density of the samples was then derived from the apparent volume (Vp) 
value (Abdel Rahim, et al., 2015). Before the sample measurement, the
equipment was calibrated according to (Mustafa & Chaw, 2016). The 
purpose of the calibration was to obtain the reference volume (VR) and
the total volume of the system (VC). The equation used to determine VP
was as follows; VP= VC – VR [(P1/ P2)-1], where P1 and P2 are the
pressures determined in the reference and sample cells, respectively.
iii. Force tensiometric analysis
It is a system for measuring various physical properties, including
surface tension of liquids. The force tensiometer (Attension and One-
Attension software, Sigma 700, Helsinki, Finland) was used to
determine the physical characteristics of the coating dispersions. The





       
        
          
        
           
   
    
     
         
       
         
         
        
          
     
    
        
       
      
         
       
       
        
         
          
        
         
        
  
 
force tensiometric study conducted in this work is the surface tension.
The lower is the surface tension, the better are the spraying efficiency,
wetting, and the spreadability of the coating liquid during the coating
process. The samples were analysed using the Du-Nouy ring probe. The 
ring will be immersed and detached from the liquid surface, while the
measurements are taken automatically.
2.4.2. Intermediate product testing: core pellets
i. Sieve size analysis
A nest of 9 sieves (pore sizes=0.25-2 mm) were placed on a vibratory 
sieve shaker (British Standard; BS sieves of Endecottes® EFL 2000).
The shaker was used to sieve the dried core pellets for 10 minutes.
Then, the pellets in each sieve were weighed, to determine the size
distribution of pellets (Sungthongjeen, et al., 2006). For the purpose of
further testing, the desired size range of core pellets is in the narrowed
size fraction of 1-1.18 mm.
ii. Sphericity and swelling testing using image analysis
The core pellets were analysed for shape, using Feitz Dialux 22 light
Microscope, with an attached camera (AxioCam MRc5, Magnification is 
40X, Zeiss software). Thirty core pellets where captured from each
batch, processed and analysed for each batch (Gupta, et al., 2011). The 
parameters determined from the software are Feret diameters,
perimeter, circularity, area, and aspect ratio.
The swelling per diameter study was also based on image analysis. It
uses the diameter, Dvolume, and surface area values. The individual
coated pellet was placed in a glass dish and mounted on the
microscope’s stage. The images were captured at fixed intervals (0, 0.5,
1, 2, and 4 hours) before and after immersion in either medium of
distilled water or 0.1N HCl. Then, the percentage increase in pellet’s 





      
       
          
      
      
     
    
          
        
    
       
      
         
       
         
      
     
       
         
          
         
         
      
       
         
        
         
          
      
   
iv. Friability study using the abrasion drum
The friability of the core pellets was measured by a friabilator (Copley®),
where the core pellets were used (10 g). The abrasion drum is designed
specifically for the pellets friability testing. The rotation speed was set
for 200 rpm (Sungthongjeen, et al., 2006). The mechanical strength 
index (MSI) was calculated as follows; MSI%=(W2/W1)*100. While the
weight loss % was calculated as follows; WL%= [(W1-W2)/W1]*100. The 
W2 is the remaining integrity of the core pellets after the test, W1 is the
total weight of the core pellets before the test.
v. Scanning electron microscopy (SEM) 
The pellets were captured for images and analysed using scanning
electron microscopy (SEM) (Hitachi, S-3000, 2ry electron detector). The
SEM was used to analyse the core pellets, coated pellets before and
after dissolution. Also, the SEM was used for the coated pellets after 
crushing the ensemble pellets, and after the dissolution of the dis-
assembled tablet. The procedure below was adapted from 
(Sungthongjeen, et al., 2006) as possible. 
The dry coated pellets samples were mounted onto stages. The stages 
were glass stub with a double-sided adhesive tape. Some of the
coated pellets were bisected into two halves by a sharp blade, where a
thin wax piece was placed underneath the pellet before suctioning, to
avoid squashing the pellets. The mounted pellets were coated with
gold-palladium, using the Quorum Mini Sputter Coater (SC 7620),
under a vacuum of an argon atmosphere (specifications not shown).
Then, the samples were ready to be observed under the SEM.
That is the SEM image analyser software was used, where a manual
ruler tool was used to measure the coating thickness of the bisected
coating pellets. At the 500 µm capture magnification, the smallest and






    
   
        
 
   
     
       
         
        
     
          
        
  
  
      
     
              
           
            
          
        
         
            
           
           
          
          
        
             
        
2.4.3. End product testing: coated pellets
i. Dissolution study
The procedure below was adapted from (Sungthongjeen, et al., 2006)
as possible.
Theophylline absorbance calibration
The absorbance was measured using Single Beam UV/Vis 
Spectrophotometer (Camspec, M501). To enable the quantification of
the drug theophylline, a calibration curve was produced. First, the
concentrated drug solution or the stock solution of 200 mg/L was made. 
Subsequently, dilutions were made separately from the stock solution
(20, 16, 8, 4, 2, 0.4, and 0.2 mg/L). The absorbance was determined at 
268nm λ (USP25, 2002). The latter value was determined as the λmax by 
an equipment scan.
Dissolution procedure
USP type 2/ paddle apparatus (Copley DT6) was used for the dissolution
process of the coated pellets and ensemble pellets (37.0±0.5 °C, 50 
rpm, 900 ml, 0.1N HCl, n=3). Based on the 200 mg dose of theophylline,
drug loading (DL), and the coating weight gain (WG), the coated pellets 
were weighed. The drug loading is based on the initial amount of drug
powder. It was assumed that any loss of the drug amount during the
making of core pellets is comparable to the loss of the other 
compositions. Weight of core pellets in mg (for 40% DL)= [(targeted drug
dose in mg*1000 mg)/ 400 mg= 500 mg. Weight of coated pellets in mg
(for 6% WG)= [(weight of the core pellets in mg* targeted WG in %)/100]
+ dose of the core pellets in mg= 530 mg. The latter weight is used.
Also, the tablets of the corresponding dose were directly placed in the
dissolution vessels. The absorbance measurements were at 0.5, 1, 2, 4,
6, 8, 12, and 24 hours. The 5 ml samples were filtered through 0.25 µm 
membrane filter, then diluted with 0.1 N HCl to reach the required dilution





            
        
     
        
      
    
        
        
        
          
         
         
         
        
        
           
      
          
         
        
               
              
   
   
          
       
         
         
       
         
        
        
absorbance value of 1. The value of 1 is based on the calibration run. 
The dissolution equipment used is shown in Figure 2.5.
Model-dependent approach to compare dissolution profiles
For analysing the dissolution kinetics of the coated floating pellets in
literature, the zero-order and Higuchi kinetics are commonly used
(Sungthongjeen, et al., 2006). In this project, only the zero-order kinetics 
applied. From the calibration curve, the regression equation was used
to determine the drug concentrations and the drug cumulative
percentage of release from formulation at a specific time. If data fitting -
of all time points shown in the results- produced a straight line, a 
regression value >0.9 should be confirmed to indicate high linearity that
implies a high accuracy for calculating the slope. The slope here is the
rate constant of the zero-order reaction, which determine how much
drug dissolved over time. The rate-limiting mechanism of the sustained
drug release from the dosage form can be a zero-order kinetics rate
(Sungthongjeen, et al., 2006), (Allen, et al., 2005) and (Shargel, et al.,
2012). The equation; [A]t-[A]0= -kt, is a form for the integrated rate law
of the zero-order reaction (Pugh, 2013). It can be re-written as follows;
[A]t= -kt + [A]0, which is in a similar form for the straight line (the
regression line) equation; y=mx+b. Hence, [A]t is the concentration of
the drug at a specific time on the y axis, -k is the slop of the line, t is the
time on the x axis, and [A]0 is the concentration of the drug at a zero time 
on the y intercept.
ii. Floating study
The procedural set up of floating study was below was adapted from Li, 
et al., (2014), which is similar to the dissolution procedure above. The 
onset of floating/floating lag time/time to float (TTF) and the duration of 
floating were all measured by visual observation. The percentage of
floating pellets was calculated as follows, % of floating pellets = the
number of floating pellets at the measured time/the initial number of the
pellets)×100 (Hung, et al., 2014). The floated pellets were counted on






           
        
          
          
     
      
     
           
             
         
             
             
          
          
     
    
          
        
           
        
          
         




(made in this project)
Figure 2.5: It shows the traditional dissolution type 2 USP paddle apparatus, where
the floating pellets were either on or approaching the surface of the dissolution 
medium. The author took the image during the enhancement phase of the single-
coated pellets systems.
iii. Surface tensile strength (STS) study
The procedure below was adapted from Bashaiwoldu, et al., (2004). The 
coated pellets were tested for their mechanical strength, prior 
compression into tablets. To ease the coated pellet positioning, the test
position was set to 1.7 mm, the return position was set to 1.1 mm, and
the Z-distance was automatically set to 5.4. The speed of 5 kg load was 
set to 1 mm/min (Puah, et al., 2014). After zeroing the force, one coated
pellet at a time was carefully placed in the middle of the stage, and then
the force was loaded. Then, the force was recorded in kg. This force was 
applied to cause deformation of the surface/film of the pellet, which was 
converted into Newton (1kg=9.80665N).
v. Swelling study per weight
One hundred milligrams of the coated pellets were poured in 300 ml
beaker in the dissolution medium of either distilled water or 0.1N HCl. At
pre-determined times (0, 0.5, 1, 2, and 4 hours), pellets’ weight was 
checked. The pellets were removed and gently blotted with tissue
papers, to remove the excess amount of the liquid found on their 
surfaces before being weighed. The pellets then returned to the beaker. 





    
        
          
        
     
   
     
    
            
        
          
     
          
        
     
       
      
      
        
   
      
       
        
           
        
          
        
        
   
uptake (DMU) was as follows; DMU= (weight after immersion- weight 
before immersion)/weight before immersion) × 100%. The DMU is also
referred to as the swelling index (Ishak, 2015). In the project, the term 
swelling will be used instead of swelling index.
2.4.4. End product testing: ensemble pellets
i. Apparent porosity test
The apparent tablet density (g/cm3) was calculated as follows,
density=the tablet’s mass/tablet’s volume. The tablet’s volume was 
based on the volume of the cylinder, which equals to πhr2, where π is 
the circular constant that equals to ~3.14, and h is the tablet’s thickness 
in mm. The r is the tablet’s radius, which is the half of the tablet’s 
diameter in mm. The tablet’s thickness (h) and the tablet’s diameter (d) 
were measured (n=12), using a micrometre (Moore and Wright Metrics,
Sheffield, UK) (Abdel Rahim, et al., 2015). The apparent tablet porosity 
(unit-less) was calculated as follows, porosity=1-(density/1.4). While the
percentage of the apparent tablet porosity was calculated as follows,
porosity %=(apparent tablet porosity/true tablet’s porosity)*100. The true
tablets porosity was calculated from the tested volume of the tablet’s 
composition, using the multi-pycnometer (Abdel Rahim, et al., 2015).
ii. Hardness and tensile strength test
The hardness tester of LabX Schleuniger was used (2E, Midland,
Ontario, Canada), to examine the tablet’s mechanical property (n=6).
Breaking loads in kilograms-force (KgF) were recorded and were used
to calculate the tensile strength (σt), according to the equation described
by (Fell & Newton, 1970). The tensile strength (N/m2) was calculated as 
follows; σt = 2P/πdt, P is the crushing load in Newton (N), d is the
diameter in meter (m), and t is the thickness in meter (m). A unit
conversion to mega Pascal (MPa) is needed as follows; MPa=Pascal or 





   
     
       
      
          
          
          
        
      
       
     
   
          
           
         
          
          
          
         
    
  
        
       
      
         
         
       
          
       
         
          
          
iv. Disintegration test
The disintegration of tablets was determined using Copley tester 
(DTG2000IS, Nottingham, UK), where the disintegration time was 
recorded. The disintegration basket consists of six tubes, each tube was 
used for one tablet (n=6). A vessel was filled with 800 ml distilled water 
and heated to 37±2 °C, where the basket was moved in and out. If 1 or 
2 tablets failed to disintegrate, then the test will be repeated for 12 new
tablets, where 16 tablets out of 18 tablets tested should disintegrate to 
pass the test (British-Pharmacopoeia, 2017). The tablets in the basket’s 
tubes have ~1-4 cm depth of immersion into the disintegration vessel. 
The dipping rate was 30 dips per minute.
v. Friability study
Based on BP, 6.5 g of tablets were used. The de-dusting of tablets was 
before the initial weighing and before the final weighing. The drum speed
was set at 25 rpm. The drum rotations were of 100 rounds/revolutions.
If the pellets disassembled after tumbling, then the test was failed. If the
powder loss was more than the targeted 1%, then the test will be
repeated twice, and a mean of three values to be determined (British-
Pharmacopoeia, 2017). The MSI and weight loss were calculated as in
the friability test of core pellets.
2.5. Statistics 
Independent two samples t-test was used, using Excel of Microsoft
Office (Redmond, WA, USA), to obtain the p-values of various 
responses of the selected factors combinations (Sungthongjeen, et al.,
2006). The statistical significance was tested using the t-test, unless if
specified otherwise in the results. The scoping studies were performed
for selecting the liquid binder amount, where the cubic-regression was 
applied, using the SPSS 21 software. The latter is to test the significance
of water level interactions with other formulation factors in the core
pellets. That is, the latter is to provide critical insights for the water level
effect during the wet massing stage, to allow for determining the
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2.6. Risk Assessment for the Floating Pellets 
Development
Within the scope of this project, the risk assessment was the appropriate
QbD category of choice. See the risk assessment framework used in
this project, in Figure 2.6. The risk assessment work in this project will
identify all risks, analyse the level of risk for each factor, and to evaluate
some of the high risk factors in details.
EARLY RISK ASSESSMENT: 
Literature Review, Research 
Aims and Objectives, Materials
and Methods 
(Chapters 1 and 2) 
EARLY RISK ASSESSMENT
(continued): 
Based on Pre Knowledge:










Preparing and Characterising 
the Double Coated Floating















Modifications to get the
"Optimum (Enhancement ),
Compression results 
(Chapters 5 and 6) 
Figure 2.6: Show the framework for the risk assessment used in this project, with
regards to the floating pellets development. This risk assessment framework
summarises most of the spent efforts in making the story of this thesis journey.
The risk assessment is the bases for the subsequent QbD
investigations, namely, for the risk control and the risk review categories 
of the QbD. The latter two risks activities are more relevant to the
pharmaceutical industry. Hence, the risk assessment will ease the
scale-up of the enhanced formulations, owing to its virtue of being the
backbone of the QbD.
2.6.1. Risk identification
The quality target product profile (QTPP) was filled, to identify all
attributes for the best product. The best product will consider the patient
factors, like compliance and drug deliverability, the manufacturer 
factors, like cost-effectiveness and patency, as well as any other 





     
       
         
      
        
        
  
        
       
        
     
          
          
          
     
        
      
        
         
            
     
     











critical quality attributes (CQAs) or the product quality attributes (CPAs) 
were determined (based on literature as possible), to define the most
critical attributes in QTPP table. The CQAs are defined based on the
preliminary knowledge from literature. After then, the product, the
process, the environment and the operator factors were identified and
illustrated in the Ishikawa/Fishbone diagram (Wang, et al., 2015).
2.6.2. Risk analysis
The failure mode effect analysis (FMEA) tool was used, which can imply 
the risk estimation matrix (REM) tool as well. It was used to semi-
quantitatively analyse the factors listed in the Ishikawa diagram, based
on the preliminary knowledge from literature and preliminary studies 
(Wang, et al., 2015). After the literature review, the severity/impact of
failure (S), the probability of failure (P), and the detectability of failure (D) 
were all explained for each factor, based on the risk definitions in Table
2.9. This explanation was further edited after preliminary studies (Wang,
et al., 2015). Based on the provided explanation, each failure category 
was risk numbered. Then the numbers for each factor were multiplied
by each other, to bring about what so-called the risk priority number 
(RPN). The numbering will be based on the risk definitions as well
(Wang, et al., 2015). An intuitive threshold score for the RPN was set,
where any factor exceeding this value was considered as a potentially 
high-risk factor. Hence, the critical process parameters (CProcPs) and











    
           
     
 
  
       
 
 





       
     
       
 
 
          
   
        
         
         
               
  
  
       
       
        
        
         



















Risk Definition Risk Label*
Severity (S) 1 No impact or influence on product quality No S
2 Low impact or influence on product
quality
Low S
3 Moderate impact or influence on product
quality
Medium S





1 Rare failure can happen Low P
2 Occasional failure can happen Medium P
3 Frequent failure can happen High P
Detectability
(D)
1 At all times, failure can be detected High D
2 In some cases, failure can be detected Medium D
3 Rarely, failure can be detected Low D
4 At all times, failure cannot be detected No D
*Risk labels can be used to build the so-called the risk estimation matrix (REM).
However, in this project, the risk scores will be used instead, to obtain the priority
risk number (PRN). This allows a semi-quantitative analysis of the risk measures.
2.6.3. Risk evaluation
During the risk evaluation, the statistical design of experiments (DoE) 
was not used. Rather it is the traditional (non-QbD) approach of
development was conducted during the risk evaluation stage. Some of
the high risk factors, in particular the composition factors of the core
pellets were evaluated, which have the highest PRNs. Also, some other 
































        
      
       
        
        
        
         
      
    
         
      
        
       
         
       
        
       
      
        
       
      
          
          
         
      
           
         
          
       
        
          
           
3.1. Introduction
The gastro-retentive drug delivery systems (GRDDSs) are a type of the
sustained release drug delivery systems (SRDDSs). The SRDDS is a
major category in the modified release (MR) drug delivery systems. The
GRDDS intended for slowly releasing the drug in the stomach. Floating
drug delivery systems (FDDSs) are a type of GRDDS. The FDDSs have
three categories, the effervescent system, non-effervescent system, and
the mixed- system. The FDDS can be a single-unit or multiple-units of
particulates (MUPS) system. The most common multiple units of
particulates (MUPS) system is the millimetre sized pellets. Floating 
pellets (mupFDDS) will be buoyant on the gastric fluids, owing to its 
decreased bulk density when compared to the liquid’s density. Floating 
pellets achieve floating as they contain floating agents and retard
polymeric agents, usually through the application of coating layer/s.
Using the extrusion and the spheronisation method, there are various 
designs for the floating pellets, ranging from no coating or matrix design
to quadruple coating design. These layered designs are described in
detail in section 1.3.4. The floating pellets formulations design used in
this chapter is the double-coated design. The drug bioavailability is a
major concern during the drug product development. It is affected by 
many drug products factors and physiological factors. Example of an
important physiological factor is the gastric residence time (GRT). If the 
GRT is short and variable, then the drug release is incomplete above
the absorption zone. The latter can cause reduced drug efficacy. The
GRDDS prolong the GRT, to improve drug absorption, and the
subsequent drug bioavailability (Sungthongjeen, et al., 2008).
In literature, the reason why more coating layers were added to the core
pellets is to better control the performance of floating and the sustained
drug release, and also to differentiate the drug product for increasing
innovation. However, applying multiple coating layers is time consuming
and not cost-effective. The development of floating pellets was intended
first to be in the double-coat design, because the two layers system was 





           
        
      
       
     
          
          
     
        
      
        
         
       
     
      
           
        
        
         
         
      
      
          
         
    
       
         
        
       
      
      
        
         
to be a logical option to start with, where each layer has a distinctive and
critical function. In this work, all attempts for making the matrix design
failed as early as during the wet massing process of pelletisation. The 
results obtained in this chapter will be considered as a preliminary work
for increasing the understanding and to uncover challenges prior to 
making a more intricate design (the single-coat design). Because the
single layer will need to provide floating and drug release properties,
which usually require hydrophilicity and hydrophobicity by the same
retarding polymer, respectively. Hence, two opposing functions will need
to be enhanced by only one layer of coating. The aim in this chapter is 
to screen for the feasibility of making the double-coated floating pellets 
systems, using a new spheronisation aid (Avicel HFE102). Screen for 
the feasibility of tabletting the obtained double-coated floating pellets 
systems. The objectives are to obtain new functionality for the Avicel
HFE102 grade (as a spheronisation aid), by obtaining the drug-loaded 
pellets with an acceptable sphericity, and high usable size yield. Also, to
understand the complications in the development of the double-coated
floating pellets and the tabletted systems. For the tabletting studies here,
the form of the cushioning agent will be addressed for the double-coated
floating pellets, regarding the effect of the cushioning form on the
tableting efficiency of pellets binding and film protection. Prior to
conducting experiments, some early risk assessment is needed to
ensure the selection of the high risk factors. When compared to less 
important factors, the high risk factors are expected to highly affect the
quality of the floating pellets.
This chapter start with an early risk assessment work, to identify and
analyse the risk factors involved in the development of the single-coated
floating pellets. The risk assessment work is in line with the quality by 
design (QbD) initiative or methodology. The QbD is a development
approach to the pharmaceutical formulations. This approach has 
relatively new concepts and tools to the pharmaceutical industry that
oversees and improves the quality of the pharmaceuticals. It gives a new





       
      
         
     
       
       
          
      
        
         
      
        
        
        
          
       
    
     
       
        
        
   
       
     
      
         
      
      
       
            
         
        
proactive manner and in a patient-centric view. Therefore, it recognises 
the shortcomings, and consequently, increases understanding, cost
effectiveness, and the total quality. It will complement the basic quality 
requirements regarding efficacy and safety in the pharmaceutical
industry. First, the quality target product profile (QTPP) table was 
constructed, out of which, the critical quality attributes (CQAs) were
identified. The number of factors listed and analysed were 95, out of
which, 27 factors were identified as potentially very high risk factors.
Some of the high risk factors were studied intensively as seen in this 
part of the chapter and subsequent chapters. However, the floating
pellets will finally be enhanced in chapter 5.
3.2. Early Risk Assessment of Floating Pellets
This section will discuss the risk identification and the risk analysis of the
floating pellets, regardless of the formulation design made in this thesis. 
Hence, the information here is also applicable to the single-coated
pellets design as well. The risk evaluation per DoE is not conducted in 
this work. The risk evaluation was conducted through the 
characterisation tests in all results chapters, where various statistical
analysis made (t-testing, and non-linear cubic modelling). However, the
statistical design of experiment (statistical DoE) was not conducted.
3.2.1 Defining the Quality Target Product Profile (QTPP)
and the Critical Quality Attributes (CQAs)
As recommended by FDA and ICH (ICH, 2009), the risk assessment per 
QbD was conducted by considering three risk sub-categories; risk 
identification, risk analysis, and risk evaluation. Quality target product
profiles (QTPPs) were used to identify all the attributes of the best
product characteristics, while the critical quality (product) attributes
(CQAs/ CPAs) were determined from QTPPs, based on preliminary 
knowledge obtained from the floating pellets literature. The QTPP table,
see Table 3.1, lists all of the desired attributes in the dosage form. These
desired attributes are of benefit to the pharmaceutical industry and to









        
        
           
         
         
       
           
     
  
     
    
       
   
      
 
  
    
    
   
 
    
     




        
   
  
    
     
 
    
      
      
          
      









attributes, which needed more efforts to optimise and to control. The 
CQAs were selected from the QTPP table as follows; >60% yield of
cores, >90% yield of 0.71-1.4 mm size, ~1.1 aspect ratio (AR) for shape,
12-24 hrs sustained drug release, 6-12 hrs floating on liquids’ surface,
<1% weight loss of the tablets’ friability, and 6-8 KgF (58.84-78.45 N)
crushing force of the tablets’ hardness.
Table 3.1: Shows the QTPP for the theophylline-containing floating pellets, where the
CQAs are highlighted in grey*.
Attribute QTPP
Dosage Form Pellets in capsule
Route of Administration Oral
Shape Spherical, <1.2 aspect ratio (AR)
Strength 200 mg
Manner of drug release (membrane
matrix)
Membrane-controlled system
Mechanism of drug release Diffusion-controlled system
Dissolution specifications 12-24 hrs with R2>0.9 regarding
a zero-order drug release. (8 hrs 
drug release is acceptable).
Spheronisation yield >60% after drying
Sieving yield >90% 0.71-1.4 mm size range
Floatability >50% floating for >4 hrs (preferably >90%
floating for 6-12 hrs), floating lag time <15
min (preferably <3 min, and acceptable <30 
min).
Surface hardness of coated pellets >0.2 and <1.2 KgF (>1.96 and <11.77 N)
Mechanical Strength Index (MSI) 
coated pellets
>99%; <1% weight loss
Mechanical Strength Index (MSI)
tablets
>99%; <1% weight loss
Hardness of tablets 6-10 KgF (58.84-98.06 N) crushing force**
Disintegration time of tablets <5 min
*The hardness and friability of pellets were not studied in this results chapter. The T 
enhancement chapter for the single-coated pellets addressed all of these attributes.







       
          
         
          
     
       
      
         
    
3.2.2. Risk Identification by the Fishbone Diagram
The product, process, environment and operator factors were identified
and illustrated in the Fishbone diagram similar to (Wang et al., 2015). 
Factors of 95 were identified during the literature review process that
have potential risk effect on the identified CQAs of floating pellets, see
Figure 3.1. The variables of characterisation process parameters can
also be important, especially, the dissolution process parameters.
However, the optimisation of the characterisation process parameters is 
out of the scope in this project. Therefore, the characterisation






                 
            
      
Figure 3.1: Fishbone (Ishikawa; Cause and Effect) diagram, where most possible causes/factors that contribute to the quality of multiple units of pellets as a
floating drug delivery system (mupFDDS) are stated. Namely, the variables of the formulation components and the preparation processes, that leads to the





      
 
       
     
        
     
        
        
         
     
      
           
            
    
          
           
     
        
         
       
         
 
  
3.2.3. Risk Analysis by the Failure Mode Effect Analysis
(FMEA)
After identifying all the contributory factors in the previous section, failure
mode effect analysis (FMEA) was used to semi-quantitatively analyse
each factor for the severity, probability and detectability of failures. The
risk was assessed by obtaining the risk priority number (RPN) (Wang et
al., 2015). After identifying all the contributory factors, an intensive and
critical risk analysis of all factors was undertaken using FMEA, to reduce
the number of factors to the most important ones only. The FMEA will
semi-quantitatively analyse each factor for the severity, probability and
detectability of failures. The risk was assessed by obtaining the priority 
risk number (PRN) (Wang et al., 2015). Based on the PRN threshold of
15, factors of 48 out of 95 exceeded the threshold and were identified
as potentially high-risk factors. However, this number of factors is still
high to investigate in the scope of this project. Therefore, a second PRN
threshold of 20 was set, and 27 out of 95 factors were obtained as 
potentially very high-risk factors, see Figure 3.2. From the FMEA 
outcomes, the coating process variables are most numerous, and most
of which are potential high-risk factors. This is owing to complexity of the
coating process, regarding scale, operation and the other numerous 








             
  
        
        
   
  
        
    
     
     
        
       
            
          
         
          
           
          
   
  
 
        
       
        
         
        
        
        
         
          
         
        
    
Figure 3.2: Risk priority number (RPN) graph of the identified 95 factors for floating
pellets formulation components and preparation processes. The risk score of each 
factor was determined semi-quantitatively through the failure mode effect analysis
(FMEA), two thresholds were set for these RPN values; at 15 and 20, above which
potentially high risk and very high-risk factors were identified, respectively.
3.3. Characterisation of the Core Pellets
The compositions of floating pellets are succinctly outlined in the codes 
table of pellets batches (Table 2.2) and detailed in Table 2.3. The 
preparation process parameters for the pelletisation, coating, and
tabletting listed in Table 2.5.
The double-coated systems are expected to have floating and sustained
drug release profiles that highly controlled by their coating layers.
Hence, the variation in the size of the core pellets is expected to have
low significance to the floating profile, as the floating will be highly 
controlled by the two layers. Hence, unlike the single-coated systems,
the floating here is more dependent on the efficiency of the sub-coated
layer rather than the swelled core pellets. Note that, a decrease in the
core pellets size to 0.71 mm can reduce floating of a swelling system 
(data not shown).
3.3.1. Formulation and process variables for the core 
pellets 
Core pellets were prepared according to the formulation and process 
parameters as outlined in chapter 2. The extrusion and spheronisation
method of pelletisation is considered of a compaction mechanism.
During preparation, long mixing time and higher mixing speed were
avoided, as an increased swelling may result, where a reduced
compactibility of the MCC can be obtained. The latter can affect the 
quality of the core pellets (DFE-Pharma, 2011) and (Muley, et al., 2016). 
Therefore, as recommended by Pauh, 2013, the mixing time, mixing
speed and the extrusion time were at medium values, while the extrusion
speed, spheronisation speed and spheronisation time were kept at high
values (parameters shown in chapter 2). According to the initial





        
          
           
          
   
        
        
     
          
      
         
          
 
             





   
 
 





   
   
   
  





   
 
   
 
   
 





   
 
   
 
   
 
   
             
      
   
     
  
extrusion and the spheronisation processes are more critical to changes 
in the formulation when compared to the tabletting process, like changes 
in water: MCC ratio and drug: MCC ratio. Therefore, the water level was 
maintained fixed at (62.5%), as it was fixed after some trial and error.
3.3.2. Coating weight gain as the coating yield
The coating yields for the sub-coating and the retard-coating layers are
seen in Tables 3.2-3, respectively. In this work, the sub-coating
dispersion of 11±1 % solids produced about 11±1 % weight gain within 
90-135 minutes (i.e., 1.5-2 hours). Also, the retard coating of the
aqueous Eudragit NE15 for ~11% weight gain takes 90-135 minutes 
(i.e., 1.5-2 hours). The approximate quantity used for the coating liquid
was about 21±3 ml/batch, as the flow rate of the coating liquid was 
12ml/h.
Table 3.2: Shows a summary of the coating process worksheet for the first layer (sub-
coating layer of the HPMC and NaHCO3), where the coating weight gain values (the


















yield yield) after 135 
minutes of coating
and 45 minutes of

































Notes: (1) The weight equilibrium step was used prior the coating to minimise the
false negative weight gain effect during coating. Nevertheless, the weight loss
during the coating can also result due to other reasons, as observed with 0.725-1 






              
      
 
 
              
















   
   
   
  









   
 
   
 
   
 
   
 
   
 
   
 
   
 




         
           
     
         
        
      
      
        
    
(2) The pump was set to 100% to clean tube and the nozzle with the distilled water 
after 2-3 batches and for 20-30 minutes. The isopropanol (IPA) was used as well to 
clean the blocking caused by the polymethacrylates dispersion.
Table 3.3: Shows a summary of the coating process worksheet for the second layer



















yield yield) after 135 
minutes of coating
and 45 minutes of

































3.3.3. Visual characteristics of the core pellets during 
preparation
The physical appearance, spheronisation yield, and the used narrowed
size range of the different batches are presented in Table 3.4. The
extrudates can show different visible thicknesses and surfaces (thick or 
thin, and smooth or perforated). The core pellets can show different
visible shapes as well (dumbbell, irregular, rounded or round pellets). In
this study, no dumbbell or irregular shapes were obtained. The batches 
(B1D-B14D) of high microcrystalline content (60%) showed thick and
smooth extrudates, which is owing to the increased MCC content that 





        
        
        
      
            
       
        
          
     
         
         
      
         
        
          
          
    
       
     
 
  
       
    
  
 




































For the first time, a new functionality was discovered for the mannitol-
containing Avicel HFE102 grade (as a spheronisation aid), which was 
successfully applied to make pellets using the extrusion and the
spheronisation processes. Results revealed that the Avicel HFE102
grade can be at least as efficient as the Avicel PH101 grade.
The Avicel HFE102 consistently provide higher spheronisation yield and
more narrowed size range (1-1.18 mm sieve yield) that reaches for up
to 100%, and 44%, respectively. Regardless of the Avicel grade, the
batches of higher MCC content (60%) can results in lower 
spheronisation yield 76.1-83.3% when compared to the batches of the
lower MCC content (40%). Although that the high Avicel HFE102
content (60%) showed relatively less spheronisation yield (76.1%), the
yield of the used narrowed size range (1-1.18 mm sieve yield) was 
higher than any other batch (44.2%). The latter may be owing to the
mannitol content -in addition to the MCC content-, which could further 
increase the absorption of the distilled water, resulting in a better 
consistency for the wet mass.
Table 3.4: Summary of the visual observations of the core pellets during preparation 
and the total yield of the core pellets after spheronisation, drying and sieving.
Batch
code***



































































       
             
          
      
  
       
   
 
  
         
           
          
         
            
         
        
         
         
            
          
         
      
        
           
         
      
          
          
        
          

















*The spheronisation yield: is the dry core pellets yield after spheronisation that 
based on the weight of the wet core pellets and the weight of the starting materials
(powders). The sieving yield: is the size fraction yield of the 1-1.18 mm core
pellets that based on the weight of the latter size fraction and the total dry core 
pellets.
**The extrudates appearance had a medium length (~1cm).
***Batches codes can be defined in Table 2.3.
3.3.4. Particle size analysis 
A set of nine sieve stacks ranging from 0.25-2 mm were used to
separate the sizes of the core pellets. The summary of the core pellets’
size analysis is seen in Table 3.5 and Figure 3.3. In the size analysis of
the core pellets, different fractions were calculated, including the used
narrowed size range, the useable yields, and the fine and the coarse
fractions. Also, the inter-quartile range (IQR) and the median class were
calculated. For all batches, the IQR values were less than 0.4 mm,
indicating that the variation from the mean is not highly skewed. The
median values were about 1mm, which is within the usable range (0.72-
1.4 mm), and highly close to the used narrowed size range (1-1.18 mm).
Moreover, the coarse and the fine fractions were low (<15%), as desired,
because these fraction are not usable for the subsequent coating.
Large usable yields (83-95.4%) and negligible coarse fraction (0-1.4%) 
were obtained for Avicel HFE102 containing core pellets, regardless of
the drug loading level. In particular, when the Avicel HFE102 was used,
a higher yield of the 1-1.18 mm size (27-44%) was obtained, while a
slightly smaller yield of 0.71-1.4 mm core pellets was obtained. These
findings were in comparison with the Avicel PH101. The Avicel HFE102
containing core pellets showed IQR values in the range of 0.28-0.3 mm,
which indicates that the size distribution of these pellets is less scattered
when compared to the core pellets of the Avicel PH101 grade





        
          
       
     
         
         
        
    
          
         
     
        
            
           
             
           
           
           
          
        















          
          
          
          
    
 
loading batches (B7 and B8). This low scattering may indicate that the
mannitol could slightly lower the overall spread of the core pellets’ size
during the spheronisation process, especially at higher drug loading. As 
complied with the latter finding, slightly higher usable yields (83-95.4%) 
with maintained sphericity were obtained. Hence, the mannitol in the
Avicel HFE102 grade can provide a comparable or further aid in the 
spheronisation process, indicating that the Avicel HFE102 provided
better plasticity for the wet mass.
The above quality attributes of the usable yields and aspect ratio are
highly desirable during the pellets making using the extrusion and the
spheronisation processes (Chu & Chaw, 2014). Besides, owing to the 
mannitol pore forming ability, this grade of mannitol-containing MCC
may have a potential aid in floating, as it will be seen later in this chapter.
Moreover, the core pellets of the Avicel PH101 with 40% drug loading
showed an IQR value of 0.29 mm. In the first instance, this could indicate
that a small fine fraction and a small coarse fraction were obtained.
However, these fractions were found to be more than 14% of the
spheronisation yield. Therefore, the low IQR value was not due to the
small fine fraction and/or the coarse fraction. Instead, the low IQR was 
due to the large yield of the 1.18-1.4 mm core pellets (>45%).
Table 3.5: Shows the summary of the core pellets size analysis.















B1D and B2D 24.82 85.73 10.26 4.01 0.29 1.18 mm (45.17%)
B3D and B4D 44.21 82.96 15.78 0.03 0.30 1.00 mm (44.87%)
B5D and B6D 20.16 82.80 12 5.20 0.39 1.18 mm (41.12%)
B7D and B8D 27.00 95.40 3.42 1.42 0.28 1.18 mm (46.8%)






          




    
    
    
    

















B1 and B2; Avicel PH101, 
40% drug loading 
70 
B3 and B4; Avicel HFE102, 
40% drug loading 60 
B5 and B6; Avicel PH101, 
60% drug loading 50 
B7 and B8; Avicel HFE102, 
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Core Pellets Size (mm) 
Figure 3.3: Shows the particle size distribution based on the cumulative undersize (%) of the sieved core pellets (n=1) intended for double-coating. The red 






       
       
        
         
          
       
           
         
            
        
          
          
          
         
        
      
         
      
      
         
          
       
          
     
       
         
          
3.3.5. Sphericity testing by the image analyser
The core pellets were quantitatively analysed using the images from the
light microscope, where the shape-related parameters were calculated.
These parameters were the Feret diameters, the perimeter, the
circularity, the area, and the aspect ratio. The core pellets (n=30) 
showed an average aspect ratio (AR) of 1.07-1.11, with <4% relative
standard deviation (RSD%), where the average circularity values were
close to a value of 1. As complied with (Chu & Chaw, 2014), these
values are desired for achieving high sphericity of the core pellets, see
Table 3.6. It is because that if the AR increase for more than 1.2, it
means that the difference between the Fmin and Fmax diameters of the
same core pellet is large enough to violates the spherical shape. The
circularity of a sphere is equal to one, which means that the core pellets 
should approach the circularity value of one to ensure sphericity. The
feasibility of the Avicel HFE102 grade as a new spheronisation aid was 
evident according to this core pellets studies, and it was at least as 
efficient as the Avicel PH101 grade.
It was encouraged in literature to find alternative spheronisation aids that
are co-processed with other materials (Jain, et al., 2010). This 
alternative and new spheronisation aid may help in addressing the 
drawbacks of the MCC, which encourages more studies to be made in
this grade of Avicel. The drawbacks of MCC claimed in the literature are
the absorption/adsorption of drugs, deactivation of drugs like ranitidine,
and inducing long dissolution time due to the non-disintegration of
pellets (Jain, et al., 2010). 
In this project, the latter issue was not evident in the preliminary study 
of Avicel PH102 and HFE102 grades done, because the uncoated core





        




   
 




   
 
              
   
 
             
   
 
             
   
 
             
         
  













1.11 ± 0.05 1.23 ± 0.08 0.91 ± 0.03 3.91 ± 0.23 0.96 ± 0.02 1.1 ± 0.04
B3D and B4D
(HFE,40)
1.11 ± 0.05 1.21 ± 0.07 0.91 ± 0.03 3.88 ± 0.19 0.96 ± 0.01 1.11 ± 0.04
B5D and B6D
(PH,60)
1.05 ± 0.05 1.13 ± 0.05 0.93 ± 0.02 3.66 ± 0.18 0.96 ± 0.02 1.07 ± 0.02
B7D and B8D
(HFE,60)
1.07 ± 0.06 1.14 ± 0.06 0.94 ± 0.02 3.69 ± 0.20 0.97 ± 0.01 1.07 ± 0.02
*Values were entered in the following format: (Mean±SD), n=30. Definitions and equations are seen in the Abbreviation page. Batches 







      
   
          
           
         
        
         
            
  
         
         
          
        
           
             
        
       
      
     
        
          
          
      
         
       
           
       
         
         
3.4. Characterisation of the Sub-Coated Pellets
For the sub-coated pellets, only the floating study was performed.
3.4.1. The floating study
According to the preliminary work, when the MCC was used alone with
the drug in the core pellets, it could neither provide sustained drug
release nor maintain the floating, until a suitable coating was applied to
the core pellets. Therefore, the sub-coating layer was applied solely to
initiate and maintain the floating. However, the sub-coating layer alone
will not be sufficient for fulfilling the purpose of floating, as seen in the
next paragraphs.
The sub-coated pellets were tested for their floating in a 0.1N HCl
medium, see Figure 3.4. The floating duration for each batch was 
recorded (n=100 pellets), and the floating duration started once the sub-
coated pellets were introduced into the beaker. For the floated sub-
coated pellets, no floating lag time was seen. For the sunken ones, there
was no ability to rise again to the surface, due to the lack of the controlled
swelling and the gas entrapment mechanisms. The lack of the latter 
mechanisms resulted in an excessive swelling and quick gas release,
which substantially impaired the sub-coating layer.
The sub-coated pellets containing the film of the 3.33: 6.66 w/w% 
NaHCO3: HPMC dispersion showed a prolonged floatation when
compared to the film of the opposite ratio (p-value<0.001). That could
be due to the binding ability of HPMC that may relatively reduce the gas 
escape from the pellets. This gas is responsible for lowering the density 
of the pellets. This finding is consistent with the relationship obtained by 
(Sungthongjeen, et al., 2006). This was caused by the higher HPMC
ratio, which may indicate an aid in the entrapment of the gas generated
in the floating process. Subsequently, the relatively prolonged
entrapment of the gas will maintain the lowered density status of the







      
        
        
      
          
           
        
         
    
 
      
              
            
       
           









None the sub-coated pellets showed satisfactory floating duration.
Nevertheless, it was found that the higher the HPMC, the better the 
synergistic effect in prolonging the floatability. According to (Treesinchai,
et al., 2016), the HPMC K100LV + >10% foam powder of the
polypropylene will allow the tablet to float immediately upon contact with
the liquid surface and for a duration of >12 hours (remained floated when
the last measurement was taken). The latter in that study was achieved
without the addition of a retarding polymer and without applying any 








B1-S1 B2-S2 B3-S1 B4-S2 B5-S1 B6-S2 B7-S1 B8-S2 
Batch
Figure 3.4: Summary of floating study for the sub-coated cores*.
*Values were entered in the following format: (Mean±%SD). The runs were under no
mixing and no control of temperature; i.e. under an ambient room temperature of 22°C. 
*”6” stands for a sub-coating film made of the dispersion strength of 6.66: 3.33 w/w%
NaHCO3: HPMC ratio, while “3” was a vice versa. All batches have a second layer; the
retard coating film of the Eudragit NE15D without ethanol. N=100 pellets. The Batches





















   
       
      
  
 
     
        
       
           
             
       
          
     
         
      
          
              
           
          
            
        
          
      
      
          
         
          
          
   
         
        
3.5. Characterisation of the Double-Coated Pellets
The double coated pellets were initially studied for their floating profiles,
then for their sustained drug release profiles and morphological
features.
3.5.1. The floating study
The double-coated pellets were tested for floatability, i.e., floating lag 
times, floating duration, on-surface floating, and redundant floating.
Batches were all tested in triplicate; see Table 3.7 and Figure 3.5. For 
all batches, the floating lag time was 0-7 minutes, floating duration for 3
to >12 hours, the floating % of the coated pellets counted on surface
was 34-98%. Where most of the coated pellets (>85%) maintained the
floating on the liquid surface for a minimum of four hours. The floating
profiles preferred the high-level drug loading of 60% (p-values<0.01),
then to the lesser extent, for the presence of the mannitol-containing
Avicel grade (Avicel HFE102) (p-values>0.05). The floating was 
maintained for a minimum of 4 hours, where >50% of the pellets floated
without a lag time to start the floating upon immersion in the liquid.
To lesser extent, the channel formation can also increase when the MCC
is being co-processed with the 10% mannitol (Avicel HFE102 grade). It
is worth noting here that the MCC only can swell, hence, that can also
accommodate for the generated gas. The channel formation provided
larger space for the generated CO2 gas to be entrapped, resulting in the
decreased pellets’ density, followed by a better buoyancy/floatability.
This discussion is also described by (Sungthongjeen, et al., 2006). Upon 
the gas generation, the presence of Avicel PH101 along with the lower 
drug loading (40%), and higher NaHCO3: HPMC ratio sub-coat layer will
ease the escape of the air bubbles, as seen for B1. Hence, the quick 
gas release or escape to the outside of the coated pellets resulted in
poor floating profiles.
The floating is due to the immediate gas/air generation and entrapment







         
      
           
      
          
        
        
      
          
        
        
         
         
       
   











      
      
      
      
      
      
      
      
       
             
         
        
    
            
 
          
         
   
 
is owing to the nearby sub-coating layer that is concentrated with the
gas-generating agent. Another explanation for the immediate floating
can be attributed to the coating process. The sprayed dispersion that
contains the gas generating agent (NaHCO3) may had interacted with
some of the slightly acidic drug molecules on the surface and in the
inside of the core pellets. This possible salt-acid interaction or 
neutralisation reaction will generate some entrapped gas that induced
the low-density of coated pellets for an immediate floatability. Therefore,
the use of Avicel HFE102 along with the higher drug loading,
supplemented with a double coating system is a promising design for 
the floating pellets and the subsequent gastro-retention of pellets.
However, the dissolution results were not sufficient as most of the
coated pellets showed a complete drug release in four hours. Therefore,
further investigations were conducted to lengthen or to sustain that
period for longer hours.
Table 3.7: Summarises the floating duration and floating percentage of the double 
coated pellets (n=3, based on mean values, SD of total floating shown in Figure 3.5). 














B1D-PH,40,6* 5 3 34 10 44
B2D-PH,40,3 5 6 57 8 65
B3D-HFE,40,6 5 6 69 16 85
B4D-HFE,40,3 7 8 72 14 86
B5D-PH,60,6 0 8 97 3 100
B6D-PH,60,3 0 8 96 3 99
B7D-HFE,60,6 0 >12 98 2 100
B8D-HFE,60,3 0 >12 97 3 100
*”6” stands for a sub-coating film made of the dispersion strength of 6.66: 3.33 w/w%
NaHCO3: HPMC ratio, while “3” was a vice versa. All batches have a second layer;
the retard coating film made of the Eudragit NE15D dispersion without ethanol.
**The lag time was recorded when >40% total floating of the double coated pellets 
was obtained (by counting).
***The values were selected based on the period that maintains 40-100% total
floating (by counting). 
****All percentages were averaged for the period of 4hrs floating. On surface
floating % was calculated based on the counting method (Sungthongjeen, et al., 








          
      
    
 
*****Total floating %= on surface floating % + suspended pellets %. The suspended 
pellets term relates to when the pellets show a tendency of floating, but, yet






                   
                     
            
Figure 3.5: The total floating percentages of the double coated pellets. S1 stands for the film made of the sub-coating dispersion: 6.66: 3.33 w/w% NaHCO3: 
HPMC, while S2 stands for the film made of the dispersion of the latter opposite ratio, S3 is the retard coating film made of the Eudragit NE15D dispersion




    
         
         
         
       
       
         
          
           
      
         
               
             
         
          
        
 
 
          





3.5.2. Quantification of the drug powder, theophylline 
This section is relevant to the drug release profiles obtained in all results 
chapters, regarding the calculation of drug release. For convenience, it
was placed before the drug release profiles of the double-coated floating
pellets. To enable the quantification of the drug theophylline, a
calibration curve was made from the UV absorbance of diluted
concentrations of the drug theophylline in the 0.1N HCl. The readings 
were graphed, and a linear line was obtained with a high regression
value (R2=0.9999). That is, the regression equation will be used to
quantify the theophylline concentration for the drug formulations. The 
regression line equation (y=mx+b) is also shown in Figure 3.6. The y is 
the value in the y-axis, the m is the slope of the line, the x is the value in
the x axis, and b is the intercept of the line in the y-axis. From the
regression line equation here, the x represents the concentration of the
drug at a specific absorbance value (y). This is based on the given
values of the slope (m) and the intercept (b).
Figure 3.6: Calibration Curve of Theophylline using UV spectrophotometer at 268 nm






   
        
        
         
         
     
       
           
         
          
         
           
         
        
       
       
      
        
         
       
       
         
         
        
      
 
3.5.3. Dissolution study
The double coated pellets were tested for their sustained drug release
characteristics via the dissolution study, as shown in Figure 3.7. Batches 
were all in triplicate. The drug release profiles of all formulations nether 
showed sufficient sustained drug release for the 12 hours’ period, nor 
for the 4 hours’ period.
The sustained drug release performance requires a zero-order drug
release, where the slope in the regression line equation can be
considered as the rate constant if the regression line coefficient (R2) is 
high (usually accepted if >0.9). Hence, the regression line equation also
considered a form of the integrated rate law for the zero-order reaction:
[A]t=-kt+[A]0. Where the rate constant (k) equal to the slope value (m).
For all formulations, the regression line equations were not linear, even
for the first four hours of the drug release (R² = 0.2341-0.5094). Hence,
there was no zero-order drug release obtained for all formulations.
Hence, this confirms that the drug release profiles did not sufficiently 
show a sustained drug release.
Although that, increasing the coating weight gain may improve the
sustained drug release profiles. This appears to be discouraged here as 
the floating profiles can be further compromised when the retard coating
gain increases further. Forward to this point, further screening was 
attempted to enhance the retard coating layer of the batch B7D-
HFE,60,6 (which showed the best floating), and examine the feasibility 
of tabletting this batch of the double-coated pellets, to understand the






                
                      
      
 
 
    












0 2 4 6 8 10 ,
Time (Hours) 
B1 (PH101-40%theo-soln1) B2 (PH101-40%theo-soln2) B3 (HFE102-40%theo-soln1) B4 (HFE102-40%theo-soln2) 
B5 (PH101-60%theo-soln1) B6 (PH101-60%theo-soln2) B7 (HFE102-60%theo-soln1) B8 (HFE102-60%theo-soln2) 
Figure 3.7: Dissolution of the double coated pellets formulations. S1 stands for the film made of the sub-coating dispersion: 6.66: 3.33 w/w% NaHCO3: HPMC, 
while S2 stands for the film made of the dispersion of the latter opposite ratio, S3 is the retard coating film made of the Eudragit NE15D dispersion without the


















        
         
     
        
    
       
          
           
      
         
        
       
        
           
          
   
3.6. Characterisation of the Double-Coated 
Pellets, Further Screening and Tabletting 
Feasibility
Further screening was attempted to optimise the retard coating layer of
the batch B7D-HFE,60,6 (which showed the best floating) and examine
the feasibility for tabletting this batch of the double-coated pellets, to 
understand the compression complications of the double-coated pellets.
3.6.1. The coating weight gain for the pellets
The coating parameters depicted in the chapter 2. The coating process 
worksheet and the weight gains are recorded in Tables 3.8-9. The core
pellets of a 1-1.18 mm size where sub-coated by the 6.66: 3.33 w/w%
NaHCO3: HPMC dispersion. The latter dispersion has a lower tendency 
for blockages in seen in the lab for the previous screening work, and
because of its higher spraying efficiency, owing to the lower surface
tension (39.13±0.66 instead of 48.34±2.00 mN/m) for the opposite
strength). For more details about the surface tension study of liquids,
results are listed in Table 5.1. The retard coating layer resulted in an






                   
    
  
  
   
 
 
   
    
  
    
    
    
   
   











      
                        
      
                       
             
 
          
    





    
 








   
 
 
     
       
Table 3.8: Shows the coating process worksheet, where the monitoring of the coating weight gain can be seen.






at 60 °C (%)*
Weight of core pellets
after drying 10 
minutes at 60 °C (g)
The final wet weight















11.17 00.02 11.17 12.89 12.87 1.85
*This refers to the drying equilibrium step, where the weight of the core pellets will be recorded once there is no further decrease in the weight 
upon further drying or less than 0.1% weight loss was obtained.
**The wet weight gain was taken twice or trice during the coating process to speculate the remaining time for the targeted dry CWG% to be
reached. The ait temperature exposed to the core pellets under coating was at 50 °C.
Table 3.9: The coating weight gain (CWG) obtained for attempting to optimise the double-coated systems.
Batch code Targeted dry weight
gain on the core
pellets (g)*
Targeted dry weight
gain on the core
pellets (%)
Dry weight gain obtained on 
the core pellets (g)








01.78 16.00 01.70 15.31
* The targeted CWG solids (g)= (batch size in mass*targeted CWG%)/100. 





        
        
        
     
        
           
      
  
   
         
      
           
       
        
      
          
        
      
          
           
          
          
        
        
      
       
        
     
         
        
        
3.6.2. The tabletting studies
A feasibility study was conducted to develop tablets that contains the 
double-coated pellets. Effects were studied of using different cushioning
forms on the tablets’ thickness, diameter, hardness, disintegration,
friability, dissolution, and floatability parameters. These outcomes will 
provide some information for the quality control regarding the tablets 
made from the double coated pellets. It is desired that the double-coated
pellets show similar drug release and floating profiles to the tabletted 
double-coated pellets.
i. The composition of tablets
The B7D batch (has the higher NaHCO3 content in the sub-coating
layer) was selected, because the higher NaHCO3 will cause less 
blockages in the coating tube and the nozzle of the coater. The latter 
observation was also supported by the lower surface tension obtained
by this coating dispersion (39.13±0.66 mN/m), when compared to the
lower NaHCO3 content dispersion (48.34±2.00 mN/m). More details 
about the surface tension results of other coating dispersion not used in
this chapter, the reader is kindly advised to see Table 5.1. And also
because it showed good floating.
The tablet weight was 400 mg, the maximum weight available for the die
tooling in the tabletting machine. Hence, the tablet weight was limited to
400 mg. The total coating weight gain of the two layers was 27% while 
the drug loading for the core pellets of B7 was 60%. For the tablets’
compositions, see Table 3.10. During the compression of double-coated
pellets, it is important to allow for a sufficient cushioning and binding. 
Therefore, the cushioning excipient was used, and it was at >29% of the 
tablet weight to fill the voids between the coated pellets as possible 
(Chen, et al., 2017). Thus, a strong and non-friable/indurate tablets and 
protected coated pellets can be obtained.
Moreover, the cushioning should protect the films of the coated pellets 
from crushing during compression. The Avicel HFE102 was used as the





        
         
          
              
           
         
              
 
     
    
  
   
 
  
   
    
  
     
     
             
         
             
               
          
 
       
      
            
           
          
      
       
          
          
           
      
    
          
      
           
       
two different forms were assessed to determine which cushioning form 
is the most effective in the pellets tabletting. From the above information,
at least two tablets were needed to accommodate for the one dose of
200 mg theophylline. That is, 50% of the dose is in one tablet, and the
drug: excipient ratio is 1:4 in one tablet, as seen in Table 3.10. For the
future scale up manufacturing, a study for the tablet’s weight change
from 400 mg to 800 mg is needed, to allow for one full dose in one tablet
to be tested. 
Table 3.10: Shows the summary of the tablets compositions






The number of tablets
per batch**
B7D2CPowder 210.83 (52.7%) 189.17 (47.3%) 61
B7D2CPellets 210.83 (52.7%) 189.17 (47.3%) 61
*The amount was calculated based on the 60% drug loading (DL) and 27% coating
weight gain (CWG), and based on the cushioning amount.
**The batch outcome is 12.8683g coated pellets, considering that 60% DL and 27%
CWG were applied, then the dose is 421.66 mg, half of the dose was 210.83 mg
that comprise one tablet, and that half of the dose was available for the 61 tablets
to make.
ii. Falling on the floor friability study
This test is an early indication for the friability of the tablet. The 
compression force was set to 21.5 kN, based on trial and error (data not
shown). To pass the test, the falling of a tablet on the ceramic floor from 
a meter-high distance should show no visual loss, like tablet’s chipping
or breakage. Based on the preliminary observations obtained, the
compression force for tabletting should provide a minimum strength of 5
in kilograms-force (KgF) or 49 N for the tablet of 400mg weight
(1KgF=9.80665N), to avoid a friable tablet upon falling. The desired
maximum strength was set to be around 10 KgF or 98.05 N, to minimise
the film’s rupture and/or film’s fusion upon compression. The film’s 
rupture and/or film’s fusion may negatively or positively affect the
dissolution and the floating profiles, and at worse, that may cause a
complete failure to the film.
When the die depth of 5 rounds was set, the tablets containing the





           
          
         
            
      
             
      
           
          
       
   
   
       
       
      
        
       
     

























   
 
        
              
        
   
 
    
      
         
       
         
falling, which were largely weak with a crushing strength of 3 KgF (29.42
N). However, when the die depth decreased to 5.5 rounds, these tablets 
were demonstrated an intact form upon falling without visual losses.
Hence, the effect of the same compression force increase when the die
depth decrease. The tablets containing the cushioning powder were
strong and intact at the die depth of 5 rounds. Therefore, based on this 
preliminary test for the tablets strength, when the powder cushioning
was used (at 21.5 kN compression force), the tablets are shown to be
non-friable, without the need to decrease the die depth to 5.5 rounds. 
Hence, the latter parameters’ values were set for making the tablets for 
the quality control testing.
iii. Hardness study
Complying with the findings above, tablets containing the cushioning
pellets result in hardness strength of 7.13±0.9 KgF (69.92 N). On the 
other hand, the tablets containing the cushioning powder showed higher 
hardness strength of 10.14±0.59 KgF (99.44 N) without decreasing the
die depth, as seen in Table 3.11.
Table 3.11: Shows the tablets properties (thickness, diameter and hardness)













































*20 tablets were used as per the (British-Pharmacopoeia., 2017).
**The cushioning pellets will be capable of accommodating in a less die depth, owing
to their higher poured packing properties that result in a lower poured volume. It was
capable of accommodating in 5.5 rounds die depth instead of 5 rounds die depth.
iv. Drum friability study
The drum friability study of the tablets was conducted to assess the
strength of the tablets, to confirm whether the tablets can tolerate the
subsequent stresses of coating, shipping, and handling. As complied





       
           
        
          
         
         
       
 
      
     
  
 
   
 
 
   
    
    
          
   
 
   
         
       
          
        
         
          
        
  
        








    
    
        
  
      
       
       
the cushioning powder containing tablets showed strong and intact
tablets at the die depth of 5 rounds. An acceptable loss of materials was 
obtained (<1%), see Table 3.12. Although that the cushioning pellets at
a die depth of 5.5 rounds produced intact tablets upon falling, the tablets 
failed in the drum friability test (~9% weight loss). The cushioning pellets 
showed weaker binding with the double coated pellets resulting in friable
tablets, due to that the surface area available for pellets is smaller than
that of the powder. 
Table 3.12: Shows the tablets firability results.







B7D2CPowder 6.5g 6.47g 0.3%
B7D2CPellets 6.55g 5.92g 9.6%
*16 tablets were used as per the (British-Pharmacopoeia, 2017), which is based
on the weight of the tablet.
v. Disintegration study
Tablet disintegration or the disassembling of the coated pellets from the
ensemble pellets was studied. Regardless of the cushioning form used
in the tablet, the disintegration time needed to disassemble all pellets 
was only one minute, as shown in Table 3.13. This is a fast disintegration
time, which means the complete contact with the surrounding liquids will
be quick for double coated pellets. Hence, the initiation of the floating
mechanism will be quick as well. These tablets can be named as 
disintegrating tablets.
Table 3.13: Shows the tablets disintegration results.








B7D2CPowder 10 sec 1 min 1 min
B7D2CPellets 10 sec 1 min 1 min
*6 tablets were used as per the (British-Pharmacopoeia, 2017).
vi. Dissolution study
Interestingly, the tabletted pellets showed similar drug release profiles 
to the non-compressed ones, regardless of the cushioning form used.





        
           
       
          
        
       
         
         
       
          
        
      
was highly protected upon compression as seen in Figure 3.8. However,
all drug release profiles showed complete drug release within 4 hours.
Although that the other quality control tests for tablets were promising
regarding the use of the powder cushion, the sustained drug release
function is not sufficient for the double coated systems to succeed. The 
latter was even after the coating weight gain increased from ~11 w/w% 
(in the previous screening work) to 15.3 w/w%. Even the ~4 w/w%
increase in the coating weight gain did not sufficiently slow down and 
streamline the drug release profiles (the regression coefficients; R2=0.8-
0.9). Further excessive increase in the coating weight gain was not
encouraged, because that would highly compromise the acceptable yet






                   
                   
  
 
   15.3% 15.3% 15.3%
Figure 3.8: The drug release profiles, as an attempt to optimise the double-coated systems, using ~11% weight gain of the 3.33: 6.66% HPMC: NaHCO3 and 






   
       
         
         
         
         
            
          
      
        
      
      
        
      
    
          
        
         
        
       
           
       
           
          
         
         
      
vii. Floating study
Regardless of the cushioning form used, the floating profiles were
comparable to those of the non-compressed pellets and maintained at
least a 70% floatation for 10 hours. Afterward, the non-compressed
pellets remained floating for more than 24 hours, but the percentage
dropped to around 40% for the tabletted pellets, see Figure 3.9. The 
drop in the floating percentage is due to the effect of compression on
the integrity of the retarding film and the sub-coating film, where some
pellets may have ruptured during compression. Therefore, an
acceptable but not optimum value of floating (>50%) for 10 hours can
be obtained when double coated pellets are compressed.
Moreover, the tablets prepared from the cushioning powder required
shorter lag times to reach the surface and become buoyant/floated
(9.75±0.35 minutes) while the tablets prepared from the cushioning
pellets took longer and displayed heterogeneous lag times (20.5±9.9
minutes). Hence, a fusion for the retard film might result upon the
compression with cushioning pellets, making the film less permeable to
the dissolution medium. Therefore, the surrounding liquid intended to
reach the sub-coat film will be delayed or slowed.
The compression with the cushioning powder is providing tabletted
pellets with a desired but not optimum floating lag time (i.e. <15 minutes,
but >3 minutes). The latter finding complied with the non-compressed
pellets, where a lag time of 7.5±3.54 minutes was needed to reach the
surface. When compared to B7 from the previous screening work of the
double coated systems, the non-compressed batch here showed ~20%
decrease in floating. The latter decrease in floating is expected as the







                





Figure 3.9: The floating profiles of the double-coated system, using 11% weight gain of the 3.33: 6.66% HPMC: NaHCO3 and 15.3±0.7% weight gain of the 






       
        
        
       
            
     
          
   
           
        
        
        
         
      
           
     
         
           
       
      
       
         
          
        
         
      
          
         
        
           
      
3.7. Conclusion
For the first time, a new functionality was discovered for the mannitol-
containing Avicel HFE102 grade (as a spheronisation aid), which was 
successfully applied to make pellets using the extrusion and the
spheronisation processes. Results revealed that the Avicel HFE102
grade can be at least as efficient as the Avicel PH101 grade. The Avicel
HFE102 consistently provide higher spheronisation yield and higher 
narrowed size range (1-1.18 mm sieve yield) that reached up to 100%,
and 44%, respectively.
For the floating of the double coated pellets, nearly 80% of the double
coated pellets showed immediate floating without a lag time to float. The 
latter finding is due to the immediate gas/air generation and entrapment
upon pouring to the dissolution medium. This immediate gas generation
is owing to the nearby sub-coating layer that is concentrated with the
gas-generating agent. Another explanation for the immediate floating
can be attributed to the coating process. The sprayed dispersion that
contains the gas generating agent (NaHCO3) may had interacted
through a neutralisation reaction with some of the slightly acidic drug
molecules on the surface and in the inside of the core pellets. This 
possible salt-acid interaction or neutralisation reaction will generate
some entrapped gas that induced the low-density of coated pellets.
Successful floating profiles for the coated pellets were achieved when
the Avicel HFE102 was used. Where most of the coated pellets (>85%) 
maintained the floating on the liquid surface for a minimum of four hours.
The floating profiles preferred the high-level drug loading of 60% (p-
values<0.01), then to the lesser extent, for the presence of the mannitol-
containing Avicel grade (Avicel HFE102) (p-values>0.05). Therefore,
the use of Avicel HFE102 along with the higher drug loading,
supplemented with a double coating system is an efficient design for the
floating to occur. However, the dissolution results were not sufficient as 
most of the coated pellets showed a complete drug release in four hours.






      
      
         
        
       
           
           
         
        
       
        
        
     
        
       
     
        
        
        
     
         
       
        
       
          
          
       
          
       
          
          
     
sustain that period for longer hours. The chosen formulation for further 
investigation (B7) has the core pellets containing the Avicel HFE102, 
with 60% drug loading. The higher ratio of the NaHCO3: HPMC
dispersion was selected for the sub-coat layer. Also, a higher coating
weight gain (~15.3%) was used instead of (~11%) of the Eudragit NE15
dispersion, to ensure the increase of the retarding layer effect. The latter 
attempt was to enhance the sustained drug release profile of the double
coated systems. However, the drug release profiles did not improve,
even after tabletting of these coated pellets. More studies were done on 
the B7 to assess the feasibility for the tableted double-coated pellets.
Two types of the cushioning excipients were used, the Avicel HFE102
powder and the Avicel HFE102 pellets. The cushioning powder of the
Avicel HFE102 showed the optimum results regarding the tablet's 
strength and friability. However, regardless of the cushioning form used,
similar floating profiles were obtained for 10 hours and similar drug
release profiles were obtained as well.
To sum it up, it was feasible to successfully attain the core pellets by a 
new spheronisation aid (Avicel HFE102). It was encouraged in literature 
to find alternative spheronisation aids that are co-processed with other 
materials (Jain, et al., 2010). This alternative and new spheronisation
aid may help in addressing the drawbacks of the MCC, which
encourages more studies to be made in this grade of Avicel. The 
drawbacks of MCC claimed in the literature are the
absorption/adsorption of drugs, deactivation of drugs like ranitidine, and 
inducing long dissolution time due to the non-disintegration of pellets
(Jain, et al., 2010). Also, the understanding of the double-coated floating
pellets design was important before reducing the system into the single-
coated floating pellets design. The latter is more intricate yet more cost
effective design. This intricacy is owing to the eliminating of the sub-
coated layer, and using only one layer to achieve both the sustained
drug release and the floating by a controlled swelling mechanism with












   

















     
           
       
           
          
           
           
          
         
          
           
     
        
          
          
       
           
         
           
       
      
          
          
      
      
       
         





The gastro-retentive drug delivery systems (GRDDSs) were described
in the introduction of the previous chapter and described in detail in the
introduction chapter. The chapter aim is to screen for the feasibility of
making the single coated pellets, where the core pellets are intended to
swell under the control of the Eudragit NE15 retard layer. The objectives 
are to apply a single coating layer of the Eudragit NE15 dispersion, to
produce the floating and the sustained drug release properties. Also, to
obtain the drug-loaded pellets with an acceptable sphericity, and with a
large usable yield. And to understand the complications in the
development of such system. The targeted outcome is to make an
effervescent type and non- effervescent type of such system, to improve
design efficiency. This chapter will provide the bases for further 
enhancement work in the single-coated floating systems. These coated
pellets are expected to reduce a coating step in the floating pellets 
design. Because the pellets are to be floated with or without an
effervescent agent, and aimed for less preparation time and less 
materials to be used, owing to the single coating stage. Hence, the
floating layer in the double coated floating pellets could be removed with
a maintained floating profile, with a pH-independent manner, and in an
easier and more cost-effective manufacturing procedure. The used tools 
of risk assessment allowed for more process understanding and allowed 
for a subsequent improvement in the drug product development. In the
making of core pellets intended to be single-coated, the addition of
polyvinylpyrrolidone (PVP) and NaHCO3, make the liquid binder 
optimisation becomes more challenging. That is, only the non-PVP 
containing core pellets were made successfully (AR<1.2). The floating
and the sustained drug release properties were variable for all coated







       
   
          
           
         
          
           
       
        
           
      
          
            
 
     
  
 
       
       
         
       
        
        
      
        
        
          
       
    
         
         
4.2. Characterisation of the Core Pellets
4.2.1. Considerations for drying and curing
The long drying of both core pellets and coated pellets was to provide
<5% moisture in the coated pellets. Hence, that can increase protection
to the coated pellets from the microbiological, chemical and physical
instabilities. Also, the long drying time ensures that curing occurred. The
curing during storage will not be expected to happen, as the remaining
water is <5 % in the coated pellets.
During a preliminary study, the additional drying and curing times did not 
affect the drug release and the floating profiles when compared to the
non-cured batches (data not shown). Therefore, from this chapter and
beyond, the 24 hours drying time for the core pellets and 24 hours curing
time for the coated pellets, will be anticipated here and in the next
chapter.
4.2.2. Physical examination of the wet mass, the 
extrudates, the core pellets, and the spheronisation 
yields
The compositions of floating pellets are succinctly outlined in the codes 
table of pellets batches (Table 2.2) and detailed in Table 2.4. A scoping
study was conducted to select the feasible distilled water levels. The wet
mass consistency was examined using the hand squeeze method. The
PVP containing batches (B1S, B3S, and B6-8S) favoured less distilled
water. When compared to the non-PVP containing batches, the PVP-
containing batches showed large and sticky granules and extrudates.
Also, the PVP-containing batches showed spheronisation product of rod
or dumbbell shape, as seen in Table 4.1. The latter outcomes persist
even after the scoping study of the distilled water level, as seen in the
next section. Although the PVP is considered as a water-soluble
polyamide (Chemical-Book, 2017), it showed poor wetting with the 
distilled water, resulting in a poor rheology in the wet mass. This is 






        
       
           
          
         
       




        
            
            
      
          
          
       
         
        
        
         
          
       
   
         
      
        
        
            
    
cohesion and adhesion. The latter was evident during processing and
as complies with (Holman, 2013), where only 2.6% increase of PVP from 
3% to 5.6% caused a 205% increase in the work needed for granulation
in a twin-screw granulator. It is also in agreement with (Yu, et al., 2016), 
where the povidone (PVP) has less effective binder spreading in the bed
and potentially showing less inter-particle bonding than the copovidone
(PVP/VA). For more details regarding the scoping study, see section
4.2.3.
4.2.3. Scoping study for selecting the liquid binder
amount
The wet mass consistency showed a significant change with regard to
small addition in liquid binder. E.g. 3 ml of liquid per 1 kg of powder will 
affect the overall performance of the wet mass in the extrusion and the
spheronisation processes. Issues like stickiness and powdering were
common, resulting in a failure for making the core pellets. The water 
level needed was decided based on the “eye and hand” method (Caleva,
2017). The right wet powder consistency is achieved when the capillary 
phase is reached between the solid-liquid molecules, where a complete
liquid saturation is expected (Caleva, 2017). The capillary phase can be
seen in chapter 1 (Figure 1.11). Using SPSS, a cubic curvilinear (non-
linear) regression model was chosen for the scoping study, as it showed
the best data fit (R2>0.95). The relationship between the enhanced
water level and the floating agents’ levels showed cubic regressions.
The liquid binder interactions with powders is evident in the non-linear 
regression fitting, which prove significant effects occurred during the wet
massing process. Less liquid binder was needed with increasing PVP 
fraction (p-value=0.001, R2=0.986), and the reversed was seen with
increasing NaHCO3 fraction (p-value=0.013, R2=0.957), see Figure 4.1.
The targeted MCC: drug ratios were around the range of 1:1, to ensure





            
    
 












   
 
   
 
 
       
          
          
          
      
          
                
Table 4.1: Shows the visual properties of products during the core pellets preparation and the spheronisation yields %.
Batch code Wet mass
appearance
Extrudates appearance Spheronisation product appearance Spheronisation 
Yield 
(%)*
B1S-25P Medium large granules Long, smooth and too sticky Rods 55.38
B2S-25N Wet sand-like Short, dry, rough and very porous Round/ spheres 69.1
B3S-20P Medium large granules Long, smooth and too sticky Dumbbells 57.23
B4S-20N Wet sand-like Very dry and short Round/ spheres 70
B5S-22.5N Wet sand-like Very dry and short Round/ spheres 64.56
B6S-22.5P Medium large granules Long, fragile and slightly sticky Mostly dumbbells and some ellipsoids 54.34
B7S-12P,12N Large granules Long, very fragile and sticky Rounded 72.6
B8S-11P,11N Some large granules Long, smooth and some pores Rounded and some irregular 63.88




           
          
         
          
        
     
 
     
          
     




          
     
      
      
       
         
              
          
         
   
 







































Therefore, the MCC: drug was not expected to have an effect on the 
relationships above, that is, due to the tight range of operability of this 
ratio in the constructed DoE model. Another important finding is that in
the same formulation, when both PVP and NaHCO3 have almost the
same concentration (about 11-12% for each component), the water level





























Theophylline Avicel HFE 102 NaHCO3 PVP Distilled water 
Figure 4.1: Fraction of composition on core pellets*. 
*The fraction of the applicable water amount was calculated based on the 80g powder
batch size. It was not assumed that the added water is an addition to the formulation 
batch weight, as a negligible amount of distilled water of less than 5% will remain in 
the core pellets after drying for 24 hours.
4.2.4. Sieve analysis
The cumulative undersize percentages of the core pellets are shown in
Figure 4.2. Non-PVP containing batches showed steep curves that
indicates narrow size distribution, also, they showed acceptable
sphericity (AR<1.2). Other curves tend to have high skewness toward
the coarse pellets. The skewness issue was also seen by (Slavkova, et 
al., 2016), where the core pellets made of the semi-synthetic hard fat,
which were of a coarse size and in a wide size distribution (~1.2-3 mm).
Hence, the skewness is not favorable, as the size distribution of the core






       
       
         
      
        
         
       
  
        
        
      
      
         
          
     
        
       
 
         
         
      
         
       
      
 
         
        
           
         
      
The sieve analysis data is summarised in Table 4.2. Most batches 
showed >60% spheronisation yields, and >40% 0.72-1.4 mm fraction
yields (except that core pellets continuing 11.25% PVP and 11.25%
NaHCO3). Regardless of the PVP presence, variations for the size
distribution were evident, as the inter-quartile range (IQR) values were
0.17-0.35 mm. These variations are owing to the difficulties of obtaining
a highly consistent wet mass when the PVP was used.
4.2.5. Image analysis
The shape diameters of the images were obtained, as seen Table 4.3. 
The aspect ratio (AR) values were 1.09-1.8, while Feret ratio (FR) values 
were 0.58-0.91, and circularity values were 0.78-0.93. Moreover, only 
the non-PVP containing batches (B2S, B4S and B5S) were successfully 
forming spherical cores with an average ARs of 1.09-1.1 (<1.2), with
<5% relative standard deviation (RSD%), and where the Feret ratios and
circularities are >0.9. These values are desired for optimum spheres as 
complied with (Chu & Chaw, 2014). The aspect ratio values comply with
the finding in the physical examination above.
4.2.6. Floating study
The core pellets (n=10) did not float when introduced into a beaker 
contains 0.1N HCl medium. Therefore, a gas retard layer, namely, the
Eudragit NE15 layer was needed, to slow water uptake/permeability.
The latter is needed to reach an equilibrium swelling and/or to slow the
gas release for lowering the pellets density. Also, this layer of coating is 
needed to sustain the drug release.
4.2.7. Friability study
The friability results are presented in Table 4.4, where all batches were
shown to have an acceptable mechanical strength index values (>99%
MSI), as complied with (Abdel Rahim, et al., 2015). Hence, the core
pellets are expected to withhold the coating and the tabletting stresses 
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Figure 4.2: Shows the particle size distribution based on the cumulative undersize (%) of the sieved core pellets (n=1) intended for a feasibility of single-coating.







            
   
  
 











   
 
        
        
        
        
        
        
        
         
          
 
     




      
 
   
         
        
       
        
       
       
        
             
        
           
Table 4.2: Shows the size distribution values of the core pellets.














IQR (mm) Median class
(mm)
B1S-25P 55.38 78.19 18.27 0 21.81 0.17 1.18-1.4
B2S-25N 69.1 80.14 28.58 14.71 5.16 0.35 1.18-1.4
B3S-20P 57.23 59.41 16.82 0.24 40.35 0.35 1.18-1.4
B4S-20N 70 93.76 41.69 4.78 1.47 0.24 1-1.18
B5S-22.5N 64.56 96.79 50.87 2.63 0.59 0.18 1-1.18
B6S-22.5P 54.34 68.24 26.80 1.98 29.78 0.33 1.18-1.4
B7S-12P,12N 72.6 40.65 16.10 0.03 59.32 0.98* 2
B8S-11P,11N 63.88 14.72 5.03 0.06 85.22 1.05* 2
*Due to the poor size distribution, an estimated value is based on an approximate extrapolation. However, the extrapolation can suffer inaccuracy.





Feret Ratio Perimeter (mm) F-Circle
(Circularity)
Aspect Ratio
B1S-25P** 1.27 ± 0.11 2.31 ± 0.57 0.58 ± 0.12 6.57 ± 1.35 0.78 ± 0.10 1.80 ± 0.36
B2S-25N 1.14 ± 0.06 1.24 ± 0.07 0.91 ± 0.03 4.05 ± 0.25 0.92 ± 0.03 1.09 ± 0.04
B3S-20P 1.17 ± 0.08 1.63 ± 0.33 0.74 ± 0.11 4.90 ± 0.83 0.89 ± 0.06 1.38 ± 0.22
B4S-20N 1.09 ± 0.07 1.20 ± 0.08 0.91 ± 0.02 3.87 ± 0.26 0.93 ± 0.02 1.10 ± 0.03
B5S-22.5N 1.08 ± 0.07 1.18 ± 0.08 0.91 ± 0.02 3.85 ± 0.026 0.90 ± 0.03 1.09 ± 0.03
B6S-22.5P 1.22 ± 0.09 1.90 ± 0.34 0.66 ± 0.10 5.76 ± 1.09 0.80 ± 0.12 1.55 ± 0.26
B7S-12P,12N 1.18 ± 0.06 1.56 ± 0.24 0.77 ± 0.10 4.78 ± 0.59 0.89 ± 0.05 1.32 ± 0.19
B8S-11P,11N 1.17 ± 0.09 1.47 ± 0.20 0.81 ± 0.09 4.50 ± 0.48 0.92 ± 0.06 1.25 ± 0.16
*The values were entered in the following format: (Mean±SD), n=30.





            
 
     
   
 
   
   
 
  
    
    
    
    
    
    
    
    
              
       
    
  
     
 
            
         
           
         
        
          
      
        
        
         
      
          
         
        
        
        




Table 4.4: Shows the mechanical strength index (MSI) values for the core pellets after
the friability test.
Batch code Weight of core Weight of core MSI* (%)
pellets before test pellets after test
(g)* (g)
B1S-25P 2.99 2.98 99.67
B2S-25N 9.99 9.98 99.90
B3S-20P 2.77 2.75 99.28
B4S-20N 10.01 9.95 99.40
B5S-22.5N 10.03 10 99.70
B6S-22.5P 10.01 9.97 99.60
B7S-12P,12N 9.31 9.31 100.00
B8S-11P,11N 1.88 1.87 99.47
*The amount to be tested was 10g. However, some batches were having a low
spheronisation yield of 1-1.18 mm core pellets, noticeably, for B1, B2 and B8.
Smaller samples were tested for these batches to give some indication about their
weight loss.
4.3. Characterisation of the Single-Coated Pellets
4.3.1. Coating weight gain yields
The coating time to reach the target weight gain and the coating
efficiency will be affected by various factors, namely, the size and the
shape of the core pellets, coating batch size, the coating process and
the coating formulation variables. The coating weight gain values were
15.6±1%, as seen in Table 4.5. Blockages in the nozzle and the tube 
were observed, which resulted in the frequent poor spraying of the
coating dispersion and poor fluidizability of the pellets under coating.
Consequently, the coating time was variable (1-1.5 hours), as well as 
the coating thickness as seen shortly in the section 4.3.5. The poor 
fluidizability was sourced to be mainly induced by the small size of the
coater machine and the poor properties of the aqueous coating
dispersion. The shape of the core pellets will affect the coating
uniformity. The spherical core pellets were more likely to have the near 
perfect coating than any other shape. However, the obtained core
pellets did not have a uniform coating thickness (51±21 µm). The latter 
can also be affected by the effects of coating dispersion compositions 





          



















   
 
       
       
       
       
       
       
       
       
       
        
       
                                                                                      
               
   
        
         
             
        
       
            
         
   
         
        
      
      
      
      
           



























B1S-25P 5.01 68 0.87 17.40 0.82 16.40
B2S-25N 5.00 95 0.81 16.20 0.78 15.60
B3S-20P 5.00 35 0.89 17.80 0.83 16.60
B4S-20N 5.00 73 0.89 17.80 0.83 16.60
B5S-22.5N 5.01 65 0.80 16.00 0.73 14.60
B6S-22.5P 5.00 50 0.87 17.40 0.76 15.20
B7S-12P,12N 5.00 55 0.86 17.20 0.73 14.60
B8S-11P,11N 1.83 115 0.31 16.91 0.27 14.70
Average - 69.50 - - - 15.54
*It is calculated as follows: (coating solids obtained before drying*% of the target weight
gain)/ target coating solids. Drying was maintained for 2 hours at 55 °C to ensure curing.
Coated B2 pellets: Coated B3 dumbbells:
Table 4.5: Shows the coating yields after drying and coating*.
4.3.2. Surface hardness study
The deformation force values were presented in Table 4.6. For most
batches, the coated pellets showed sufficient strength of an average
force of 0.77-1.21 KgF with SD <0.35 KgF (7.55-11.87 N with SD <3.43
N). Hence, the coated pellets will be expected to withstand the 
compression stress without fractures. However, during tabletting, a
cushioning excipient, like the MCC, will be needed, to ensure that the
film on the core pellets will be sufficiently protected and with sufficient
binding after tableting.
Table 4.6: Coated pellets compression force values, upon surface hardness study*.
Batch code Force (KgF) Batch code Force (KgF)
B1S-25P 2.25 ± 0.95** B5S-22.5N 0.77 ± 0.14
B2S-25N 0.77 ± 0.14 B6S-22.5P 0.77 ± 0.14
B3S-20P 0.95 ± 0.32 B7S-12P,12N 1.21 ± 0.34
B4S-20N 0.81 ± 0.16 B8S-11P,11N 1.08 ± 0.19
*The values were entered in the following format: (Mean±%SD), n=30.






        
        
     
        
          
      
       
      
          
           
        
           
          
       
        
         
       
         
        
            
        
       
        
       
          
         
          
        
       
        
        
4.3.3. Dissolution study
The single coated pellets were tested for their sustained drug release
profiles and exhibited drug release variably for 24 hours, as shown in
Figure 4.3. Batches were in triplicate. 
When either the 25% PVP or 25% NaHCO3 containing batch was used
(B1S and B2S, respectively), a significant difference in the drug release
profiles were obtained when compared with other batches (p<0.05).
Unlike the PVP containing batches, the non-PVP containing batches
showed significant differences in their drug release profiles (p<0.05).
The differences were attributed to the differences in the amount of the
CO2 formation and liberation, which affected the facilitation of the drug
solubility and diffusion of the dissolved solute (from the core pellets 
matrix to the surrounding media). That is, the core composition in the
coated pellets play a significant role in influencing the drug release. The
latter finding was consistent with (Fahier., 2017). For all batches (except
B1-3), the mechanism of the drug and gas release was mainly by the
diffusion through a membrane, because the layer of the Eudragit NE 
provided a zero-order rate (R2>0.95) of drug release. The latter 
information is needed to ensure that the sustained drug release profiles 
are streamlined. Interestingly, when compared to the double-coated
pellets of ~16 % coating weight gain, the 15.3 % coating weight gain
(obtained by the Eudragit NE15 dispersion diluted with distilled water 
only) caused highly prolonged drug release regardless of the core
pellets compositions. The reason is because the sub-coating layer in the
double-coated design has the sub-coated layer that has the entrapped
gas, where the gas can be released, which enhances the drug release
as well. Hence, it is expected here that the sub-coating layer will impair 
the retard coat layer to a great extent for several reasons: (1) the
increase in the film's water solubility due to the nearby concentrated salt
of the NaHCO3. (2) The increased retard film elongation from the swelled
sub-coating film (hydrocolloid film of the HPMC). And (3) the increased






       
        
       
              
        
        
         
         
       
          
       
          
         
         
       
     
     
         
       
       
       
      
          
         
          
          
        
        
          
         
           
4.3.4. Floating study
After the screening for the attributes of sphericity and yields, the
screening for the floating attribute is the next major concern. The single-
coated floating pellets showed that they exhibited >50% floated variably 
on surface for at least 2 hours, with a lag time of <15 minutes, as shown
in Table 4.7 and Figure 4.4. Batches were all in triplicate. Only three
batches were successfully floated for at least 4 hours. The successful
floating batches were the B2S that contained 25% NaHCO3 (AR=1.09),
the B6S that contained 22.5% PVP (AR=1.55), and the B8S that 
contained 11.25% NaHCO3 and 11.25% PVP (AR=1.25). The former 
batch (B2S) is the only one to be passable for both aspect ratio and
floating. However, more improvement is needed to have reasonably 
longer floating hours, to ensure a sufficient floating strength in the
stomach. B6S was the most successful in floating, though its drug
release is not sustained sufficiently. This floating success of the 22.5%
PVP containing batch might be an artefact, as higher PVP% (25%) 
containing batch showed significantly less floating (p=0.01).
The 22.5% PVP containing batch (B6S) showed significantly better 
floating profile (p<0.05) than the 22.5% NaHCO3 containing batch (B5S).
As expected, the 25% NaHCO3 containing batch (B2S) showed
significantly better floating profile (p=0.01) than both 20% and 12.5%
NaHCO3 containing batches (B4S and B7S). That is because the
increased sodium bicarbonate causes an increased gas generation and
entrapment, resulting in a further density lowering of the floating pellets.
It is reasonable that the floating percentage was dependent on the
NaHCO3 amount. Because when the amount of the NaHCO3 increased
to a certain level (25%), the generated gas and the gas entrapment
increased. The latter allows for an enhanced and prolonged lowering of
the coated pellets' density. Consequently, the floating profile was 
improved. According to (Treesinchai, et al., 2016), the HPMC K100LV
(LV; Low Viscosity) + >10% foam powder of the polypropylene will allow





          
        
   
for a duration of >12 hours. The latter in that study was achieved without
the addition of a retarding polymer and without applying any coating
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Table 4.7: Shows the floating study for the single coated pellets.










B1S-25P 2 10 ~18 50 ± 28 68 ± 26
B2S-25N 8 8 ~05 84 ± 10 89 ± 09
B3S-20P 2 8-10 ~18 51 ± 29 69 ± 32
B4S-20N 2 8-12 ~18 33 ± 13 51 ± 19
B5S-22.5N 1 12 ~08 63 ± 30 71 ± 29
B6S-22.5P 12 12 ~07 88 ± 25 95 ± 10
B7S-12P,12N 2 8-10 ~16 36 ± 13 52 ± 12
B8S-11P,11N 4 10 ~07 64 ± 12 71 ± 16
Percentages values were entered in the following format: (Mean of 0.25-4hr+-%SD), n~220 for B1 (due to its elongated or rod shape) and
n~500 (for all other batches), the number of coated pellets tested was calculated based on the 200mg dose.
*Values were selected based on the period that maintains at least 50% total floating, which reach up to 100%.
**Percentages were averaged between 15min-4hrs.





      
     
         
     
         
 
          
       
          
          
   
  
   
 
 
           
     
 
4.3.5. Scanning electron microscopy (SEM) study
The respectively coated pellets of the successfully spheronised core
pellets were tested for their exterior and interior morphologies. Hence,
the core pellets were of Feret ratio and circularity approaching unity, 
while their aspect ratio is below 1.2.
i. SEM images of the intact and the bisected coated pellets before
dissolution
Some pores and protrusions were observed on the surface of the intact
coated pellets, as seen in Figures 4.5. The protrusions may be mainly 
because of the poor fluidizability during coating. While in the coated area
of the bisected coated pellets, the coating film is shown some variable
thickness, see Figures 4.6.
B2S-25N B4S-20N
Some grooves are there due
to some non-uniformity in 
coating thickness
B5S-22.5N






    
 
 
                           
         
 
         
            
          
        
      
   
          
         
          
     
       





dissolution (51±21 µm), 
the varied thickness can
be seen.
B5S-22.5N
Figure 4.6: SEM images of the bisected coated pellets before dissolution.
iii. SEM images of the intact and the bisected coated pellets after
dissolution
Due to the effect of dissolution, fewer pores but large protrusions were
observed on the exterior surface of the coated pellets, as seen in Figure
4.7-8. In overall, the external surface of the coated pellets maintained its 
integrity, and no breakages were observed. Hence, the film layer of the 
aqueous Eudragit NE15 dispersion will withstand the dissolution 
process for 24 hours at least.
The internal surface showed voids as a result of the entrapped carbon
dioxide (CO2) and the released drug, as seen in Figure 4.8. The CO2
was formed upon the neutralisation reaction of the acidic media with the
sodium bicarbonate. The air entrapment/ impediment can confer 





         
          
          
          
  
   
 
 




      
 
resulting in floating. The latter finding complied with other work like (Li,
et al., 2014). Moreover, the pressure of the generated gas in the core
pellets did not affect the integrity of the coated layer, which is desired for 
maintaining the floating and the sustained drug release profiles.
B2S-25N B4S-20N
More grooves are seen, as a
result of dissolution
B5S-22.5N






   
 
 
             
         
    
     
          
   
        
         
       
      
        
          
        
  
 






Voids in the core of the
coated pellets, as a 
result of dissolution
Coating thickness after 
dissolution (48±29 µm)
B5S-22.5N
Figure 4.8: SEM images of the bisected coated pellets after 24 hours dissolution.
iii. Coating layer thickness study of the bisected coated pellets,
before and after dissolution
The coating thickness values were recorded approximately for the
smallest and the largest regions of the coating film, and for before and
after dissolution. The pellets after dissolution showed negligible 
decrease in the coating thickness values when compared to those
before dissolution. The average values of the coating thickness before
dissolution is 51.31±20.95, and after dissolution is 48.25±28.99 µm. The
standard deviation is considered high for the coating thickness, 
regardless of the dissolution effect, which may explain the variability in
the floating and the drug release profiles. Three pellets were tested for 







        
           
      
        
        
          
       
           
          
           
     
           
        
     
        
          
      
        
          
       
       
            
         
     
         
         
       
          
             
         
        
           
4.4. Conclusion
The chapter aim is to screen for the single coated floating pellets, where
the core pellets are intended to swell under the control of the Eudragit
NE15 retard layer. This chapter will provide the bases for further 
enhancement work in the single-coated floating pellets. These coated
pellets are expected to reduce the complexity of the floating pellets 
design. Because the pellets are to be floated with or without an
effervescent agent, and aimed for less preparation time and less 
materials to be used, owing to the single coating stage. Hence, the
floating layer in the double coated floating pellets could be removed with
a maintained floating profile, with a pH-independent manner, and in an
easier and more cost-effective manufacturing procedure.
In the core pellets making that intended to be single-coated, the addition
of the polyvinylpyrrolidone (PVP) and the NaHCO3, makes the liquid
binder optimisation becomes more challenging. The distilled water 
showed significant interaction effects with the PVP and the NaHCO3 (p-
values<0.05). The PVP favours a small amount of water in the wet mass,
while the NaHCO3 was vice versa. The PVP containing core pellets 
exhibited poor quality, and the NaHCO3 was easier to process into the
desirable core pellets than the PVP, and the NaHCO3 can better meet
the desired outcomes than the PVP. The floating was proportionally 
dependent on the PVP and the NaHCO3 amounts. As their amounts 
increase to 25%, the extent of the swelling and the CO2 entrapment
increase, respective to these excipients. The sustained drug release
was dis-proportionally dependent on the NaHCO3 amount, as the
increase in the NaHCO3 will increase the liquid uptake process, by a
salting-out process, resulting in a faster drug release in the highly 
concentrated NaHCO3 containing batch (25%; B2S). It was 
recommended to increase the MCC amount over the PVP amount in the
core pellets, to improve the aspect ratio and to ease processing of the
PVP containing batches (B1S, B3S, and B6S-B8S). It was decided to do
further modifications to obtain the optimum formulation, by the use of the





             
            
       
          
       
         
           
      
          
        
        
        
         
      












size of 1 mm. Moreover, the ethanol is also recommended to be used
in the coating liquid, to enhance the coating efficiency and to provide a
uniform coating thickness. Additionally, the coating weight gain is 
recommended to be decreased to <14%, to streamline the sustained
drug release profiles for 12 hours only. The latter attempts are expected
to improve the coating uniformity and the film quality and to ease
processing, to meet the desired outcomes of the floating and the drug
release of the single-coated floating pellets.
To sum it up, the attainment of the single-coated floating pellets design
through a screening study was feasible. Specifically, the attainment of
the core pellets where the effervescent and hydrating polymers are
incorporated into the matrix (core pellets). However, when these pellets 
were coated, the floating and the sustained drug release properties for 
all formulations were variable. Therefore, an enhancement work is 












   


















     
        
        
          
         
         
        
         
        
 
        
           
          
      
       
       
       
        
         
           
           
           
         
          
        
        
         
          
         
         
          
5.1. Introduction
The enhancement is concerned with choosing inputs that allows for 
obtaining an improved outcome. Hence, previous knowledge in the
studied formulation design is requested, as seen in the previous chapter.
Based on the latter, some recommendations were stated to improve the
formulation design. It was recommended that the wet mass and the
coating dispersion compositions need to be changed, to improve the
ease of manufacturing, usable size distribution, sphericity, floating, and
drug release outcomes. As it was noted before, the prolonging of gastric 
retention can improve the drug bioavailability for some drugs, such as 
theophylline.
The enhancement work had some limitations, namely, the liquid binder 
effect may not be easily isolated on the quality of the final product. It may 
have an effect in obtaining different spheronisation yields. However, the
main outcomes mentioned above showed no statistical differences (p-
values>0.05) for the different amounts of liquid binder used in all
formulations. Moreover, the coating process and the film formation
mechanisms require further understanding, and how that understanding
reflects to the quality of the final product (Felton, 2013).
The aim in this work was to enhance the core pellets and the coated
layer in the single-coated floating pellets. The first objective is to use 10
w/w% ethanol as the liquid binder in the wet massing process. Also, a
higher MCC amount will be used, and a smaller pore size of the extruder 
screen was used (1 mm instead of 1.2 mm). These modifications were
made to improve the extrusion and spheronisation process and the core
pellets quality. In particular, it was expected that these modifications can
potential reduce the sticking ability of the PVP-containing extrudates will
be expected. The second objective was to apply a single coating layer 
from the Eudragit NE15 dispersion, out of which is 25 w/w% ethanol
(15Eud25Eth dispersion). The ethanol was used to improve the coating
process and the resulted film quality. The pellets can expand in the





        
           
        
         
         
       
         
 
          
         
       
         
       
   
  
      
        
       
       
        
         
      
         
        
         
          
        
         
      
    
       
and crospovidone (cros-PVP) polymers, and with or without the need for 
a gas forming agent. The extent of swelling to be controlled by the
coating layer, which made from the 15Eud25Eth dispersion. The
controlled swelling -as determined shortly- will improve the floating and
the sustained drug release properties. Hence, in this work, the single-
coated floating pellets system designs of the effervescent type and the 
non-effervescent type are expected to be feasible and show optimum 
efficiency.
Although more intricate to make, the single-coated floating pellets have
reduced the number of coating layers into one layer only, reducing the
cost of manufacturing. The enhanced core pellets are suitable for being
applied to further processing, like coating and tabletting. The enhanced
retard coating layer was made from the 15Eud25Eth dispersion.
5.2. Characterisation of Coating Liquids and 
Liquid Binders; Surface Tension
A force tensiometric study was conducted for the coating liquids and the
liquid binders, to examine their physical properties regarding the surface
tension of liquid. A summary of the results is shown in Table 5.1. The 
coating process efficiency will be affected by the coating liquid
formulation variables and the coating process variables. The effect of
dilution by an aqueous liquid and a non-aqueous liquid was assessed.
For the 15 w/w% Eudragit NE dispersion with 10 w/w% ethanol
(15NE10eth), the surface tension was 45.65±0.05 mN/m, while the
Eudragit NE15 dispersion, of which 25 w/w% ethanol (15Eud25Eth) 
showed a surface tension of 34.07±0.03 mN/m. This decrease in surface
tension is related to the increase in the ethanol content, that is owing to 
the ability of ethanol to make less hydrogen bonding than water,
resulting in a weaker liquid surface. The latter is a desired property for 
consistent spraying, uniform liquid spreading, and uniform film formation
(Cole, et al., 2002). The high-HPMC containing dispersion has relatively 





          
         
         
       
         
         
         
  
             







    
 
 









   
   
          
         
  
           
         
           
         
        
      
       
        
          
         
         
  
when compared to the other dispersions shown in the Table 5.1. This 
variation in the surface tension measurements of the latter could be
owing to the HPMC presence, as the HPMC was visually observed to
be more viscous (the exact viscosity values not determined). Resulting
in a potential variation between the dynamics readings of the same
sample. The reading frequency was set every ~15 seconds, that rate of
measurements may be fast enough to make a redundant reading of
viscous liquid.
Table 5.1: Shows the surface tension results for the coating liquids and liquid binders*, 







10% ethanol Eudragit NE15D
(15Eud10Eth)
43.65±0.05









10 w/w% ethanol 46.70±0.04
Distilled water 70.90±0.80
* All results were measured at ambient room temperature (~22 °C). 
** The surface tension measurements were 10 dynamic measurements for the
same sample.
There are common failures in a coating process, which result in the
coating in-efficiency. The coating failures are likely to be sequential, like
an increased sedimentation of the coating liquid can result in blockage
of the coating tubes and spraying nozzle, poor spraying pattern and rate 
consistency, uneven spreading of the sprayed droplet, and poor 
fluidisability of pellets under coating. The tendency of failure can
increase when a fully aqueous coating liquid is used (Cole, et al., 2002).
The Eudragit NE30D dispersion has 30% solids. Based on Evonik 
guidelines of the Eudragit NE grade, it is recommended to use a diluted
concentration during coating, which is 20% or less, to reduce the






       
           
  
     
        




        
           
        
      
         
       
        
           
        
          
          
          
      
  
           
         
          
       
         
       
        
Since, the use of non-aqueous solvent incurs safety concerns, it is 
desirable to focus first on the use of an aqueous solvent, which is safe
for coating.
5.3. Characterisation of the Core Pellets
The compositions of floating pellets are succinctly outlined in the codes 
table of pellets batches (Table 2.2) and detailed in Table 2.4
5.3.1. Physical examination of the wet mass, the
extrudates, the core pellets, and the spheronisation 
yields
The physical examinations during the core pellets making were recorded
in Table 5.2. The wet mass of most batches appeared as a wet sand,
which is a desired appearance that usually indicates a consistent wet
mass. The extrudates of all batches appeared as non-sticky and either 
as smooth or perforated with a length diameter of 1-1.5 cm. The non-
stickiness and short diameter of extrudates can indicate their ease of
spheronisation. The core pellets of all batches appeared as round.
The ethanol usage and the high MCC: PVP ratio were needed, to
decrease the stickiness of the PVP. The decreased stickiness will
improve the processing and the usable yield as well as the sphericity of
the core pellets. Moreover, when compared to the PVP, the cros-PVP 
was showed a large water uptake to reach the consistent wet mass,
because the cros-PVP is considered as a water-insoluble polyamide
polymer (Chemical-Book, 2017). 
The decrease in surface tension of a liquid binder can decrease the
viscosity and maximum torque of that liquid, resulting in an increased
binder spreading and distribution (Sakr, et al., 2012). The latter outcome
is desirable for obtaining a consistent wet mass prior extrusion and
spheronisation processes. Also, the decrease in surface tension also
decrease the work of cohesion and adhesion (Ebnesajjad, 2011). 





     
           
         
          
        
      
        
         
     
        
      
          
            
 
           
    
        
    
        
    
          
         
         
       
        
          
       
     
       
         
            
      
The cros-PVP polymer is water-insoluble, owing to its cros-linking
nature, which also impart high retention of liquid. The cros-PVP ease the
extrusion and spheronisation processes, due to its effect on producing
a high consistent wet mass, owing to low sticking (low adhesion) that
was visually checked during processing. A 1:1 ratio of liquid binder:
powder was needed for the powder mix that contained the cros-PVP.
That is owing to the crosslinking of the cros-PVP polymer, which allows 
for high swelling capacity. Rowe, et al., 2009 confirms that the cros-PVP 
will rapidly exhibits high capillary activity and hydration capacity. The 
spheronisation aid of the cros-PVP was explained by (Jain, et al., 2010). 
The core pellets containing the cros-PVP (B11S) were easily made with
a superior yield (>80%) when compared to other batches, owing to the
high swelling of cros-PVP. It had a comparable sphericity to that of the
other batches.
The low surface tension of the 10 w/w% ethanol solution (46.7±0.035
mN/m) compared to distilled water only (70.9±0.8 mN/m) explains the
improved wet mass consistency when ethanol is used. Resulting with
core pellets of improved spheronisation yields (70.4-81.2%) and 
sphericity (Aspect ratio; AR<1.2) in all batches when compared to the
core pellets made with distilled water only (chapter 4; 54.3-72.6% and 
AR of 1.05-2.16 respectively). Hence, the addition of the organic solvent
decreased the preferential liquid migration toward the PVP. This allowed
the PVP to decrease its sticking propensity to the equipment tooling and
to the adjacent pellets during spheronisation (Ebnesajjad, 2011).
On the other hand, the ethanol may excessively weaken the integrity of
the extrudates, due to the potential induction of the excessive
channelling in their internal structure as the ethanol evaporates
increasing the agglomerates porosity (Nordström, et al., 2013). That 
weakness can de-agglomerate the extrudates into powder upon the first
contact by the high-speed effect of the rotating disc spheroniser. Hence,
the powdering of the extrudates can be avoided using a small ratio of





            
     
 
    
 
    
 
 
    
 
   
 
     
  
  
   
  
   
   
 
   
 
      





      
 
   
 
     
   
   
 
 
     
   
   
        
 
         
        
    
          
         
          
         
         
         
          
        
            
           
      
         
Table 5.2: Shows the visual observations of the intermediate products during the core
pellets preparation, and the total yields of the core pellets after spheronisation and 
drying.
Batch code Wet mass
appearance










Wet sand-like Fragile, smooth no
















Wet sand-like Smooth no stickiness and
medium to large size (~1.5
cm)
Majority rounded and 















Wet sand-like Smooth no stickiness,
medium length (~1 cm)
Round/ Spheres
*If the core pellets appearance is round/sphere, then the expected AR will be <1.2.
5.3.2. Sieve analysis
The cumulative undersize distribution of the core pellets graph is shown
in Figure 5.1. Most batches exhibit steep curves that indicates narrow
size distribution, while B12S demonstrates the widest distribution. The 
narrow size distribution is favourable as it indicates that the yield of the
core pellets is mostly within the usable size fraction yield (0.71-1.4 mm).
The size distribution values of the core pellets were summarised in Table
5.3. The cumulative undersize curves showed usable size range of
>80.30% for all batches of the core pellets, except B12S. Also, all
batches showed a narrowed size range (1-1.18 mm) of >24% yield,
while B11S and B13S showed <11% yield. Despite the high amount of
MCC in the latter batches, they did not relatively show highly narrowed
size distribution. That could be due to the liquid binder amount, but that
potential cause cannot be isolated in this work. The narrowed yield of 1-
1.18 mm of all batches (7.4-44.6%) was narrower when compared with





        
      
          
       
            
       
        
            
           
          
        
       
          
           
     
     
         
           
         
             
     
  
          
        
           
        
        
         
        
         
       
     
was also narrower when compared to those in chapter 4 (14-97%).
Hence, the narrowing of the yields was relatively improved.
The IQR values of all batches were ranging from 0.15 to 0.62 mm, where
some batches (B12S and B14S) were positively skewed, due to some
avalanching during spheronisation. It could be due to the use of Avicel
PH101 and the high NaHCO3 amount, respectively, that made the wet
mass to be not as consistent as those of other batches. The median
diameter values of all batches were 0.88-1.12 mm. The use of the Avicel
PH101 resulted in the lowest usable yield (62%). The presence of cros-
PVP required a double increase of the liquid binder amount, to achieve
a consistent wet mass that is applicable for extrusion and
spheronisation. The resulted wet mass was extruded with negligible
losses, resulting in the highest usable yield (99.65%) with the lowest
scattering from the mean (IQR=0.15 mm). That can be attributed to the
high swelling ability of the cros-PVP.
The core pellets yield after drying for all batches ranges from 70-81%. 
Interestingly, although B11S showed a wet mass of sticky and large
granules, it resulted with the highest spheronisation yield of 81%. And
although its narrowed size yield of 1-1.18 mm was only 10%, it showed
up to 90.6% usable size yield of 0.71-1.4 mm. Hence, it resulted with
negligible coarse and fine yields.
5.3.3. Sphericity testing by the image analysis
The core pellets were analysed using the images of the light microscope,
where the shape diameters were calculated using the Ziess software,
data shown in Table 5.4. Like the screening experiments of the non-PVP
containing batches (B2S, B4S and B5S), the core pellets have
successful sphericity with aspect ratio (AR) values of 1.09-1.17 with SD
of less than 0.1, the circularity values approaching unity with SD of less 
than 0.03. The spheronisation yields were all above 70%. The obtained
values were as desired for good quality of the core pellets. Hence, the
core pellets are enhanced, which is beneficial for a uniform coating
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Figure 5.1: Shows the particle size distribution based on the cumulative undersize (%) of the sieved core pellets (n=1) intended for applying an enhanced


















   
 
        
        
        
        
        
        
 
 
       
               
            










Table 5.3: Shows the size distribution values of the core pellets.











IQR (mm) Median class
(mm)
B9S-8P,3N,10E 71.42 31.30 94.88 05.01 00.10 0.23 0.71-1
B10S-12P,47HF,10E 71.18 44.59 93.71 00.68 05.61 0.35 1-1.18
B11S-12CP,47HF,10E 81.22 10.32 99.65 00.23 00.12 0.15 0.71-1
B12S-12P,47PH,10E 70.37 24.33 61.99 00.27 37.75 0.62 1-1.18
B13S-60DL,10E 76.61 07.46 89.60 10.40 00.00 0.16 0.71-1
B14S-2P,17N,10E 76.12 28.33 86.93 00.00 13.07 0.33 0.71-1
B15-Cushioning
Pellets**
56.00 57.25 90.58 09.15 00.27 0.23 1-1.18
*% of the dried core pellets yield 2= (weight of the dried core pellets after spheronisation/ weight of the initial powder materials used)*100.
**Although that the cushioning pellets will not be used in the upcoming chapter (as proved less efficient than the cushioning powder in chapter 3), it will be 





      




         
       
       
       
       
       
       
   





Feret Ratio Perimeter (mm) F-Circle (Circularity) Aspect Ratio
B9S-8P,3N,10E 1.09±0.06 1.23±0.10 0.86±0.05 4.05±0.26 0.95± 0.02 1.12± 0.06
B10S-12P,47HF,10E 1.14±0.06 1.24±0.07 0.91±0.03 4.05±0.25 0.92± 0.03 1.09± 0.04
B11S-12CP,47HF,10E 1.06±0.06 1.20±0.07 0.87±0.04 3.85±0.21 0.93± 0.02 1.13± 0.04
B12S-12P,47PH,10E 1.14±0.06 1.29±0.08 0.84±0.06 4.16±0.03 0.93±0.03 1.13±0.05
B13S-60DL,10E 0.83±0.06 0.91±.07 0.91±0.03 2.83±0.21 0.97±0.01 1.10±0.08
B14S-2P,17N,10E 1.05±0.08 1.18±0.08 0.88±0.04 3.75±0.30 0.94±0.02 1.12±0.05






       
      
        
        
     
        
            
 








     
     
     
     
     
     
      
 
          
      
       
            
          
        
  
 
          
        
         
         
         
          
  
5.3.4. Friability study, using the abrasion drum
The friability results of the core pellets were summarised for all batches 
in Table 5.6. Similar to the previous chapter, the weight loss values were
within the acceptable limits (<1% weight loss; MSI>99%) as agreed by
(Sungthongjeen, et al., 2006). Hence, the core pellets were
mechanically strong and showed sufficient integrity to withhold 
subsequent processes of coating, tabletting, packaging, and shipping.
Table 5.6: Shows the mechanical strength index values of the core pellets upon the 
friability study.








B9S-8P,3N,10E 10.0273 10.0258 0.015 99.98
B10S-12P,47HF,10E 10.0113 10.0078 0.035 99.97
B11S-12CP,47HF,10E 10.0238 10.0102 0.408 99.59
B12S-12P,47PH,10E 10.0420 10.0110 0.310 99.69
B13S-60DL,10E 06.7091 06.7085 0.009 99.99
B14S-2P,17N,10E 10.0390 10.0220 0.017 99.83
B15-Cushioning Pellets 10.0390 10.0220 0.017 99.83
5.3.5. Floating study, using the beaker method
Expectedly, the core pellets did not float, which is similar to the core
pellets made in the previous chapter. All the core pellets sank to the 
bottom of the beaker after few seconds of pouring in either distilled water 
or 0.1N HCl media, due to the excessive wetting of the core pellets.
Hence, for floating to be achieved, a layer of a polymeric membrane was 
needed for the gas entrapment and/or to control the matrix swelling.
5.4. Characterisation of the Coated Pellets
5.4.1. Coating weight gain yields
After 24 hours of drying and curing, the coating weight gain was 6±1%,
as seen in Table 5.7. Hence, fewer materials were needed for the
coating. The coating time was short, which was completed in 30 minutes 
to reach 6±1% weight gain by the 15Eud25Eth dispersion. Applying a
layer of a pH-independent and swellable retard coat is essential for the



















   
    
  
 
       
       
       
       
       
       
        
       
                     
        
            
           
            














drying and curing (g)
Weight gain after
drying and curing 
(%)**
B9S-8P,3N,10E 6.70 45 0.3305 4.72 0.35 5.00
B10S-12P,47HF,10E 6.70 45 0.3494 4.99 0.37 5.23
B11S-12CP,47HF,10E 6.70 45 0.5406 7.72 0.46 6.60
B12S-12P,47PH,10E 7.00 55 0.5600 8.00 0.48 6.93
B13S-60DL,10E 4.54 47 0.3300 7.27 0.26 5.73
B14S-2P,17N,10E 7.00 50 0.4200 6.00 0.42 6.00
B15-Cushioning Pellets 7.00 55 0.4800 6.86 0.46 6.57
Average - 48.86±4.56 0.43±0.1 6.51±1.3 0.39±0.08 6±0.73***
*The wet and the dry weight will be used to calculate the wet and the dry weight gain percentages, respectively, which are based on the weight 
before the coating. Then, based on previous trial and error, a speculation of the remaining time for the coating will be estimated.
** The % of the CWG obtained= [(CWG solids*targeted % CWG in a fraction)/targeted CWG solids]*100.
The targeted CWG solids= (batch size in mass*% of targeted CWG)/100.





        
         
            
         
          
      
      
      
         
        
     
       
    
      
    
      
          
         
         
        
  













   
 
   













5.4.2. Surface hardness study
The compression force values applied on the coated pellets were
summarised in Table 5.8. The hardness of floating pellets of all batches 
was 0.9-1.01 KgF, SD <0.23 KgF (8.82-9.9 N, SD <2.25 N), such a
range of values considered more narrowed when compared to those
batches in chapter 4 (0.77-1.21 KgF, SD <0.35 KgF; 7.55-11.86 N, SD
<3.43 N). That was because the former batches coating thickness was 
10±2 µm, while the latter batches coating thickness was more varied
51±21 µm. Hence, the less varied coating thickness ensures less varied
surface hardness of coated pellets. The latter implied that the coated
pellets can withstand the tableting force upon compression without
breakage. However, cushioning excipients such as MCC or waxy 
materials may still be needed to ensure complete protection from film 
deformation and/or fractures (Dwibhashyam and Ratna, 2008). 
The MCC only cushioning pellets (B15 core pellets) were weak (0.57 ± 
0.17). When coated, this weakness was significantly reduced (0.76 ± 
0.13) by the added strength from the polymeric film (p-value=0.05). That
complied with the density study in section 5.4.4, where the coated and
uncoated cushioning pellets (of only Avicel HFE102) had a low density
of ~0.5 g/cm3, implying large voids in the pellets’ structure. That is when 
compared to the coated and uncoated medicated pellets density of 1.45-
1.49 g/cm3.






















































        
        
          
        
      
         
         
         
         
        
       
      
       
         
           
           
           
           
          
     
          
         
        
          
          
         
              
  
          
        
           
5.4.3. Dissolution study
Figures 5.2-3 show drug release profiles from 0-24 hours. The sustained
drug release is achieved were all batches being streamlined and
enhanced for 24 hours in both media of 0.1N HCl and distilled water. 
There was no significant difference in the drug release profiles (p-
values>0.05). The dissolution profiles for the coated pellets of some
batches (B9S-B11S) showed a complete drug release in duration of 24
hours in both the 0.1N HCl and the distilled water media. Other batches 
had ~90% drug release after 24 hours of dissolution, that for some
batches (B9S and B10S) could be due to their lower coating gain (5 and 
5.23%, respectively), when compared to B12S and B13S (6.73 and
6.93%). The drug release results for all batches may fit for the zero-order 
model (R2>0.8) during the 24 hours dissolution, indicating a diffusion-
based mechanism predominating the drug release mechanism, which is 
an outcome that is comparable to (Sungthongjeen, et al., 2006) and 
(Katakam, et al., 2013). All batches of the coated pellets that placed in
the 0.1N HCl medium showed a complete drug release in the range of
the 100±5%, while those placed in the distilled water showed a complete
drug release in the range of the 98.5±3.5%. Regardless of the core
pellets composition and the medium of dissolution, all of the drug release
profiles were not significantly different (p-values<0.05).
The ethanol uses in the coating dispersion resulted in a film that
increased and streamlined the sustained drug release profile from the
coated pellets. The study done by (Nokhodchi, et al., 2010) has 
suggested that the non-volatile cosolvent is vital in the sustained drug
release property of some of the liquisolid tablets. Although, tablets can
be usually different from pellets in size and shape, the volatile solvent
like ethanol, was found in the work here to have a vital effect on the drug
release as well.
There could be two patterns of drug release in your curves, from 0-6 hrs 
and from 6-24 hrs. The former (6 hours period) is a bit faster where 40-





         
           
          
         
       
 
         
        
         
            
         







times longer) is a bit slower where also 40-60% of the drug released.
Hence, approximately half of drug release was seen in the initial 6 hours,
where the other approximate half of the dose was released at a longer 
time (18 hours). A zero-order rate can be more accurately obtained in
each of these time ranges separately (R2>0.95 and R2>0.99,
respectively).
As discussed earlier in section 1.5.3.ii, it was assumed that the drug
theophylline may show more ionization (dissociation) at a medium pH of
1.2 instead of 5.8, and perhaps more streamlined dissolution profiles.
However, the less ionization of the drug at a medium pH of 5.8 (distilled
water) still showing a comparable dissolution profile when compared to






               










B9S-8P,3N,10E B10S-12P,47HF,10E B11S-12CP,47HF,10E 
B12S-12P,47PH,10E B13S-60DL,10E B14S-2P,17N,10E 
Figure 5.2: The sustained drug release curves of the single-coated pellets in the 0.1N HCl medium (pH ~1.2) (n=3). This figure shows the streamlined drug 












































Figure 5.3: The sustained drug release curves of the single-coated pellets in the distilled water medium (pH ~5.8) (n=1). This figure shows the streamlined drug






   
         
       
       
          
        
           
      
        
        
         
        
         
         
      
          
        
       
         
        
         
          
       
            
           
          
 
       
           
5.4.4. Floating study and the related studies for the 
anticipated floating mechanisms
i. Floating study
The floating profiles were summarised in Tables 5.9-10, and graphed in
Figures 5.4-5, for 0.1N HCl and distilled water media, respectively.
There was no significant difference in the floating profiles (p-values 
>0.05). The lag time to float was 10 minutes. The floating was 
maintained for at least 24 hours in 0.1N HCl and 12-24 hours in distilled
water. The percentage of floating was at least 90% for a minimum of 12
hours. B10S was showing less floating after 8 hours of dissolution in 
0.1N HCl medium, however, that was not a significant change (p-
value<0.05). Unlike the previous chapter, the results here showed
shorter lag time, longer duration, and complete floating. Some of the
pellets immediately floated upon pouring into the medium, owing to their 
initial low density. After then, the pellets initiated swelling within 10
minutes, to maintain the floating. Hence, they initiated the swelling
during the floating lag time.
The critical quality attribute of the floating duration response is to be from 
6-12 hours, favorably for 12 hours. Therefore, the results obtained using
the distilled water medium for floating are also considered optimum,
regardless of the drop occurred somewhere between 12-24 hours in all
batches, except the cros-PVP containing batch (B11S), as shown in
Figure 5.5. The latter batch may improve floating in the distilled water 
medium, however, that would to be determined in future work by making
replicates. The results indicate that the floating performance of floating 
pellets are likely to withstand the pH increase in the stomach at the fed
state. Hence, the floating of the floating pellets is not dependent on the
gas generating agent to occur. The latter will lower the risk of failure in
floating. 
The coating layer that was made from the 15Eud25Eth dispersion can





        
        
      
         
        
     
           
           
         
          
           
      
         
      
         
         
             
         
        
         
       
         







in a controlled swelling. The expected mechanisms are (1) gradual
increase in the pellets’ volume, as the coating layer (made from 
15Eud25Eth dispersion, where the emulsifier concentration was 1.5%
nonoxynol) can help in allowing and controlling the extent of this 
expansion in the film layer. And (2) increased pores by the swelled
polymer and/or by the generated gas from the NaHCO3 (Singh & Kim,
2000). Based on (Popova, et al., 2016), they needed to increase the
concentration of ethanol -as a liquid binder- from 40% to 80% to induce
a sustained drug release from the ethyl cellulose (EC) containing matrix 
pellets. Relating to the latter finding, the work here showed, upon the
addition of 25% ethanol to the coating liquid, an increased and enhanced
sustained drug release profiles as well as floating profiles were obtained 
for the single-coated pellets. However, in the floating profiles, the
enhanced water-retarding layer made from the 15Eud25Eth dispersion
will have the prominent effect over the hydrating polymers’ swelling.
Hence, this outer layer will control the swelling of the hydrating polymers,
like cros-PVP, in the core pellets. That is, the prominent control of the
resulting coating layer will shrivel the high swelling capacity of the cros-
PVP polymer. Therefore, the PVP-containing coated pellets will have no
significant difference in the swelling when compared to the cros-PVP-
containing coated pellets. Additionally, the microcrystalline cellulose



















       
 
      
 
      
 
     
      
 
     
 
 




     
            
              
  
  
              
  
              

























Table 5.9: Shows the floating study for the single coated pellets in 0.1N HCl medium*.

















B9S-8P,3N,10E >24 10 15 100 ± 0 99 ± 1
B10S-
12P,47HF,10E
>24 10 15 100 ± 0 98 ± 2
B11S-
12CP,47HF,10E
>24 10 15 100 ± 0 99 ± 1
B12S-
12P,47PH,10E
>24 10 15 100 ± 0 100 ± 0
B13S-60DL,10E >24 10 15 100 ± 0 100 ± 0
B14S-
2P,17N,10E









0 NA NA 0 0
*The percentages values were entered in the following format: (Mean of 0.25-4hr
±%SD), n~500 for all batches (except for B13; n~350), the number of the coated
pellets tested was calculated based on the 200mg dose. All results were based on 
“the on-surface” floating only. 
** The values were selected based on the period that maintains at least 90% on-
surface floating.
*** Floating % values were averaged for the values in the period between the end 



















      
 
     
 
     
 
     
      
 
     
 
 




     
       
Table 5.10: Shows the floating study for the single coated pellets in a distilled water
medium*.


















B9S-8P,3N,10E 12-24 15 15 100 ± 0 98 ± 2
B10S-
12P,47HF,10E
12-24 15 15 100 ± 0 100 ± 0
B11S-
12CP,47HF,10E
>24 15 15 100 ± 0 100 ± 0
B12S-
12P,47PH,10E
12-24 15 15 100 ± 0 100 ± 0
B13S-60DL,10E >24 15 15 100 ± 0 100 ± 0
B14S-
2P,17N,10E









0 NA NA 0 0






                  
 

































               
        
 


















0 5 10 15 20 !
Time (Hours) 
B9S-8P,3N,10E B10S-12P,47HF,10E B11S-12CP,47HF,10E 
B12S-12P,47PH,10E B13S-60DL,10E B14S-2P,17N,10E 
B15S (coated cushioning pellets) 
Figure 5.5: Shows the floating profiles of the single-coated pellets in a distilled water medium (n=3, error bars were not seen because 100% reproducibility was 




         
         
         
      
       
         
         
         
            
     
          
         
         
     
          
        
       
            
         
          
          
        
         
         
         
        
      
          
        
     
       
        
          
ii. Swelling study per weight, using the beaker method
The coated pellets were immersed in a beaker of either the distilled
water or the 0.1N HCl media. After 30-60 minutes of immersion, all of
the coated pellets re-weighed and possessed 20-30% liquid mass
uptake regardless of the medium used (n=1). These percentages were
maintained for at least 4 hours. These fluid uptake percentages were
deemed desired for the floating to occur. The cros-PVP-containing batch
(B11S) was showing the high end in the values range (30%). The latter 
is due to the high swelling capacity of the cros-PVP. All of the fluid
uptake percentages were not significantly different from each other (p-
value >0.05), confirming that the small variation in the coating levels 
(6±1 w/w %) is not significant. The swelling of the coated pellets was 
also examined through the increase in diameters of coated pellets, as 
seen in the following paragraph.
iii. Swelling study per diameter, using the image analysis method
The diameter increase and mass increase of the single coated pellets 
were seen in Figures 5.6-7. The restricted permeability or diffusion of
the liquid in to and out from the coated pellets will allow for the required
swelling to occur, which is needed for the floating as well as the
sustained drug release to take place. Also, this restriction is needed to
ensure that the floating is sustained over time with a reduced variability.
This floating enhancement was due to that the liquid uptake percentages 
were enhanced for initiating and maintaining the low density in the
coated pellets that is below the media density, i.e. below 1 mg/cm3, 
which render the pellets to float on surface. The optimum fluid uptake
percentages were 20-30% in the previous paragraph. In this study, the
optimum fluid uptake (20-25%) is comparable to the latter.
An increase of 8-16% in the diameter of the coated pellets was obtained
at 30 minutes of dipping, and their diameters remained high during four 
hours of measurements. The mass increase was of 20-25% in the 
coated pellets after 30 minutes of immersion. The most desired fluid 
uptake threshold was determined in this study to be averaged for 22.5%,





         
         
        
       
            
         
          
           
            
          
         
           
        
        
        
          
          
         
         
        
           
          
        
         
        
       
        
        
        
        
       
After 0.5 hour of immersion into distilled water, the volume increase was 
51.56-82.36% for the coated pellets. Where also the surface area
increase was 32.93-49.33% for the coated pellets. While the surface
area to volume (SA:V) ratio decreases by 13.15-17.98% for the coated
pellets. It is known that the decrease in size of spheres can increase the
SA:V ratio, providing a decreased diffusion path and faster drug release
(Rizvia & Saleh, 2018). Here, the SA:V ratio decreased to some extent,
which indicates an increase in the diffusion path in the coated pellets,
owing to the increase in swelling to some extent. However, the drug
release was constant since the beginning of the dissolution, where it was 
also constant before the swelling became in a steady state.
The SA:V ratio did not exceed the 20% decrease. The latter is critical to
ensure an enhanced floating and sustained drug release profiles. It
implies an enhanced controlled swelling. At this SA:V ratio, a swelling
threshold and equilibrium is obtained where it is assumed that the
density of the coated pellets would be lowered to <1g/cm3. It is where
the floating phenomena can be initiated, completed and sustained until
an imbalance in this threshold start to occur after 12-24 hours of pouring
the coated pellets into the medium. Hence, after the latter period elapse,
further swelling may occur, resulting in a further decrease in the SA:V 
ratio. The latter can result in an increase of the coated pellets mass that
exceed the increase in volume, allowing the coated floated pellets to 
increase in density and subsequently sink to the bottom of the vessel
after 12 hours of floating, as seen in Figure 5.5. Moreover, excessive
swelling can cause film rupture and fast drug release.
The coating layer made from the 15Eud25Eth dispersion controls the
fluid in-flux and the fluid out-flux, and avoids the over-increase in mass 
and ensures the attainment and the maintenance of the optimum SA:V 
ratio. Moreover, this behavior will protect the film and the core pellets 
from over-swelling and rupture, and avoid the subsequent unfavorable





          
          
          
      
           
         
    
           
           
        
        
          
         
           
           
          
          
        
     
 
             
        
 
After 0.5 hour of immersion into distilled water, the volume increase was
185.56% for the cushioning core pellets. Where also the surface area
increase was 100.88% for the coated pellets. While the surface area to
volume (SA:V) ratio decreases by 29.65% for the cushioning core
pellets. After 1 hour of pouring, a sudden drop in the weight and diameter 
that is comparable to the original weight prior pouring. Hence, the SA:V 
ratio increased by ~30%.
The excessive increase in volume and surface area of the core pellets 
is owing to the lack of the retard coating layer, resulted in a non-
restricted liquid permeation followed by an over-swelling, where a
potential excessive mass increase could have occurred, rendering the
core pellets to be heavy and unable to float. After which, a sudden
shrinking occurred where excessive decrease in volume and surface
area of the core pellets occurred. The latter resulted in a complete drug
release in 1 hour time (drug release data not shown for the cushioning
pellets). Hence, the latter resulting in an uncontrolled swelling, which will
not provide the insufficient time for the uncoated pellets to reduce in
density and to maintain that reduction. Therefore, the uncoated pellets 
will not initiate nor maintain the floating as well.
Figure 5.6: The changes in diameter over time in the distilled water for the single-
coated pellets. Refer to Table 2.4 for the compositions of these formulations. B15 is






          
           
          
             
   
       
         
        
          
        
          
       
     
          
        
       
   
         
        
           
          
        
       
       
     
Figure 5.7: The changes in diameter and mass after 30 minutes of immersion in the
distilled water for the single-coated pellets. Refer to Table 2.4 for the compositions of 
these formulations. B15 is the cushioning pellets not coated, where the mass increase
measurement was not feasible, as the wet uncoated pellets will squash upon handling.
iv. Density study
The mean density values of theophylline, Avicel HFE102, PVP, cros-
PVP and NaHCO3 were 1.59, 1.76, 1.38, 1.1 and 2.22 g/cm3, 
respectively. Noticeably, the density of the NaHCO3 was the highest
amongst all other raw materials, see Figure 5.8. On the other hand, the
cros-PVP density showed a low value, owing to its micronised size,
where a large inter-particulate void is expected. Based on (Abdel Rahim,
et al., 2015), the relationship between density and porosity can be
manifested as follows; porosity=1-(density/1.4), where porosity can
increase when the density decrease. However, that did not lower the
density of the core pellets as well, owing to the compaction mechanism 
of the extrusion/spheronisation method. Notably, the coated and the
uncoated cushion pellets showed significantly smaller density values 
(~0.5 g/cm3) when compared to the medicated pellets. The density of
the core and the coated pellets were highly similar (1.45-1.49 g/cm3).
The similar density was due to that the thin coat did not contribute much
to the density of the core pellets. Also, the high density NaHCO3 was not
used in high proportions. Interestingly the coated pellets tend to possess 
lower density than the core pellets. This lowered density could be partly 
due to the air entrapment during the coating process. Although the cros-





        
         
       
        
         
          
         
         
         
         
       
        
 
 
           
      
         
        
         
         
































































































containing batch (B11S) was not different when compared to other 
batches. That because the extrusion and spheronisation will densify the
agglomerates of powders. Therefore, the relatively low amount of cros-
PVP used was not affecting the total pellets density. The latter argument
is also applicable to the NaHCO3 in the opposite direction.
At the first instance, the high density of NaHCO3 may increase the
overall density of the core pellets containing the NaHCO3. However,
there were no significant differences in the density values of the core
pellets of all batches, including the non-NaHCO3 containing core pellets.
The reason for this indifference in the density of the core pellets is that
the extrusion and the spheronisation processes will densify the





















Figure 5.8: The density of the powder, the core pellets, and the single-coated pellets.
Refer to Table 2.4 for the compositions of these formulations.
Also, the used amount of the cros-PVP and the NaHCO3 were relatively 
low, as the maximum amount used was 25%. Therefore, for these two
reasons, the overall density of the core pellets was not affected.
Moreover, the density of the core pellets and the coated pellets were







         
      
       
         
        
          
       
           
        
             
         














5.4.5. Scanning electron microscopy (SEM) study
The SEM images were shown for the intact and the bisected coated
pellets in Figure 5.9-12. The film membrane formed was thin, typically 
10±2 µm, as observed in Figure 5.12.
After dissolution, the coat of the coated pellets was intact without a
reduction in the coating thickness. Hence, the coating thickness 
remained with a diameter of 10±2 µm. This observation showed that the
film of the coating layer made from the 15Eud25Eth dispersion was very 
flexible, as agreed with (Chen, et al., 2012). It can withstand the
expansion in the coated pellet’s dimension, which induced by the
physical changes, like swelling in the core pellets and in the coat of the
coated pellets. The coat tolerability of swelling correlate to the success 





          








         
 

































































            
  
          
       
           
          
       
        
        
         
        









The thin coating thickness 




Figure 5.12: The SEM images of the bisected coated pellets after dissolution.
5.4.6. Differential scanning calorimetry (DSC) study
The free films -made from the coating liquids- that comprise the coated
layers were thermally studied. The DSC study can be used for further 
correlation to the performance of the enhanced floating pellets. The DSC
can measure the melting point (MP) and glass transition (Tg) of a sample
upon melting and softening, respectively. The MP indicates crystal
melting, while Tg indicates amorphous softening. The free film of 6.66%
HPMC: 3.33% NaHCO3 solutions showed melting points at 119.25 °C
and 151.85 °C, respectively. The peaks intensity/size and shape change
when the ratio of the film's components change, as noticed in Figures 




      
    
          
         
          
   
       
 
         
       
           
      
        
           
     
        
       
           
       
      
          
          
      
        
       
       
     
     
     
       
         
    
liquids, a potential polymorphic change was occurred prior the film 
formation, as explained shortly.
In Figure 5.15, the thermogram of the Eudragit containing film (where no
dilution made for the dispersion where the film was made), at nearly 54
°C, a relatively decent intensity melting point of the crystal regions of the
polymethacrylates (PMA) polymer was seen. This melting point intensity 
may indicate a decent number of crystal regions in the
polymethacrylates (PMA) polymer.
In Figure 5.16, the thermogram of the Eudragit containing film (where
only distilled water was used for diluting the dispersion where the film 
was made), at nearly 53 °C, a low intensity melting point of the crystal
regions of the PMA polymer was seen. This low melting point intensity 
may indicate a reduced number of crystal regions in the PMA polymer.
The dilution of Eudragit dispersion is expected to result in a reduced
number of crystal regions in the polymer.
In Figure 5.17-18, the thermograms of the Eudragit containing films 
(where ethanol was used for diluting the dispersions where the films 
made from), at nearly 50 °C, a step change may be seen from the
baseline that may indicate a softening of a predominantly amorphous 
polymethacrylates (PMA) polymer, where no distinctive crystal melting
point can be seen. Also, the emulsifier concentration will be diluted as 
well, resulting in less stability for the PMA polymer, causing it to have an
increased precipitation. These precipitated crystals may affect the
quality of the crystal regions in the polymer upon drying, and may 
undergone a polymorphic change into a higher amorphous content in
the polymer, as a step change of glass transition (Tg) was likely 
occurred. However, the precipitated crystals may maintain their order 
after precipitation, because the water evaporation is slower when
compared to the ethanol evaporation.
The increased amorphousity is expected to occur upon diluting the
Eudragit dispersion with ethanol, prior and during the drying the




       
          
         
     
         
       
        
       
        
         
       
       
         
       
          
        
     
       
         
         
   
         
      
            
       
         
         
       
          
         
        
       
cause a preferential solvation that causes amourphosisation. During
drying, the ethanol causes a rapid process, owing to its rapid
evaporation. The rapid drying can cause amporphosisation as well. The
obtained amorphous polymer of PMA is expected to incur high
toughness, as it showed an enhanced sustained drug release and
floating profiles for the enhanced floating pellets with a small coating 
gain. As complies with the latter, the (Taylor & Shamblin, 2009) stated
that the amorphous ionic polymer, like the PMAs, can favorably 
precipitates in the aqueous ant-solvent. Hence, adding a solvent like
ethanol, which can provide a preferential solvation. That may render the
distilled water to act as aqueous ant-solvent. Along, with the relatively 
quicker evaporation of ethanol, an increased amorphosisation of PMA 
will be induced, and a favorable precipitation of the PMAs amorphous 
material were obtained upon cooling. In (Donnelly & Evans, 1991), a 
stating that an increased toughness can be due to amorphosisation. In
(Aulton, 2018), a stated that some “tougher materials can undergo
plastic flow, which allows strain energy relaxation without crack 
propagation”. Hence, the increased toughness allows for the swelling to
take place without rupturing the coating film, the latter enhanced the 
sustained drug release and the floating profiles of the single-coated
floating pellets.
Upon administering the coated floating pellets to the patients, the
increased toughness of the amorphous PMA polymer may not soften at
a temperature below 50 °C, like the dissolution temperature of 37 °C.
Thus, a glassy state is maintained, where a sufficiently hard film is 
maintained. However, if softening occurred to the film during dissolution,
the polymer is expected to maintain the control regarding the liquid
permeation, because no melting is expected to occur.
Therefore, in the Eudragit NE dispersion, upon liquid dilution with the
ethanol content and upon drying, physical changes are expected to
occur for the dried film. This change is dependent on the ethanol




           
      
        
   
        
      
 
       
 
            
 
 
more DSC studies need to be done to quantify the amount of the
amorphous regions in the PMA polymer, and elongation at break study 
is needed for the free film to quantify the toughness of the enhanced
film. This increased polymer amorphosity would be needed to 
simultaneously enhance the sustained drug release and the floating
profiles of the coated floating pellets.
Figure 5.13: DSC thermogram made by the 6.66: 3.33% HPMC: NaHCO3 solution.





           
 
          
         
    
 
           
    
 
 
Figure 5.15: DSC thermogram for the film made by the Eudragit NE30D dispersion.
Figure 5.16: DSC thermogram for the film made by the Eudragit NE15D dispersion. $
Figure 5.17: DSC thermogram for the film made by the Eudragit NE15D dispersion,
out of which 25 w/w% ethanol.
Figure 5.18: DSC thermogram for the film made by the Eudragit NE15D dispersion,





        
         
         
        
        
        
         
          
        
          
       
         
      
           
         
         
           
           
         
         
       
        
         
        
          
       
        
         
        
        
        
         
5.5. Conclusion
As a sequential continuation from the screening studies, the single
coated floating pellets were enhanced. During the pelletisation, the core
pellets were enhanced mainly for the shape and the ease of the
extrusion and spheronisation processes. The enhanced core pellets are
suitable for being applied to further processing, like coating and
tabletting. Successful floating and drug release profiles were obtained
as stated shortly. The single-coated floating pellets are intricate to make
due to demanding two main functions from a single layer. Although these
pellets were more intricate to function successfully, these pellets of
single-coating reduced the cost of making floating pellets. The enhanced
retard coating layer was made from the 15Eud25Eth dispersion, which
was applied to the enhanced core pellets. The efficiency of coating
process takes into account of several features such as consistent
spraying, adequate wetting of the core surface by the coating liquid, the
film drying rate, the pattern of pellets movement (fluidizability), and the
liquid flow property in tube and nozzle. It is governed by multiple factors 
including the operation of the coating process, that is owing to the ability 
of ethanol to make less hydrogen bonding than water, resulting in a
weaker liquid surface. The latter is a desired the property of coating
formulations and the nature of cores to be coated such as their sizes,
shapes and integrity (Srivastava & Mishra, 2010). An aqueous based
coating liquid is usually the preferred approach for coating, because it is 
less hazardous. However, the presence of organic solvent in the coating
liquid tends to lower the surface tension, property for efficient spraying
and film formation. Owing to the decreased surface tension, the coating
efficiency was shown by the reduced sedimentation in the tubes and
nozzle (observed visually), increased uniformity in the spraying pattern
and droplet spreading, increased uniformity and speed of the solvent
evaporation, and the continued fluidisation of the pellets bed. The 
uniform spraying pattern and the higher droplet spreadability on the core
pellets surface is because of the lowered surface tension. This will allow 




           
         
       
           
        
       
        
        
      
          
      
         
       
         
         
        
           
           
     
           
     
         
        
        
       
         
       
      
          
         
        
        
        
     
resulting in an increased wettability of the liquid (Cole, et al., 2002).
Consequently, this results in an even coating thickness (Cole, et al.,
2002), as seen by SEM images in this chapter. On the other hand, as 
seen in chapter 4, the SEM images of the pellets that have a coat made
from the 15Eud0Eth dispersion showed uneven coating thickness, and
fluctuated floating and drug release profiles were resulted. The 
enhanced layer achieved successful floating and sustained drug release
profiles for up to 24 hours or more. The coating layer consists of 6%
solids only, where the coating thickness was relatively small and
relatively uniform (10±2 µm), obtaining a thin film. The surface area to
volume (SA:V) ratio decreases by 13.15-17.98% for the coated pellets.
The latter is critical to ensure an enhanced floating and sustained drug
release profiles. This specific range of SA:V ratio reduction implies an
enhanced controlled swelling. The successful floating and the sustained
drug release profiles in the acidic and neutral media may allow for more
predictable and consistent floating behaviours in the stomach. The latter 
will lower the risk of failure in floating, because the coated pellets will be
independent on the pH variation in the stomach. This reduced design of
the enhanced single-coated floating system offers several advantages 
as stated in the abstract of this chapter. The attainment of an enhanced
single-coated floating pellets through an enhancement study was 
achieved. Specifically, a successful attainment of the core pellets as well
as the coated layer were obtained for achieving the enhanced floating
and the sustained drug release properties. The successful pH-
independent floating may allow for more predictable and consistent
floating behaviours in the stomach. The reduced and enhanced design
of the single-coated floating pellets offers several advantages, include,
(1) reduced processing time, (2) reduced scale-up optimisation
workload, hence, reduced time to market, (3) reduced cost of operation
and materials use, (4) increased flexibility in the timing of the dosage
administration, regardless whether the stomach in the fasted state or in
the fed state, (5) offer a once daily administration, hence, increased
patient compliance, and (6) increase the bioavailability of the drug



























    
       
       
         
     
        
        
         
      
        
         
        
       
          
         
         
        
         
           
        
          
        
       
         
          
         
         
   
    
        
       
6.1. Introduction
The tableted pellets dosage form is considered highly advantageous 
when compared to other oral solids, primarily because of its cost-
effectiveness, divisibility, reduced counterfeit, scoring tolerance, high
patentability, and high drug loading capability. Hence, the multiple units 
of pellets system (MUPS) tablet is more advantageous than the MUPS 
capsule (Abdul, et al., 2010). Therefore, it is highly encouraged to do a
feasibility study on the compression of the enhanced coated pellets that
results in the ensemble pellets. The ensemble pellets consisted of the
enhanced single-coated pellets and the cushioning powder. The 
cushioning powder inside the tablets was in different ratios, to screen for 
the cushioning effects for the protection of the film structure and the film 
function. The aim in the work of this chapter is to screen the feasibility 
of making tablets made from the enhanced single-coated floating
pellets. Although that the enhanced coated pellets may be filled into hard
gelatine capsule as the final dosage form. The objective in this chapter 
is to introduce the tablet as a final dosage form for those pellets. The 
gelatine capsule need few minutes to dissolve, hence, the capsule-filling 
of those pellets will expectedly show few minutes of lag time for both
floating and drug release. However, the compression of the coated pellet
can unexpectedly affect those profiles, hence, investigating that at this 
point is more needed and it is important to understand the compression
effects on those pellets. The enhanced single-coated pellets will be
mixed with the cushioning powder and compacted by a specific 
compression force. This is needed to protect the film on the pellets and
to ensure a sufficient binding that form strong and non-friable tablets.
Favourably, the sustained drug release as well as the floating profiles of
those tablets should be maintained as possible when compared to the
non-compressed coated pellets.
6.2. Characterisation of the Ensemble Pellets
The compositions of floating pellets are succinctly outlined in the codes 




          
         
        
        
      
              
          
      
  
      
           
         
         
         
        
         
          
        
         
           
            
            
           
          
   
  
      
         
         
           
          
         
HFE102 here was used as a novel cushioning agent in the form of
powder, to protect the film structure, and subsequently, the film function
from an excessive deformation by the compression force applied. Also,
the coated pellets fusion with other pellets is an issue as stated by
(Dwibhashyam & Ratna, 2008). It is usually recommended that the
cushioning agent need to be of the same size and shape to the coated
pellets. The MCC material is the most protective as a cushioning agent,
owing to the MCC high elasticity.
6.2.1 Preliminary Findings
The tabletting parameters were set to obtain minimum hardness as 
possible to have the minimum impact of the compression force on the
coating layers of pellets. Based on the preliminary study (data not shown),
21.5-22.5 kN compression force would be appropriate to obtain tablets 
with strength of 5.5-9.0 KgF (53.94-88.26 N). However, other factors will
affect this relationship, as seen later in this chapter. To obtain sufficient
binding ability, good hardness, and non-friable tablets, the applied
enhanced compression force was 21.5 kN, the die depth was of 5 rounds 
from the bottom (the die volume capacity will vary in different dies and
machines), and the cushioning powder was of 33.33-90%. It is good to
mention here that 21 kN compression force is used in literature for making
tablets of 250 mg each that result in <100 N crushing force (IMA, 2019). 
Hence, a 21.5 kN force would be a reasonable amount of force for 
compressing a tablet of 400 mg that contain coated pellets. A lower force
than that was not giving a sufficient strength and integrity to the tablets 
made in this project.
6.2.2. The falling-to-floor friability test
The compression force was initially enhanced by this test, for the
ensemble pellets to be made with the sufficient strength. Different
compression forces were applied. The ensemble pellets were left to fall
at a distance of ~1 meter height from a marble floor. In order to initially 
accept their integrity and to pass to the next strength test, the ensemble




        
           
           
           
          
    
 
        
         
     
             
     
       
           
        
           
        
           
          
           
        
            
          
        
          
         
          
     
          
   
depth of five cycles from the bottom was fixed, where 400mg weight of 
pellets was filled to the dye hole. The compression force of 21.5 kN was 
fixed, as it found to be the least acceptable compression force for the
pellets to be ensembled into a tablet of a sufficient strength. The
compression force is expected to show the least damage of the film 
surface and structure.
6.2.3. The hardness test
Before hardness testing and subsequent testing, the tablets were stored
for 24 hours to allow for a post-compression relaxation in the tablets. As 
explained by (Zhang, et al., 2017), though the post-compression was 
expected to be at high rate at the first hour after ejection, the first 8 hours 
after ejection were also considered.
Table 6.1 summarises the physical analysis of ensemble pellets. A 
threshold of 5 KgF was set, tablets that have less than that force value
will get rejected. The average crushing forces for the ensemble pellets 
were recorded. It is quite difficult to aim for a targeted crushing force in
this study. The targeted force is usually based mainly on the friability test
outcome and the tablets’ weight. Also, the tablet's size and shape can
have an effect. Although it can be different for each formulation, usually 
the higher the weight of the tablet, the higher the crushing force is aimed
to -up to a certain threshold-. This is because the risk of the friability is 
suspected to be increased with the increasing weight of the tablets, and
a higher crushing force will be required to compensate for that.
Here, to lesser extent, the crushing force can affect other quality 
attributes in tablets, like the floating and the sustained drug release
profiles. Although cushioning powder are used to minimise that effect,
the crushing force here has to be as minimum as possible to protect the
coating layer on the pellets surface. The latter mitigations for film 
protection upon the compression of pellets are important to minimise the




        
         
     
        
        
         
        
    
Unlike the hardness of the tablets containing the double-coated floating
pellets in chapter 3 (99 N), the hardness of the tablets containing the
enhanced single-coated floating pellets showed lower strength (51-72 
N). The latter finding was when the tabletting process variables and the
cushioning agent variables were kept the same. The relatively lower
strength could be due to the less thickness of the polymeric layers on
the single-coated pellets (10±2 µm), which may require a weaker force






                                 
             
 
      
      
        
      
       
      
      
      
      
                      
          
          
 
                      
                 
            
    
     
Table 6.1: Shows the properties of the coated pellets and the ensemble pellets.
Batch code* Weight (mg)** Crushing force (N) Tensile strength (MPa) Friability (MSI) (%) Disintegration
time (min)
B9SLow 399.40±0.85 50.68±2.37 0.75±0.034 0.44 2
B10SLow 400.00±0.79 51.01±3.1 0.75±0.046 0.39 2
B11SLow 401.86±2.13 56.244± 2.27 0.83± 0.03 0.46 2
B12SLow 398.94±1.05 55.59± 5.66 0.82±0.08 0.53 1
B12SHigh 399.44±0.88 59.514± 10.8 0.88± 0.16 0.52 2
B13SLow 399.81± 0.25 57.55± 10.07 0.85± 0.15 0.67 1
B13SHigh 400.02± 0.15 72.27± 12.42 1.07± 0.18 0.48 2
B14SLow 400.09± 0.09 58.2± 4.94 0.86±0.07 0.45 1
B14SHigh 399.72± 0.39 63.44± 4.53 0.94±0.06 0.56 2
* Mean values ± SD were presented where applicable. Batches with LC abbreviation relates to the use of “low amount of cushioning powder”
based on the stated ratio in chapter 2, where those of HC batches are vice versa. N=16 for weight measurements and friability test, N=3 for
density measurements, N=6 for hardness and for the disintegration test. Exception is for B14 (HC), where N=20 for both the friability and the
hardness tests.
** The weight uniformity results were not determined based on the batch mix poured into a hopper prior feeding into the die. The results were
based on a pre-weight tablet mix poured into the die directly. These results are to ensure the filling was reproducible within the scope of the 
study here, but can neither reflect the actual hopper filling mechanism nor the automatic filling mechanism. Hence, this limitation need
optimisation work during the manufacture scale up of the formulation.





      
      
         
        
 
       
         
         
      
           
    
  
        
         
           
        
          
       
           






































6.2.4. The friability test, using the sliding drum
Regardless of the cushioning powder amount used, the tablets 
showed sufficient mechanical strength (weight loss<1%). This 
strength is owing to the MCC powder that increased the binding
strength with the coated pellets, see Table 6.1.
6.2.5. The tensile strength test
The average thickness and diameter of the ensemble pellets were
measured using the caliper. Then the tensile strength values were
measured for all batches, see Figure 6.1, and Table 6.1. The tablet 




















Figure 6.1: Shows the tensile strength values of the ensemble enhanced single-coated 
pellets. Refer to Table 2.4 for the compositions.
6.2.6. The disintegration test
The tablets should disintegrate into dis-assembled coated pellets, to
allow for the coated pellets to initiate and maintain floating. The tablets 
were placed in a beaker filled with a dissolution medium, of either a
distilled water or 0.1 N HCl. Results showed that all batches required 1-
2 minutes for disintegration to be completed, see Table 6.1. The findings 
implied that the ensemble pellets were weak enough to dis-assemble
into separate pellets in a short time. Which is a desired quality, as it





         
          
          
           
            
        
           
     
        
      
          
          
           
       
      
     
   
       
         
      
       
  
 
        
       
       
       
       
            
     
    
mechanisms. Therefore, the coated pellets will have a similar chance to
complete their floating lag time before the start of the housekeeping
wave, assuming the floating lag time was less than 15 minutes.
It is good to be reminded here, that this housekeeping wave occur in a
fasted stomach and it is initiated every 1-2 hour/s. To avoid being at the
bottom of the stomach when this wave occurs, the formulations should 
be able to reach the floating state as soon as possible after the oral
administration. Hence, a very quick disintegration time is highly 
desirable for the ensemble pellets system (Qi, et al., 2015). For more
details regarding the physiological challenges faces the floating dosage
form, the reader is advised to consult section 1.6 in the introduction
chapter. Although that all the ensemble pellets were disintegrated in a
fast time, the tablets of the low amount of the cushioning powder were
mostly disintegrated relatively faster (1 minute instead of 2 minutes).
Expectedly, the crushing force was relatively lower for the most batches 
with faster disintegration, see Table 6.1.
6.2.7. The apparent density test
The apparent density values of the ensemble pellets mixtures were 1.24
g/cm3, regardless of the amount of cushions used, see Table 6.1. This 
value was higher than the liquid medium density (~1g/cm3), which
means the tablets will inevitably sink when poured into the liquid
medium.
6.2.8. The apparent porosity test
The calculated apparent porosity was based on the density values of the
tablets' mixtures of the enhanced single-coated pellets and the
cushioning powder. The latter was important to understand the porosity 
of the tablet’s mixture pre-compression. The mixture was intended to be
compressed into ensemble pellets. The porosity values ranged between
7-9 % for all of the mixtures, see Figure 6.2. The low porosity values of






       
      
       
        
  
          
         
  
 
         
     
 
 
       
      
          
        
        
         
      
         
          








































1) Unlike the porous granules, the pellets were considered dense
agglomerates, resulting in less intra-particulate pores,
2) Unlike the irregularly shaped granules, the pellets used were highly 
spherical in shape (ARs<1.2) and dense, resulting in fewer surface
pores channels,
3) The pellets used had a narrow size distribution (1-1.18 mm), which




















Figure 6.2: Porosity percentages of the ensemble enhanced single-coated pellets.
Refer to Table 2.4 for the compositions.
6.2.9. The drug release study
Regardless of the cushions amount used, the drug release profiles 
showed zero-order drug release for 8 hours (R2 values range from 
0.885 to 0.964), see Figure 6.3. A larger amount of drug was released
per unit time when compared to the non-ensemble pellets (as 
compared to chapter 5 results). This increased drug release upon
tableting was also observed by (Qi et al., 2014). Some potential
reasons for the faster dissolution profiles, namely, (1) the insufficient
amount of the cushioning powder added, and (2) the thin coating film 
applied that susceptible to rupture by compression. Thus, the ratio of




        
          
          
          
         
         
         
        
          
       
       
       
  
       
         
        
        
         
          
        
          
         
         
        
       
        
         
       
According to (Dwibhashyam and Ratna, 2008), using typically more than
50% of the cushioning material is needed to have a minimum protection
to the films upon compression. There was no significant increase in the
drug release when compared to the pellets with high cushions, which
confirmed that the factor of cushioning level could be less significant
from the factor of compression force level. The latter still cannot be
confirmed in this study whether the presence of cushions at all can make
a significant increase in drug release or not. Despite using a low 
compression force to maintain sufficient strength of the tablets and to
avoid films rupture or fusion, the film integrity became weaker, where
the drug release profiles of the ensemble pellets were relatively faster 
as they were sustained for up to 8 hours only (as compared to chapter 
5 results).
The film is holding highly critical roles in the formulation function,
namely, the drug release and the floating control. However, when 
ensemble pellets compared to the non-ensemble pellets, the changes in
the film quality is likely -in either a negative or a positive way-, as proven
in various literature studies (Li, et al., 2016). However, some literature
also claims that the use of cushioning excipient can fully protect the film 
on the coated pellets upon compression (Zeeshan & Bukhari, 2010). 
Regardless of the core pellets size used, the core pellets did not float.
Noticeably, the smaller size of the core pellets (0.71 mm) fastens the drug
release. This is due to that the diffusion path for these core pellets is 
shorter than the bigger core pellets. Unexpectedly, the coated pellets of
smaller size (0.71 mm) showed poorer floating than larger size ranges.
These risk mitigation efforts concluded the avoidance of using the lower 
usable size range (0.71mm) of the core pellets in the subsequent coating 
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6.2.10. The floating study
The ensemble pellets floated successfully, where more than 90% of the
pellets maintained floating for 24 hours in the 0.1 N HCl medium. The
latter findings were comparable to the non-ensemble pellets in chapter 
5, except that the floating lag time for the coated pellets to float was 
within 15 minutes. This relatively small increase in the floating lag time
was expected, due to two reasons, (1) the need for the two minutes 
disintegration time, and (2) the compression force effects on the film 
quality, as potential rupture might occur. However, the floating was still
under the passable limits of the critical quality attribute of the floating lag
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6.2.11. The scanning electron microscopy (SEM) study 
The SEM images revealed important amount of information that can be used
to further characterise the obtained ensemble pellets. The evidence of the
dissolution effect and potentially the cushioning effect and can be drawn.
i. The SEM study of the intact coated pellets of the crushed tablets,
before dissolution
The coated pellet where taken from the ensemble pellets after crushing. That
is, the coated pellets were taken from the dis-assembled ensemble pellets via
the hardness tester. The tested pellets here were exposed to two forces, the
compression force and the crushing force. Regardless of the latter forces 
combined effects, the coated pellets maintained their intactness.
The deformation of the coated pellets before dissolution is due to two
confounding factors, the compression force and the crushing force.
Regardless of the amount of cushions, the images showed some deformation
from the optimal spherical shape with some protrusions. Although more than
50% cushions were recommended by the literature to obtain a sufficient film 
protection, the 66.66-90% cushion powder was not enough to fully protect the
coating film, which showed rupture, see Figures 6.5-6. These ruptures resulted 
in faster drug release profiles, though the drug was sufficiently sustained for 8









               
        










Figure 6.5: The SEM images of the intact coated pellets before dissolution. The images taken
from crushed tablets that were compacts of the coated pellets (i.e. ensemble pellets) with high









            
          
   
          
 
          
        
          
           
           
          
          
        







Figure 6.6: SEM image of intact coated pellets, before dissolution, where taken from crushed
tablets that were compacts of the coated pellets (i.e. ensemble pellets) with low amount
(33.33%, but it is 10% for B13) of non-medicated cushion powder.
ii. SEM study for "bisected" coated pellets of the crushed tablets, before
dissolution
The coated pellet where taken from a crushed tablet contained compacted
coated pellets, i.e from the dis-assembled ensemble pellets via the hardness 
tester. Some of the bisected pellets with a low amount of cushions (33&10%) 
in Figure 6.7 shows some cracks in the film. However, it can be a crack 
resulted due to the crushing force exerted to break the ensemble pellets into
individual pellets, or due to the blade effect upon bisecting the pellets into two 
halves. The images showed the thickness of the enhanced thin film (10±2 µm),
and illustrated the integrity and the uniformity of the film thickness throughout









            
     















Figure 6.7: SEM image of bisected coated pellets, before dissolution, where taken from
crushed tablets that were compacts of the coated pellets (i.e. ensemble pellets) with high









          
     
           
         
    
        
       
      
         
        
       
        
         
       









Figure 6.8: SEM image of bisected coated pellets, before dissolution, where taken from
crushed tablets that were compacts of the coated pellets (i.e. ensemble pellets) with low
amount (33.33%, but it is 10% for B13) of non-medicated cushion powder.
iii. SEM study for "intact" coated pellets of the dis-assembled pellets,
after 24 hours dissolution
The tested coated pellets were taken from the dried coated pellets after they 
undergone disintegration and 24 hours dissolution, i.e. they were dis-
assembled by the dissolution hydrodynamics from the ensemble pellets. The 
images in Figures 6.9-10 revealed potential evidence of small ruptures in the
film structure That is, the cracked film integrity allowed for a faster drug
release. After 24 hours of dissolution, the pellets images remained intact. This 
confirms that the coated film showed high integrity, regardless of the
compression force, the dissolution hydrodynamic, and the drying stresses.
However, the latter stresses were evident, because the grooves become









          
      










Figure 6.9: SEM image of intact coated pellets, after dissolution, where taken from
disintegrated tablets contained compacted coated pellets (i.e. ensemble pellets) with high
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Figure 6.10: SEM image of intact coated pellets, after dissolution, where taken from
disintegrated tablets contained compacted coated pellets (i.e. ensemble pellets) with low
amount (33.33%, but it is 10% for B13) of non-medicated cushion powder.
iv. SEM study for "bisected" coated pellets of the dis-assembled pellets,
after 24 hours dissolution
After 24 hours dissolution, the coated pellets were dried and bisected, and
studied under the SEM, see Figures 6.11-12. Although the compression force,
dissolution and the drying stresses on the coated pellets were considered
harsh, the intactness of coated pellets structure remained high and with high
reservation in the film size, shape and integrity. Consistently with the images 
in the previous sub-sections, the high cushions containing ensemble pellets 
showed no difference in shapes when compared to the low cushions ones.
Because the deformation and the ruptures of the films were primarily controlled
by the compression force of the tabletting machine and the crushing force,









          
     










Figure 6.11: SEM image of bisected coated pellets, after dissolution, where taken from
disintegrated tablets contained compacted coated pellets with high amount (66.66%, but it is 









          
     











Figure 6.12: SEM image of bisected coated pellets, after dissolution, where taken from
disintegrated tablets contained compacted coated pellets with low amount (33.33%, but it is 






     
        
        
         
        
       
       
        
             
            
            
          
          
          
          
         
      
        
           
       
            
         
           
             
        
             
       
         
          
            
         
        
   
6.3. Conclusion
The tableted pellets dosage form is considered highly advantageous as stated
in the introduction of this chapter. The ensemble pellets consisted of the
enhanced single-coated pellets and the cushioning powder. The cushioning
powder inside the tablets was in different ratios, to screen for the cushioning
effects for the protection of the film structure and the film function. When the 
cushioning powder amounts were lower (33.33&10 %). the crushing force
values ranged from ~50-58 N with standard deviation (SD) values of 2-10 N. 
However, when the cushioning powder amounts were higher (66.66&90 %),
the force needed to crush the tablet increased by about 15 %, i.e. ranged from 
~59-72 N with SD values of 4-13 N. Hence, a proportional relationship can be 
seen between the amount of the cushioning powder and the crushing force. In
other words, as the cushioning amount increase in the tablet, the crushing
force of tablet increase, indicating an increased binding forces. The tablets 
were placed into a beaker filled with either dissolution medium of the distilled
water or with the 0.1N HCl media. The disintegration of the ensemble pellets 
into the disassembled single-coated pellets will take 1-2 minutes for all tablets.
Also, all of the tablets' mixtures showed similar apparent density values 
(1.24±0.00 g/cm3). Though it is acceptable, the ensemble pellets showed drug
release profiles that only sustained for up to 8 hours. The compression of the
single-coated pellets has reduced the functionality of the sustained drug
release from 12 hours to 8 hours. That implied that the coat on pellets had
some fractures induced by the compression force, which caused an increase
in the drug release over time. It is where an acceptable zero-order drug release
(R2>0.9) can be obtained in 8 hours instead of 12 hours. The drug release rate
was ~12.5%/hour, instead of ~8.33%/hour. The MUPS tablet review of (Al-
Hashimi, et al., 2018) stated that some studied showed an increase of drug
release from coated pellets upon compression, while other studies showed a
decrease of drug release from coated pellets upon compression, due to film 
rupture or fusion, respectively. The latter review also stated that a low porosity 
in the core pellets can affect the drug release of the coated pellets upon
compression. Hence, in this work, the porosity of the coated pellets may need
to be higher than 7-9% of tablets mixtures pre-compression, to allow for higher 





       
        
             
          
           
          
        
       
         
          
          
       
            
         
           
          
          
        
         
        
    
           
          
       
        
        
        
    
 
 
After the disassembly from the intact tablet, the single-coated pellets were
showing successful floating. The coated layers on the disassembled single-
coated pellets provide controlled fluid diffusion in to and out of the pellets. The
controlled diffusion will induce the controlled swelling, which will initiate and
maintain the floating mechanism, the same applied to the sustained drug
release mechanism. But, unlike the drug release profiles, the floating profiles 
for all of the ensemble pellets batches remained optimum, as they were not
affected by the compression force. The scanning electron microscopy (SEM) 
images revealed important morphological information that can be used to
elaborate on the results of the ensemble pellets. For example, it was founded
that regardless of the amount of the cushioning powder, the SEM images of
the single-coated pellets showed some protrusions and deformation from the
optimal spherical shape, which is expected, due to the impact of the combined
forces of compression force and crushing. Regardless of the amount of the
cushioning powder, the increased drug release is due to the deformation and
the rupture of the films, which were primarily controlled by the compression
force of the tabletting machine. After 24 hours of dissolution, the single-coated
pellets remained intact, as seen in the SEM images. The latter confirms that
the coated films on the pellets showed high integrity. The latter finding was 
regardless of the compression force, the dissolution hydrodynamics, and
regardless of the subsequent drying stress after dissolution. This intactness 
here is desirable to allow the single-coated pellets to remain functional and to
withstand the harsh environment of the GIT. Hence, the ensemble pellets 
dosage form is expected to have a desirable biopharmaceutics performance.
The work in this chapter attained the tablets of an enhanced single-coated
floating pellets. Specifically, it sufficiently maintained the functions of the
coated layer, which is simultaneously responsible for the floating and







































   
     
         
         
          
        
        
         
         
       
          
      
        
          
        
           
           
         
      
             
         
         
             
     
          
      
            
          
          
         
           
          
        
       
7.1. General Conclusion
Pharmaceutics is a voyage of multi-disciplinary collections of theories and
technologies that mainly focus on the physical chemistry and the design of the
dosage forms of the drug products, and the accompanying methods of
preparation and testing. In this project, the dosage form design of interest is 
the pellets-containing dosage form. The specific designs of interest are the
double-coated and the single-coated floating pellets designs, which could
potentially be compressed into tablets. Pellets can be defined as oral solid
intermediate formulations, spherical in shape, relatively small in size, and
made by a pelletisation technique, usually by extrusion and spheronisation
method with a spheronisation aid to obtain dense agglomerates of pellets.
Floating pellets achieve floating as they contain floating agents and retard
polymeric agents, usually through the application of coating layer/s. The pellets 
can be made to be as a gastro-retentive drug delivery system (GRDDS). The
gastro-retentive term, as the name implied, is derived from its ability to achieve
retention of the dosage form in the stomach. Unlike the other GRDDS, floating
systems are established in the marketed products, and they will avoid the
irritation to the epithelium of the gastro-intestinal tract (GIT). The latter is 
especially advantageous when the floating system is a floating pellets system,
owing to the high distribution of the dose in the pellets, which further reduce
the dose localisation. The additional advantage of floating pellets is that pellets 
will avoid the “all or none” risk of emptying. Therefore, the floating pellets 
system is said to be one of the most preferred approaches in the GRDDS. The
floating pellets system is of a particular interest for specific situations in specific 
drug substances, like the situation of the drugs with erratic absorption, like
theophylline. The erratic absorption means non-uniformity drug absorption in
the GIT, resulting in a variable drug bioavailability. The factors that affect the
drug absorption are numerous including the drug product and the physiological
factors, which subsequently affect the drug bioavailability. All of these factors 
may cause a variable absorption in the gastro-intestinal tract (GIT) for certain
drugs, like theophylline. That can result in unfavourable fluctuated plasma drug
levels. However, the risk of attaining a toxic dose or not attaining the
efficacious dose becomes more pronounced when such drugs also have a
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formulators to think of more reliable means for the delivery of such drugs. The
floating pellets are expected to ensure the consistency of the bioavailability of
the drug theophylline, by the gastro-retention and the sustained drug release
properties. Numerous preparation processes, in-vitro characterisation
processes, and methodological tools, and materials were used throughout the 




(Chapters 1 and 2) 
Risk Identification



















Figure 7.1: It shows the thesis structure showing the workflow/the risk assessment during the 
PhD research program.
It was feasible to successfully attain the core pellets by a new spheronisation
aid (Avicel HFE102) for up to 60% drug loading. It was encouraged in literature
to find alternative spheronisation aids that are co-processed with other 
materials (Jain, et al., 2010). This alternative and new spheronisation aid may 
help in addressing the drawbacks of the MCC, like drug deactivation, which
encourages more studies to be made in this grade of Avicel. The double-
coated floating pellets showed insufficient sustained drug release for <4 hours,
and where only 34-72% floated on surface (except B5D-B8D, which were
>95% floated for 8 to >12 hours). However, the understanding of the double-
coated floating pellets design was important before reducing the system into
the single-coated floating pellets design. The latter is more intricate yet more
cost-effective design. This intricacy is owing to the eliminating of the sub-
coated layer, and using only one layer to achieve both the sustained drug






         
          
       
         
       
   
         
          
        
        
           
        
         
         
         
         
         
           
         
            
          
          
       
          
       
           
        
           
       
         
          
        
          
           
For the non-PVP containing core pellets (B2S, B4S, and B5S), the attainment
of the core pellets was successful (AR<1.2), where the effervescent and the
hydrating polymers are incorporated. However, when these pellets were
coated, the floating and the sustained drug release properties for all
formulations were variable. Therefore, an enhancement work was needed to
streamline the results.
As a sequential continuation from the screening studies, the single coated
floating pellets were enhanced. All of the core pellets of B9S-B14S (these are
the core pellets made by from the 10% ethanol containing-wet mass) were
successful. During the pelletisation, the core pellets were enhanced mainly for 
the shape and the ease of the extrusion and spheronisation processes (all
batches have AR<1.2). The enhanced core pellets are suitable for being
applied to further processing, like coating and tabletting. Successful floating
and drug release profiles were obtained. The best formulations of the coated 
pellets were of the B9S-B14S (these are the coated pellets made by from the
25 w/w% ethanol containing-Eudragit NE dispersion). All of the single-coated
floating pellets showed sustained drug release for 24 hours or more in 0.1N
HCl medium, and the floating was at least for 24 hours in 0.1N HCl medium 
and 12 hours in the distilled water medium. The single-coated floating pellets 
are intricate to make due to the demanding two main functions from a single
layer. Although these pellets were more intricate to function successfully, these
pellets of single-coating reduced the cost of making floating pellets. The
enhanced retard coating layer was made from the 15Eud25Eth dispersion,
which was applied to the enhanced core pellets. The coating layer consists of
6% solids only, where the coating thickness was relatively small and relatively 
uniform (10±2 µm), obtaining a thin film. The surface area to volume (SA:V) 
ratio of the coated pellets decreases by 13.15-17.98%. The latter ratio range
is critical to ensure an enhanced floating and sustained drug release profiles.
This specific range of SA:V ratio reduction implies an enhanced controlled
swelling, hence, where the swelling is in the desired equilibrium position. The 
successful floating and the sustained drug release profiles in the acidic and
neutral media may allow for more predictable and consistent floating
behaviours in the stomach. The latter will lower the risk of failure in floating,





        
      
          
      
         
          
  
         
           
          
         
        
            
         
       
         
        
           
        
            
       
       
      
        
         
        
              
            
        
         
          
       
      
           
stomach. This reduced design of the enhanced single-coated floating system 
offers several advantages regarding cost reduction and drug bioavailability 
improvement. The attainment of an enhanced and novel single-coated floating
pellets through an enhancement study was achieved. Specifically, a
successful attainment of the core pellets as well as the coated layer were
obtained for achieving the enhanced floating and the sustained drug release
properties.
Upon disintegration, all of the compressed or tabletted single-coated floating
pellets showed sustained drug release for up to 8 hours or more in 0.1N HCl
medium, and the floating was at least for 24 hours in 0.1N distilled water 
medium (where all batches showed complete floating for 24 hours). Hence, all
of the single-coated floating pellets sufficiently sustained the drug release (for 
8 hours) and maintained floating for at least 24 hours. That is, the best
formulations still produced useful performance. The tabletting of these best
formulations were superior over the literature findings obtained (Qi, et al.,
2015). The tableted floating pellets were floated immediately for more than 12
hours for non-compressed and compressed coated pellets (% of floating not
stated) and SR for up to 6-8 hours, though DR reach 80% in 4 hours (for both
non-compressed and compressed coated pellets and comparable to PK data
of absorbed drug in animals). The medium used for drug release is not stated.
The significance of this work is that these best floating pellets formulations 
(containing the drug theophylline) encourages further testing in animals, to
obtain bioequivalence prior manufacturing. These best floating pellets 
formulations will also reduce the cost during manufacturing, because only 
single and thin coating layer will be needed on the core pellets made by the
extrusion and spheronisation method. The latter is unlike the respective
literature (Qi, et al., 2015), (Hung, et al., 2014), (Chen, et al., 2012), where all
failed to consistently obtain more than 8 hours of drug release, though all of
them had batches floated for >12 hours. In particular, the researchers of (Qi,
et al., 2015) were the most successful (respective to similar literature) in using
one layer of coating with a non-effervescent system, where the core pellets 
made by the extrusion and spheronisation. Their developed formulations were
noticeably different from the formulations made in this project by five means; 





          
      
          
       
         
           
         
           
             
          
             
          
       
           
             
         
          
           
        
             
        
         
            
        
         
           
        
        
        
         
           
          
          
         
         
dual functionality in one coating layer, while in this project, only one retard
polymer was used, the Eudragit NE30D. (2) They used only distilled water for 
diluting the Eudragit coating dispersion, while in this project ethanol was used
for dilution. (3) They used larger coating weight gains (10, 20, and 25%), while 
in this project it is only 6%. And, (4) They used the alcoholic PVP K30 as a
liquid binder (PVP solubilised in the liquid), to obtain a consistent wet mass,
while in this project, an ethanol liquid binder was used and the PVP powder 
was used, where it is more likely for the PVP to be wetted without soaking in
the powder bed, owing to the rapid evaporation of ethanol. That is, the core
pellets were made with the wetted PVP (PVP is not solubilised in the liquid),
which will have a low risk of not restoring the swellability function of PVP. And,
(5) also, in their work, regardless of the tableting and the compression force
used, the tableted pellets as well as the non-compressed ones showed 80% 
or more of drug release after 4 hours, though it floated sufficiently for 9 hours.
The maximum concentration of the drug in the rat blood plasma reached at 3
hours. Hence, the drug is not sufficiently sustained, which render the floating
pellets to be not successful, hence that requires enhancement. While in this 
project, even after tableting, the floating and the sustained drug release were
better improved. Regardless of tableting, the floating was at least for 12 hours 
and the sustained drug release was at least for 8 hours. To sum it up, in this 
work, the core originality is in successfully making a cost effective single-
coated floating pellets, using the extrusion/spheronisation method of preparing
the spherical and narrowed size core pellets, and using a one polymer grade
in the top-spray fluidised bed coater for making the dual functional and thin
coating film. The dual functional film was made from a modified Eudragit NE 
dispersion. When the dispersion was applied to the spherical and the narrowed
size core pellets, the floating can be successfully produced without the need 
for an effervescent. The feasibility to compact such pellets into dispersible
tablets was also found to be promising and encouraged further tabletting
development. My contribution to the field was by providing a successful floating
and sustained drug release using a single-coated design, which improve cost
effectiveness. The latter was owing to (1) a reduced coating weight gain and
coating process runtime, due to the decreased material used and the
increased efficiency in coating. And (2) a reduced number of coating batches





       
        
      
  
         
         
            
          
        
       
         
        
       
        
             
         
          
         
         
         
         
         
         
       
          
       
          
           
        
       
           
        
           
      
preparation time. Hence, this work can encourage further work on this 
formulation design during pre-clinical and clinical development, as it may 
facilitate the manufacturing of floating pellets.
7.2. Future Work
The major difficulties in this project, where in obtaining consistent wet mass to
be used for extrusion and spheronisation. Moreover, the coating liquid
formulation was the most difficult and the most critical in the performance of
the coating process and of the coated pellets. Hence, it is recommended,
especially during scale up, that to focus on conducting intensive studies for 
optimising the wet mass properties (using e.g. mixer torque rheometer) and
the coating process and the coated product properties (using a laser technique
for size analysis in-process, to measure the sprayed droplet properties).
Moreover, transmission electron microscope (TEM) is also recommended, to
visualise the internal morphology of the coated pellets without bisecting them 
into two halves. The latter will remove the bias of the cutting blade effect on
rupturing the film. Also, a familiarity (f2) test between the dissolution profiles 
also need to be considered, to further investigate the differences between the
dissolution profiles. The latter will allow the increased understanding of
whether a certain change in excipients is acceptable in the drug formulation.
The work in this thesis was focused mainly on the various in-vitro testing of the
enhanced floating pellets. However, more studies in-vitro (like the short term 
and long term stability studies), and in-vivo (animal studies, to obtain supra-
bioavailability with a marketed theophylline product that is also a sustained
drug release system), in-silico (statistical and mechanistic modelling, to 
simulate formulation scale up) can be made, to further develop these obtained
formulations. Hence, the work in this thesis can serve as the bases for further 
development in the enhanced single-coated floating pellets, in order to fasten
their time to market. The work in this thesis and the future work will indeed help
to complement the efforts for supra-bioavailability, and the subsequent scaling
up of the enhanced single-coated floating pellets all the way from the lab-scale
to the production-scale production. Perhaps, the scaling up can be made
through the pilot-scaling in a continuous manufacturing mode, for instance.
Hence, the latter can be controlled and reviewed through the risk control and






             
       
          
 
        
       
   
       
        
    
      
      
       
 
            
        
         
            
    
     
     
            
      
        
     
            
      
     
      
            
      
           
   
8. References
Abdel Rahim, S., Carter, P. A. & Elkordy, A., 2015. Design and evaluation of
effervescent floating tablets based on hydroxyethyl cellulose and sodium  
alginate using pentoxifylline as a model drug. Drug Des, Dev and Therapy, 9,  
pp. 1843-1857.
Abdul, S., Chandewar, A. & Jaiswal, S., 2010. A flexible technology for  
modified-release drugs: multiple-unit pellet system (MUPS). J Cont Rel,
147(1), pp. 2-16.
Al-Hashimi, N., Begg, N., Alany, RG., Hassanin, H., Elshaer A., 2018.  
Review: Oral modified release multiple-unit particulate systems: compressed
pellets, microparticles and nanoparticles. Pharmaceutics, 10, pp. 176. 
Al-Khattawi, A., Iyire, A., Dennison, T., Dahmash, E., Bailey, CJ., Smith, J.,  
Rue, P., Mohammed, AR., 2014. Systematic screening of compressed ODT
excipients: cellulosic versus non-cellulosic. Current Drug Delivery, 11(4), pp.
486-500.
Alderborn, G., 2013. Tablets and Compaction. In: M. E. Aulton & K. M. G.
Taylor, eds. Aulton's Pharmaceutics, The Design and Manufacture of
Medicines. 4th ed. London: Churchill Livingstone Elsevier, pp. 505-506.
Allen, L. V., Popovich, N. G. & Ansel, H. C., 2005. Dosage Form Design:
Biopharmaceutical and Pharmacokinetic Considerations. In: Ansel's  
Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th ed.  
Baltimore, USA: Lippincott Williams & Wilkins, pp. 171.
Allen, L. V., Popovich, N. G. & Ansel, H. C., 2005. Dosage Form Design:
Pharmaceutical and Formulation Considerations. In: Ansel's Pharmaceutical
Dosage Forms and Drug Delivery Systems. 8th ed. Baltimore, USA,:
Lippincott Williams & Wilkins, pp. 107, 124.
Allen, L. V., Popovich, N. G. & Ansel, H. C., 2005. Solid Oral Modified- 
Release Dosage forms and Drug Delivery Systems. In: Ansel's  
Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th ed.  
Baltimore, USA: Lippincott Williams & Wilkins, pp. 260-272.
Amidon, G. L., Lennernas, H., Shah, V. P. & Crison, J. R., 1995. A  
Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation






            
      
     
             
            
          
        
 
            
      
       
  
            
      
         
         
          
 
       
            
          
   
         
            
        
   
         
      
            
      
             
       
     
           
         
Amrutkar, P., Chaudhari, P. & Patil, S., 2012. Design and in vitro evaluation
of multiparticulate floating drug delivery system of zolpidem tartarate.
Colloids Surf B Biointerfaces., 89(1), pp. 182-187.
Anuj, G. and Fuloria, N.K. 2012. Short review on quality by design: a new era of
pharmaceutical drug development, Int. J. Drug Dev. & Res., 4, pp.19-26.
Bardonnet, P. et al., 2006. Gastroretentive dosage forms: Overview and
special case of Helicobacter pylori. Journal of Controlled Release, 111, pp. 1-
18.
Aoki H, Iwao Y, Mizoguchi M, Noguchi S, Itai S, 2015. Clarithromycin highly- 
loaded gastro-floating fine granules prepared by high-shear melt granulation
can enhance the efficacy of Helicobacter pylori eradication. Europ J Pharm &  
Biopharm, 92, pp. 22-27.
Arora S, Ali J, Ahuja A, Khar RK, Baboota S, 2005. Floating Drug Delivery  
Systems: A Review. AAPS PharmSciTech, 6(3), pp. 372-390.
Ashford, M., 2013. Assessment of Biopharmaceutical Properties. In: M.
Aulton & K. M. Taylor, eds. Aulton's Pharmaceutics, The Design and
Manufacture of Medicines, 4th ed. London: Churchill Livingstone Elsevier, pp.
353.
Ashford, M., 2013. Bioavailability - Physicochemical and Dosage Form  
Factors. In: M. E. Aulton & K. M. G. Taylor, eds. Aulton's Pharmaceutics, The
Design and Manufacture of Medicines. 4th ed. London: Churchill Livingstone
Elsevier, pp. 314-333.
Ashford, M., 2013. Gastrointestinal Tract - Physiology and Drug Absorption.
In: M. E. Aulton & K. M. G. Taylor, eds. Aulton's Pharmaceutics, The Design
and Manufacture of Medicines. 4th ed. London: Churchill Livingstone
Elsevier, pp. 301-306.
Atension, 2014. Sigma700 and 701, Operation Manual of Attention Force
Tensiometer, Revision 2.1, Helsinki, Finland: Atension.
Atkins, P., 1995. Acid and Base. In: Concepts in Physical Chemistry. 1st ed.
Oxford: Oxford University Press, pp. 1 & 25.
Atkins, P., 2010. The first law: The conservation of energy. Free energy: The
availability of work. In: The Laws of Thermodynamics: A Very Short
Introduction. Oxford: Oxford University Press, pp. 31-35, 63-79.
Atkins, P., 2014. Changing the state of matter. In: Physical Chemistry, A Very  





              
          
 
              
        
    
              
        
         
            
       
       
           
            
       
     
           
      
      
          
         
 
        
        
             
       
  
              
       
    
         
        
        
Atyabi, F., Sharma, H. L., Mohammad, H. A. H. & Fell, J. T., 1996. Controlled
drug release from coated floating ion exchange resin beads. J Cont Rel, 42,  
pp. 25-28.
Aulton, M. E., 2013. Properties of the Solutions. In: M. E. Aulton & K. M. G.
Taylor, eds. Aulton's Pharmaceutics, The Design and Manufacture of
Medicines. 4th ed. London: Churchill Livingstone Elsevier, pp. 38-48.
Aulton, M. E., 2013. Dissolution and Solubility. In: M. E. Aulton & K. M. G.
Taylor, eds. Aulton's Pharmaceutics, The Design and Manufacture of
Medicines. 4th ed. London: Churchill Livingstone Elsevier, pp. 20-37.
Aulton, M., 2018. Particle Size Reduction and Size Seperation. In: 5th, ed.
Aulton's Pharmaceutics, the Design and Manufacture of Medicine. ME  
Aulton; KMG Taylor ed. London: Elsevier, pp. 159.
Aulton, M. E. & Summers, M. P., 2013. Powders, granules, and granulation.
In: M. E. Aulton & K. M. G. Taylor, eds. Aulton's Pharmaceutics, The Design
and Manufacture of Medicines. 4th ed. London: Churchill Livingstone
Elsevier, pp. 472-473 and 480-482.
Avinash, K., Abha, D., Praween, K. & Abhinav, G., 2012. Floating Drug
Delivery System a Significant Tool for Stomach Specific Release of
Cardiovascular Drugs. InterJ Drug Dev& Res, 4(4), pp. 116-129.
Awasthi, R. & Kulkarni, G., 2014. Development of novel gastroretentive drug
delivery system of gliclazide: hollow beads. Drug Dev Ind Pharm J, 40(3), pp.
398-408.
Ayad, M. H., 2014. Rational formulation strategy from drug discovery profiling
to human proof of concept. Drug Deliv, pp. 1-8.
Baert, L. & Remon, J., 1993. Influence of amount of granulation liquid on the
drug release rate from pellets made by extrusion-spheronization. Int J Pharm,
95, pp. 135-141.
Barker, S. A., 2013. Suspensions. In: M. E. Aulton & K. M. G. Taylor, eds.
Aulton's Pharmaceutics, the Design and Manufacture of Medicines. London:  
Churchill Livingstone Elsevier, pp. 427.
Barnes, P. J., 2010. Theophylline. Pharmaceuticals J, 3(3), p. 725–747.
BASF, 2009. Technical Information, Anhydrous Theophylline in Ph. Eur., USP 





            
       
      
           
     
     
            
     
          
 
           
      
           
        
        
      
           
      
          
 
         
    
           
 
    
       
      
       
    
         
        
     
        
         
   
Bashaiwoldu, A. B., Podczeck, F. & Newton, J., 2004. A study on the effect of
drying techniques on the mechanical properties of pellets and compacted
pellets. Euro J Pharm Sci, 21(2-3), pp. 119-129.
Bera, H., Kandukuri, S. G., Nayak, A. K. & Boddupalli, S., 2015. Alginate– 
sterculia gum gel-coated oil-entrapped alginate beads forgastroretentive
risperidone delivery. Carb Polym, 120, pp. 74-84.
Bhardwaj, L., Sharma, P. K. & Malviya, R., 2011. A Short Review on Gastro
Retentive Formulations for Stomach Specific Drug Delivery: Special
Emphasis on Floating In situ Gel Systems. Afri J Basic & Appl Sci, 3(6), pp. 
300-312.
Bhardwaj, V. & Harikumar, N. S. L., 2013. Floating drug delivery systems: a
review. Pharmacophore J, 4(1), pp. 26-38.
Bhattacharjya, S. & Wurster, D. E., 2008. Investigation of the drug release
and surface morphological properties of film coated pellets, and physical,
thermal and mechanical properties of free films as a function of variuos 
curing conditions. AAPS PharmSciTech, 9(2), pp. 449-457.
Biswas, S., Paul, S., Chowdhury, A. & Das, J., 2012. Preparation and
evaluation of gastroretentive floating pellets of metronidazole using Na-
alginate and hydroxyl propyl methyl cellulose polymers. Pak J Bio Sci, 15(6),
pp. 290-295.
Bodmeier, R. & Paeratakul, O., 1994. Mechanical properties of dry and wet
cellulosic and acrylic films prepared from aqueous colloidal polymer 
dispersions used in the coating of solid dosage forms. Pharm Res., 11(6), pp.
882-888.
British-Pharmacopoeia., 2017. Appendix XII-C. In: British Pharmacopoeia
2018. London: British Pharmacopoeia Commition Office, pp. V-A384/5.
British-Pharmacopoeia, 2017. Appendix XII-A. In: British Pharmacopoeia
2018. London: British Pharmacopoeia Commition Office, pp. V-A362.
British-Pharmacopoeia, 2017. Appendix XVII-G. In: British Pharmacopoeia
Caleva, 2015. Caleva Multi Bowl Spheronizer MBS, all variants, installation
and operation manual, Dorset, UK: Caleva. 2018. London: British
Pharmacopoeia Commition Office, pp. V-A539.
Caleva, 2017. Determination of moisture requirement to prepare spheroids 






     
          
           
  
     
       
  
     
     
   
    
     
     
          
     
        
          
      
           
       
  
             
      
       
   
           
       
https://www.caleva.com/Uploads/ApplicationNotes/00/00/00/19/ApplicationNo $
teFile_FILE/Determine-moisture-content-requirement-to-prepare-spheroids-
by-extrusion-spheronization.pdf [Accessed 27 09 2018].
Caleva, 2017. Inconsistent extrusion and spheronisation with a difficult active




when-using-a-difficult-active-ingredient.pdf [Accessed 27 09 2018].




Specification.pdf [Accessed 27 09 2018].
CapsuleConnection, 2018. Capsule Sizes. [Online] 
Available at: https://capsuleconnection.com/capsule-sizing-info/
Chemical-Book, 2017. Polyvinylpyrrolidone and Polyvinylpyrrolidone cross- 
linked. [Online] Available at:
http://www.chemicalbook.com/ChemicalProductProperty_EN_CB4209342.ht $
m [Accessed 05 12 2017].
Chandel, A. et al., 2012. Review Article: Floating drug delivery systems: A  
better approach. Inter Cur Pharm J, 1(5), pp. 110-118.
Chaurasia, G., 2016. A review on pharmaceutical preformulation studies in
formulation and development of new drug molecules. International journal of
pharmaceutical sciences and research (ijpsr), 7(6), pp. 2313-2320.
Chawla, G., Gupta, P., Koradia, V. & Bansal, A. K., 2003. Gastroretention:
Means to Address Regional Variability in Intestinal Drug Absorption. J
Pharmac Tech, pp. 50-68.
Chen, YC. Lee, LW. Ho, HO., Sha, C., Sheu MT., 2012. Evaluation of water  
uptake and mechanical properties of blended polymer films for preparing
gas-generated multiple-unit floating drug delivery systems. J of Pharm Sci,
101(10), pp. 3811-3822.
Chhetri, H. P. & Thapa, P., 2014. An overview on gastroretentive drug





          
      
      
              
       
 
           
        
            
            
     
            
     
        
      
  
             
     
        
    
     
         
        
       
  
 
    
      
     
        
      
    
        
         
Chiu, M. & Prenner, E., 2011. Differential scanning calorimetry: An invaluable
tool for a detailed thermodynamic characterization of macromolecules and
their interactions. J Pharm Bioallied Sci., 3(1), pp. 39-59.
Cole, G., Hogan, J. & Aulton, M., 2002. The Coating Process. In: G. Cole, ed.
Pharmaceutical Coating Technology. London: Taylor and Francis, pp. 198-
201.
Cole, G., Hogan, J. & Aulton, M., 2002. Introduction. In: G. Cole, ed.
Pharmaceutical Coating Technology. London: Taylor and Francis, pp. 4-5.
Chopra, R., Podczeck, F., Newton, J. & Alderborn, G., 2002. The influence of
pellet shape and film coating on the filling of pellets into hard shell capsules.
Eur J Pharm Biopharm. , 53(3), pp. 327-333.
Costa, P. & Lobo, J. M. S., 2001. Review; modeling and comparison of
dissolution profiles. Euro J Pharm Sci, 13 , pp. 123–133.
Chu, M. & Chaw, C., 2014. Ketoprofen loaded pellets produced by  
extrusion/spheronization using Avicel CL611 as an alternative spheronization  
aid. Sunderland.
Das, N. G. & Das, S. K., 2003. Controlled Release of Oral Dosage Forms.
Formul, Fill & Finish J, pp. 10-16.
Davis, S. S., 2005. Formulation Strategies for Absorption Windows. Drug
Disc Today Rev J, 10(4), pp. 249-257.
DFE-Pharma, 2011. Introduction to tableting by wet granulation.
Donnelly, S. & Evans, J., 1991. Fundamental Aspects of Inert Gases in
Solids. 1st ed. New York: Plenum Press. pp 153.




[Accessed 02 12 2017].
DrugBank, 2015. Theophylline. [Online] Available at:
http://www.drugbank.ca/drugs/DB00277 [Accessed 13 04 2015].
Ebnesajjad, S., 2011. Surface Tension and Its Measurement. In: Handbook  
of Adhesives and Surface Preparation, Technology, Applications and
Manufacturing. William Andrew, pp. 21-30.
Dwibhashyam, V. M. & Ratna, J. V., 2008. Key formulation variables in  





        
          
       
      
         
        
       
          
        
       
          
         
     
          
        
       
 
           
        
      
           
      
      
         
   
   
       
   
    
       
       
       
      
        
Eriksson, L., 2012. Introduction. In: User Guide to MODDE 10.1.:MKS Umetric.
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wikstrom, C., Wold, S.,
2008. D-optimal designs. In: Design of Experiments, Principles and
Apllications. Umea, Sweden: Umetrics Academy, pp. 217-230.
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wikstrom, C., Wold, S.,
2008. Appendix 2: Statistical Notes. In: Design of Experiments, Principles  
and Apllications. Umea, Sweden: Umetrics Academy, pp. 417-435.
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wikstrom, C., Wold, S.,
2008. DoE in formulation development. In: Design of Experiments, Principles  
and Apllications. Umea, Sweden: Umetrics Academy, pp. 371-372.
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wikstrom, C., Wold, S.,
2008. DoE in PAT. In: Design of Experiments, Principles and Apllications.
Umea, Sweden: Umetrics Academy, pp. 387-398.
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wikstrom, C., Wold, S.,
2008. Experimental objective: Screening. In: Design of Experiments,
Principles and Apllications. Umea, Sweden : Umetrics Academy, pp. 107-
108.
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wikstrom, C., Wold, S.,
2008. Factorial designs. In: Design of Experiments, Principles and
Apllications. Umea, Sweden: Umetrics Academy, pp. 53-74.
Eriksson, L. et al., 2008. Preface. In: Design of Experiments, Principles and
Apllications. Umea, Sweden: Umetrics Academy, pp. 1-6.
Evonik, 2016. EUDRAGIT Application Guidelines. 12 ed.
Evonik, 2017. Eudragit® Setting benchmarks in oral solid dosage forms since
1954. [Online] Available at:
http://healthcare.evonik.com/sites/lists/NC/DocumentsHC/Evonik-
Eudragit_brochure.pdf [Accessed 2017].
Fahier., J., 2017. Polymeric controlled release film coatings. [Online] 
Available at: https://tel.archives-ouvertes.fr/tel-01505652/document
[Accessed 05 04 2019].
Felton, L. A., 2013. Review: Mechanisms of polymeric film formation.
International Journal of Pharmaceutics, 457(2), pp. 423-427.
FDA-CDER, 2015. Size, Shape, and Other Physical Attributes of Generic  
Tablets and Capsules, Guidance for Industry. CDER; Center for Drug





        
     
 
    
           
        
  
          
      
            
        
      
   
             
            
          
 
           
        
         
          
        
       
       
         
       
            
       
  
         
       
    
        
        
Health and Human Services, Food and Drug Administration/FDA,
Pharmaceutical Quality/CMC. [Online] Available at:
https://www.fda.gov/downloads/drugs/guidances/ucm377938.pdf
[Accessed 27 01 2017].
Field, A., Miles, J. & Field, Z., 2012. Comparing two means, Assumptions of
the t-test. In: Discovering Statistics Using R. 1st ed. London: SAGE  
Publications Ltd, pp. 372.
Fell, J. & Newton, J., 1970. Determination of tablet strength by the diametral-
compression test. J Pharm Sci, 59(5), pp. 688-691.
Foster, K., Sun, H., Fancher. RM., Proszynski, M., Dixon, G., Ford, K.,
Cornelius, G., Gudmundsson, OS., Hageman, MJ., 2013. Utility of gastric- 
retained alginate gels to modulate pharmacokinetic profiles in rats. J Pharm  
Sci, 102(8), pp. 2440-2449.
Freire, A. C. & Basit, A. W., 2013. Dissolution testing of solid dosage forms.
M. E. Aulton & K. M. G. Taylor, eds. Aulton's Pharmaceutics, The Design and
Manufacture of Medicines. 4th Ed. London: Churchill Livingstone Elsevier, pp.
611-622.
Gaisford, S., 2013. Pharmaceutical Preformulation. In: M. E. Aulton & K. M.
Taylor, eds. Aulton’s Pharmaceutics: The Design and Manufacture of
Medicines. 4th ed. London: Churchill Livingstone Elsevier, pp. 367.
Garekani, H., Nokhodchi, A., Rayeni, M. & Sadeghi, F., 2013. Preparation
and characterization and release properties of Eudragit RS based ibuprofen
pellets prepared by extrusion spheronization: effect of binder type and
concentration. Drug Dev & Ind Pharmacy, 39(8), pp. 1238-1246.
Garg, R. & Gupta, G., 2008. Review Article: Progress in Controlled
Gastroretentive Delivery Systems. Trop J Pharm Res, 7(3), pp. 1055-1066.
George, M. L., Rowlands, D., Price, M. & Maxey, J., 2005. Identifying and
Verifying Causes. In: The Lean Six Sigma Pocket (6Q) Toolbook. 1st ed.
London: McGraw-Hill, pp. 141-196.
Ghebre-Sellassie, I., 1989. Extrusion and Sheronizing Equipment. In: I.
Ghebre-Sellassie, ed. Pharmaceutical Pelletization Technology. New York:
Marcel Dekker, pp. 71-100.
Ghebre-Sellassie, I., 1989. Pellets: A General Overview. In: Pharmaceutical





          
        
           
       
         
         
     
           
      
      
          
     
            
       
      
     
         
       
    
            
           
  
            
        
             
       
   
         
     
    
         
      
              
      
Hand, D. J., 2008. Collecting Good Data. In: Statistics, A very Short
Introduction. 1st ed. Oxford: Oxford University Press, pp. 36-54.
Goyal, A. N. K. & Sharma, P. K., 2014. Effervescent Floating Drug Delivery  
System: A Review. Glob J Pharmacology, 8(4), pp. 478-485.
Guguloth, M., Bomma, R. & Veerabrahma, K., 2011. Development of
sustained release floating drug delivery system for norfloxacin: in vitro and in
vivo evaluation. PDA J Pharm Sci Technol., pp. 198-206.
Gupta, N. V., Gowda, D., Balamuralidhara, V. & Khan, S. M., 2011.
Formulation and evaluation of olanzapine matrix pellets for controlled
release. J Daru. , 19(4), pp. 249–256.
Gupta, P. & Kothiyal, G. P., 2015. Floating Drug Delivery System: A Review.
Inter J Pharma Res & Rev, 4(8), pp. 37-44.
Habib, Y. S., Shangraw, R. & Augsburger, L. L., 2002. Production of inert
cushioning beads: Effect of excipients on the physicomechanical properties  
of freeze-dried beads containing microcrystalline cellulose produced by  
extrusion-spheronization. Int J Pharm., 233(1-2), pp. 67-83.
Hamman, H., Hamman, J. & Steenekamp, J., 2017. Review Article: Multiple- 
Unit Pellet Systems (MUPS): Production and Applications as Advanced Drug
Delivery Systems. 7(3), pp. 201-210.
Hamman, J. H., Demana, P. H. & Olivier, E. I., 2007. Targeting receptors,
transporters and site of absorption to improve oral drug delivery. J Drug Targ
Ins, 2, pp. 71-81.
Hardenia, S. S., Jain, A., Patel, R. & kaushal, A., 2011. Floating Drug
Delivery Systems: A Review. Asian J Pharmacy & Life Sci, 1(3), pp. 284-293.
He, Y., Li, Y., Yang, D. & Zhu, C., 2017. Preparation and evaluation of gastric  
adhesive-floating pellets for Bolo leaf phenols. Zhongguo Zhong Yao Za Zhi,
42(1), pp. 107-112.
Heinicke, G. & Schwartz, J., 2004. Particle size distributions of inert spheres  
and pelletized pharmaceutical products by image analysis. Pharm Dev  
Technol., 9(4), pp. 359-367.
Hendeles, L. & Weinberger, M., 1983. Theophylline. A "state of the art"  
review. J Pharmacotherapy, 3(1), pp. 2-44.
Holman, J., 2013. Assessing the use of twin screw wet granulation in a multi





      
    
           
      
        
          
      
       
  
      
    
      
 
            
     
   
         
      
      
     
    
     
    
      
     
          
            
      
      
 
    
products. [Online] Available at: https://core.ac.uk/download/pdf/30341523.pdf
[Accessed 05 04 2019].
Hossain, A., Nandi, U., Fule, R., Nokhodchi, A., Maniruzzaman, M., 2017.
Advanced surface chemical analysis of continuously manufactured drug
loaded composite pellets. J Colloid and Interface Sci, 492, pp. 157–166.
Hosseini, A., Körber, M. & Bodmeier, R., 2013. Direct compression of
cushion-layered ethyl cellulose-coated extended release pellets into rapidly 
disintegrating tablets without changes in the release profile. Inter J Pharm,
457, pp. 503-509.
Hung, S.-F.et al., 2014. Characterizations of plasticized polymeric film 
coatings for preparing multiple-unit floating drug delivery systems 
(muFDDSs) with controlled-release characteristics. PLOS ONE, 9(6), pp. 1-
10.
Hwang, K., Byun, W., Cho, C. & Park, E., 2016 . Preparation and
optimization of glyceryl behenate-based highly porous pellets containing
cilostazol. Pharm Dev Technol., 3, pp. 1-12.
Iannuccelli, V., Coppi, G., Bernabei, M. & Cameroni, R., 1998. Air  
compartment multiple-unit system for prolonged gastric residence. Part I.
Formulation study. Inter J Pharm, 174(1-2), pp. 47–54.
ICH, 2005. Quality Risk Management (Q9). [Online] Available at:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quali $
ty/Q9/Step4/Q9_Guideline.pdf [Accessed 6 2017].
ICH, 2008. Pharmaceutical Quality Systems (Q10). [Online] Available at:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quali $
ty/Q10/Step4/Q10_Guideline.pdf [Accessed 6 2017].
ICH, 2009. Pharmaceutical Development Q8(R2). [Online] Available at:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quali $
ty/Q8_R1/Step4/Q8_R2_Guideline.pdf [Accessed 5 12 2015].
Ichikawa, M., Watanabe, S. & Miyake, Y., 1991. A new multiple-unit oral
floating dosage system. I: Preparation and in vitro evaluation of floating and
sustained-release characteristics. J Pharm Sci, 80(11), pp. 1062-1066.
IMA, 2019. IMA. [Online] Available at: https://ima.it/pharma/prexima-300-
determination-of-the-effect-of-the-pre-compression-force-on-the-tablet-
hardness-obtained-at-constant-value-of-the-main-compression-force/





      
         
    
           
        
         
    
          
       
       
    
           
      
     
     
         
         
           
       
      
   
          
    
       
    
            
        
   
           
       
              
          
    
Ishak, R. A. H., 2015. Buoyancy-Generating Agents for Stomach-Specific  
Drug Delivery: An Overview with Special Emphasis on Floating Behavior. J  
Pharm Pharm Sci, 18(1), pp. 77-100.
Jain, S. P., Singh, P. P. & Amin, P. D., 2010. Alternative extrusion– $
spheronization aids. Drug Dev & Ind Pharmacy, 35(11), pp. 1364-1376.
Kadajji, V. G. & Betageri, G. V., 2011. A Review: Water Soluble Polymers for  
Pharmaceutical Applications. J Polym, 3, pp. 1972-2009.
Kallakunta, V., Sarabu, S. & Tiwari, R., 2017. Multiple Unit Particle Systems  
(MUPS), a Versatile Strategy for Controlled Drug Delivery: Focus on
Formulation and Process Concerns. Journal of Formulation Science &  
Bioavailability, 1(1), pp. 1-3.
Kadono, K., Yokoe, JI., Ogawara, KI., Higaki, K., Kimura, T., 2002. Analysis  
and prediction of absorption behavior for theophylline orally administered as  
powders based on gastrointestinal-transit-absorption (Gita) model. J Drug
Metab & Pharmacokinetics, 17(4), pp. 307-315.
Kandwal, M., Gnanarajan, G. & Kothiyal, P., 2014. Floating drug delivery  
system: A novel approach. J the Pharma Innov, 3(3), pp. 57-69.
Katakam, V., Reddy, S., Panakanti, P. & Yamsani, M., 2013. Design and
evaluation of a novel gas formation-based multiple-unit gastro-retentive
floating drug delivery system for quetiapine fumarate. Tropical J Pharm Res,
13(2), pp. 33-46.
Kavanagh, N. & Corrigan, O. I., 2004. Swelling and erosion properties of
hydroxypropylmethylcellulose (hypromellose) matrices—influence of agitation
rate and dissolution medium composition. International Journal of
Pharmaceutics, 1-2(279), pp. 141-152.
Kharia AA., Hiremath SN., Singhai AK., Omray, Jain LK., 2010. Design and
optimization of floating drug delivery system of acyclovir. Indian J Pharm Sci.,
75(11), pp. 599–606.
Klausner, E. A., Lavy, E., Friedman, M. & Hoffman, A., 2003. Review:
Expandable gastroretentive dosage forms. J Cont Rel, 90, pp. 143-162.
Kaur, B., Sharma, S., Sharma, G., Saini, R., Singh, S., Nagpal, M., Jain, UK.,
Sharma, M., 2013. A review of floating drug delivery system. Asian J Biomed





          
        
 
         
   
            
       
             
        
      
           
       
         
       
        
          
            
       
    
            
       
    
           
       
       
             
      
 
      
     
      
     
     
Koda-Kimble, M. A. et al., 2007. Theophylline. In: Handbook of Applied
Therapeutics. 8th ed. s.l.:Lippincott Williams & Wilkins, Sections: 22.5, 23.13,
92.13, and 92.8.
Koester, M. & Thommes, M., 2010. New insights into the pelletization
mechanism by extrusion/spheronization. AAPS PharmSciTech, 11(4).
Kong, Y. & Hay, J., 2003. The enthalpy of fusion and degree of crystallinity of
polymers as measured by DSC. Euro Polym J, 39(8), pp. 1721-1727.
Korakianiti, E. S., Rekkas, D. M., Dallas, P. P. & Choulis, N. H., 2000.
Optimization of the pelletization process in a fluid-bed rotor granulator using
experimental design. AAPS Pharm Sci Tech, 1(4), pp. 71-75.
Kozloski, GD., De Vito, JM., Johnson, JB., Holmes, GB., Adams, MA., Hunt,  
TL., 1992. Bioequivalence of verapamil hydrochloride extended-release
pellet-filled capsules when opened and sprinkled on food and when
swallowed intact. Clin Pharm., 11(6), pp. 539-542.
Krögel, I. & Bodmeier, R., 1999. Floating or pulsatile drug delivery systems  
based on coated effervescent cores. Int J Pharm., 187(2), pp. 175-184.
Kumaran, K. S., Manjunath, S. Y. & Wamorkar, V. V., 2010. Development of
a floating multiple unit controlled-release system for mosapride. Asian J  
Pharmaceutics, 4(2), pp. 163-167.
Kumaran, K. S., Manjunath, S. Y. & Wamorkar, V. V., 2010. Development of
a floating multiple unit controlled-release system for mosapride. Asian J  
Pharmaceutics, 4(2), pp. 163-167.
Kumar, A., Tiwari, B. K. & Kant, R., 2017. A Study on Formulation of
Multiparticulate GastroRetentive Drug Delivery System of Curcumin. Int. J.
Life. Sci. Scienti. Res., 3(2), pp. 909-913.
Kumari, M. H., Samatha, K., Balaji, A. & Shankar, M. U., 2013. Recent novel
advancements in pellet formulation: A review. Inter J Pharm Sci & Res, 4(10),
pp. 3803-3822.
LFA, 2017. LFA Tablet Presses. [Online] Available
at:https://www.lfatabletpresses.com/ [Accessed 21 11 2017].
Lightfoot, D., 2000. Capsule Filling, answers to 10 common questions about
capsule filling. [Online] Available at:
http://www.capsugel.com/media/library/answers-to-10-common-questions-





            
       
      
            
           
       
      
       
 
      
  
       
   
           
      
    
            
   
           
       
  
           
         
  
             
       
    
        
      
       
     
          
       
      
Lingam, M., Ashok, T., Venkateswarlu, V. & Raw, Y. M., 2008. Design and
evaluation of novel matrix type multiple units as biphasic gastroretentive drug
delivery systems. AAPS Pharm Sci Tech, 9(4), pp. 1253-1261.
Li, Zhao; Xu, Heming; Li, Shujuan; Li, Qijun; Zhang, Wenji; Ye, Tiantian;
Yang, Xinggang; Pan, Weisan Lin, A., Muhammad, N. & Pope, D., 2001.
Study of crystallization of endogenous surfactant in Eudragit NE30D-free
films and its influence on drug-release properties of controlled-release
diphenhydramine HCl pellets coated with Eudragit NE30D. AAPS Pharmsci,
3(2).
Loftsson, T., 2015. Basic concepts of pharmacokinetics. In: Essential
Pharmacokinetics. London, pp. 30-76.
Loftsson, T., 2015. Physicochemical properties and pharmacokinetics. In:
Essential Pharmacokinetics. London, pp. 85-93.
Lopes, CM., Bettencourt, C., Rossi, A., Francesca, B., Barata, P., 2016.
Review: Overview on gastroretentive drug delivery systems for improving
drug bioavailability. Inter J Pharm, 510, pp. 144–158.
Low, C. & Chaw, C., 2012. Ibuprofen loaded Avicel CL611 pellets: effect of
liquid binder. Sunderland.
Malode, V. N., Paradkar, A. & Devarajan, P. V., 2015. Controlled release
floating multiparticulates of metoprolol succinate by hot melt extrusion. Inter J  
Pharm, 491, pp. 345-351.
Mandal, U. K., Chatterjee, B. & Senjoti, F. G., 2016. Review: Gastro-retentive
drug delivery systems and their in vivo success: A recent update. Asian j
pharm sci, 11, pp. 575–584.
Mathur, P., Saroha, K., Syan, N., Verma, S., Nanda, S., 2011. An overview
on recent advancements and developments in gastroretentive buoyant drug
delivery system. Der Pharmacia Sinica, 2(1), pp. 161-169.
Mayur, C., Senthilkumaran & Hemant, G., 2012. Review article: Super  
porous hydrogels: A recent advancement in gastroretentive drug delivery  
system. Indonesian J. Pharm., 24(1), pp. 1-13.
Mazurek-Wadołkowska, E., Winnicka, K., Czajkowska-Kośnik,
A., Czyzewska, U., Miltyk, W., 2013. Application of differential scanning
calorimetry in evaluation of solid state interactions in tablets containing





           
            
          
 
         
       
           
          
        
  
      
    
    
      
    
        
  
     
        
     
           
         
    
         
        
 
           
    
       
             
         
    
           
         
McConnell, E. L. & Basit, A. W., 2013. Modified-Release Oral Drug Delivery.
In: M. E. Aulton & K. M. G. Taylor, eds. Aulton's Pharmaceutics, the Design
and Manufacture of Medicine. 4th ed. London: Churchill Livingstone Elsevier,
pp. 550-565.
Meenakshi, B., Santosh, K. & Annapurna, O., 2014. Floating drug delivery  
system: A review. J Drug Delev & Therap, 4(2), pp. 130-134.
Mehta, K. A., Rekhi, G. S. & Parikh, D. M., 2005. Extrusion/Spheronization as  
a Granulation Technique. In: D. M. Parikh, ed. Handbook of Pharmaceutical
Granulation Technology. 2nd ed. Research Triangle Park: Taylor and
Francis, pp. 330, 340, and 348.
Mettler-Toledo, 2017. UserCom: Interpreting DSC curves, Part 1: Dynamic  
Measurements. [Online] Available at:
http://www.masontechnology.ie/x/Usercom_11.pdf [Accessed 19 12 2017].
MedLinePlus, 2017. Theophylline. [Online] Available at:
https://medlineplus.gov/druginfo/meds/a681006.html [Accessed 6 2017].
Minitab, 2017. Factorial and fractional factorial designs. [Online] 
Available at: https://support.minitab.com/en-us/minitab/18/help-and-how-
to/modeling-statistics/doe/supporting-topics/factorial-and-screening-
designs/factorial-and-fractional-factorial-designs/ [Accessed 22 11 2017].
Montgomery, D., 2013. Introduction. In: Design and Analysis. 8th ed. London:  
John Wiley & Sons, Inc, pp. 21-22.
Mukesh, K., Shubhendra, J., Kumar, SS., Kumar, MA., Bhagat, S., 2012.
Review article: floating drug delivery system: An innovative approach. J Drug
Deliv & Therap, 2(6), pp. 117-123.
Muley, S., Nandgude, T. & Poddar, S., 2016. Extrusion–spheronization, a
promising pelletization technique: In-depth review. Asian j pharm sci, 11, pp.  
684–699.
Mura, P., Maestrelli, F., Cirri, M., Rodríguez, MLG., Alvarez, AMR., 2003.
Development of enteric-coated pectin-based matrix tablets for colonic  
delivery of theophylline. J Drug Targ, 11(6), pp. 365-371.
Murdan, S., 2013. Solutions. In: M. E. Aulton & K. M. G. Taylor, eds. Aulton's  
Pharmaceutics, the Design and Manufacture of Medicines. London: Churchill
Livingstone Elsevier, pp. 24.
Murphy, C., Pillay, V., Choonara, YE., Toit, Lisa CD., Ndesendo, VMK.;





     
       
          
       
           
        
    
         
       
          
          
      
            
        
       
     
         
          
          
 
           
      
      
         
      
    
         
      
     
           
       
     
           
       
 
Gastrofloatable and Gastroadhesive Delivery System for Narrow Absorption
Window Drugs. AAPS Pharm Sci Tech, 13(1), pp. 1-14.
Mustafa, O. & Chaw, C. S., 2016. Silicified microcrystalline cellulose based
pellets and their physicochemical properties. J of Appl Polym Sci, pp. 1-9.
Nadigoti, J., Dharani, S., Shayeda & Yamsani, M. R., 2011. Formulation and
evaluation of floating microparticles of metoprolol succinate. Asian J of
Pharm. & Clin. Res., 4.
Narang, N., 2011. An updated review on: Floating drug delivery system 
(FDDS). Int J App Pharm, 3(1), pp. 1-7.
Nokhodchi, A., Aliakbar, R., Desai, S. & Javadzadeh, Y., 2010. Liquisolid
compacts: the effect of cosolvent and HPMC on theophylline release.
Colloids and Surfaces B: Biointerfaces, 79(1), pp. 262-269.
Nordström, J., Lazorova, A. P. L., Frenning, G. & Alderborn, G., 2013. The
degree of compression of spherical granular solids controls the evolution of
microstructure and bond probability during compaction. International Journal
of Pharmaceutics, 442(1-2), pp. 3-12.
Omidian, H. & Park, K., 2010. Oral Targeted Drug Delivery Systems, Gastric 
Retention Devices. In: Oral Controlled Release Formulation Design and Drug
Delivery, Theory to Practice. 2 ed. New Jersey, Canada: John Wiley & Sons,
pp. 187.
Padfield, J. M., 1989. Assessment of gastrointestinal transit and drug
absorption. In: Novel Drug Delivery and its Therapeutic Applications.
Chichester, England: John Wiley & Sons Ltd, pp. 89-101.
Padfield, J. M., 1989. Therapeutic status of controlled oral drug delivery. In: 
Novel Drug Delivery and its Therapeutic Applications. Chichester, England:
John Wiley & Sons Ltd, pp. 177-183.
Pagariya, T. & Patil, S., 2013. Development and optimization of
multiparticulate drug delivery system of alfuzosin hydrochloride. J Colloids 
Surf B Biointerfaces, 102(1), pp. 171-177.
Pandey, A., Kumar, G., Kothiyal, P. & Barshiliya, Y., 2012. A Review on
current approaches in gastro retentive drug delivery system. Asian J 
Pharmacy and Medic Sci, 2(4), pp. 60-77.
Pant, S., badola, A. & kothiyal, P., 2016. A review on gastroretentive drug






              
       
          
       
            
        
         
           
     
  
   
       
      
    
            
      
   
          
       
    
         
  
            
         
        
 
            
       
    
          
      
         
 
Patil, J. M., Hirlekar, R. S., Gide, P. S. & Kadam, V. J., 2006. Trends in
floating drug delivery systems. J Sci & Ind Res, 65, pp. 11-21.
Patil, K. K. & Saptarshi, D., 2013. A Review on Floating Drug Delivery  
System. Int J Pharm Sci Rev Res, 21(1), pp. 276-283.
Pawar, VK., Kansal, S., Garg, G., Awasthi, R., Singodia, D., Kulkarni, GT.,
2011. Gastroretentive dosage forms: A review with special emphasis on
floating drug delivery systems. J Drug Deliv, 18(2), pp. 97-110.
Politis, S. N. & Rekkas, D. M., 2011. Recent patents on drug delivery &  
formulation. Pelletization processes for pharmaceutical applications: A patent
review, 5, pp. 61-78.
Pejchal, V., Žagar, G., Charvet, R., Dénéréaz, C., Mortensen, A., 2017.  
Compression testing spherical particles for strength: Theory of the meridian
crack test and implementation for microscopic fused quartz. J Mechanics and
Physics of Solids, 99, pp. 70-92.
Pooja, S., Shiv, G. & Monika, M., 2015. Recent advancement in floating drug
delivery system and current approaches. World J Pharmacy and Pharm Sci,
4(3), pp. 317-341.
Popova, T., Dimitrov, M. & Lambov, N., 2016. Short Paper: Ethanol as  
potential tool for extending the release rate of theophtlline from  
ethylcellulose-containing pellets, prepared by extrusion/spheronisation.
Glasgow, The 10th World Meeting on Pharmaceutics, Biopharmaceutics, and
Pharmaceutical Technology.
Porter, S. C., 2013. Coating of tablets and multiparticulates. In: M. E. Aulton
& K. M. G. Taylor, eds. Aulton's Pharmaceutics, The Design and
Manufacture of Medicines. London: Churchill Livingstone Elsevier, pp. 578-
581.
Prajapati, V. D., Jani, G. K., Khutliwala, T. A. & Zala, B. S., 2013. Raft  
forming system—An upcoming approach of gastroretentive drug delivery  
system. J Cont Rel, 168, pp. 151–165.
Prasad, MB., Vidyadhara, S., Sasidhar, RLC., Balakrishna, T., Trilochani, P.,
2013. Development and evaluation of diltiazem hydrochloride controlled- 






          
        
      
             
        
  
     
  
    
 
              
       
       
           
        
         
 
           
           
 
           
        
          
       
          
 
          
      
               
         
   
          
      
      
Prescott, L. F. & Nimmo, W. S., 1979. Important Formulation Factors  
Influencing Drug Absorption. In: Drug Absorption, Proceedings of Edinburgh
Inernational Conference. Edinbbugh : MTP Press Ltd, pp. 133-143.
Puah, S. Y., Yap, H. N. & Chaw, C. S., 2013. Production and characterization
of pellets using Avicel CL611 as spheronization aid. J Drug Dev & Ind
Pharmacy, pp. 1-7.
PubChem, 2019. Theophylline, PubChem, Open Chemistry Database.
.[Online] Available at:
https://pubchem.ncbi.nlm.nih.gov/compound/theophylline [Accessed 08 04
2019].
Pugh, W. J., 2013. Kinetics. In: M. E. Aulton & K. M. G. Taylor, eds. Aulton's  
Pharmaceutics, The Design and Manufacture of Medicines. 4th ed. London:  
Churchill Livingstone Elsevier, pp. 119 and 115-125.
Qi, X., Jiang, Y., Zhang, H. & Wu, Z., 2015. Tablets compressed with gastric  
floating pellets coated with acrylic resin for gastro retention and sustained
release of famotidine; in-vitro and in-vivo study. J of Pharm & Pharm, 67, pp.  
493-500.
Reddy, S., Das, P., Das, H. & Ghosh, A., 2011. MUPS (multiple unit pellets  
systems) tablets- a brief review. J. pharm. and Biomed. Sci. (JPBMS), 12(2),
pp. 1-5.
Rewar, S. & Shakya, V., 2015. Article review: a novel approach for floating
drug delivery system. J Glob Trends in Pharm Sci, 6(1), pp. 2417-2422.
Rizvia, S. A. & Saleh, A. M., 2018. Applications of nanoparticle systems in
drug delivery technology. Saudi Pharm J., 26(1), pp. 64-70.
Rowe, R., 1985. Spheronization: a novel pill-making process?. Int J Pharm,
6, pp. 119-123.
Rowe, R., Sheskey, P. & Quinn, M., 2009. Crospovidone. In: Handbook of
Pharmaceutical Excipients. 6th ed London: Pharmaceutical Press, pp. 208.
Sakr, W. F., Ibrahim, M. A., Alanazi, F. K. & Sakr, A. A., 2012. Upgrading wet
granulation monitoring from hand squeeze test to mixing torque rheometry.
Saudi Pharm J, 20, pp. 9-19.
Sarawade, A., Ratnaparkhi, M. P. & Chaudhari, S., 2014. Review article:
Floating drug delivery system: An overview. Inter J Res & Dev in Pharmacy  





             
        
 
          
     
         
          
  
        
       
      
        
      
   
            
        
    
          
     
    
          
           
     
 
         
       
      
     
     
     
          
          
   
Sarkar, S., Wong, T. W. & Liew, C. V., 2013. Importance of wet packability of
component particles in pellet formation. AAPS Pharm Sci Tech, 14(3), pp.
1267-1277.
Sauer, D., Cerea, M., DiNunzio, J. & McGinity, J., 2013. Dry powder coating
of pharmaceuticals: A review. Inter J Pharm, 457, pp. 488-502.
Sawicki, W. & Łunio, R., 2005. Note: Compressibility of floating pellets with
verapamil hydrochloride coated with dispersion Kollicoat SR 30 D. Euro J  
Pharm & Biopharm, 60, pp. 153–158.
Schlindwein, W. S. & Gibson, M., 2018. Pharmaceutical Quality by Design, A  
Practical Approach. A Preface. 1st ed. Chichester: Wiley and Sons Ltd.
Setthacheewakul, S., Kedjinda, W., Maneenuan, D. & Wiwattanapatapee, R.,  
2011. Controlled release of oral tetrahydrocurcumin from a novel self- 
emulsifying floating drug delivery system (SEFDDS). AAPS Pharm Sci Tech,
12(1), pp. 152-164. 
Shaha, S. H., Patel, J. K., Pundarikakshudu, K. & Patel, N. V., 2009. An  
overview of a gastro-retentive floating drug delivery system. Asian J Pharm  
Sci, 4(1), pp. 65-80.
Shargel, L., Wu-Pong, S. & Yu, A. B., 2012. Modified-Release Drug
Products. In: Applied Biopharmaceutics and Pharmacokinetics. 6th ed.  
London: McGraw Hill, pp. 469-501.
Shargel, L., Wu-Pong, S. & Yu, A. B., 2012. Application of Pharmacokinetics  
to Clinical Situations, Effect of Food in Drug Disposition. In: Applied
Biopharmaceutics and Pharmacokinetics. 6th ed. London: McGraw Hill, pp.  
597.
Shipway, P. & Hutchings, I., 1993. Attrition of brittle spheres by fracture
under compression and impact loading. J Powder Tech, 76, pp. 23-30.
Sigma-Aldrich, 2018. (Hydroxypropyl) methyl cellulose. [Online] Available at:
https://www.sigmaaldrich.com/catalog/product/sigma/h9262?lang=en&region $
=GB [Accessed 05 06 2018].
Sigma-Aldrich, 2018. Sodium bicarbonate. [Online] Available at:
https://www.sigmaaldrich.com/catalog/substance/sodiumbicarbonate8401144 $
55811?lang=en&region=GB [Accessed 05 06 2018].
Singh, B. & Kim, K., 2000. Review: floating drug delivery systems: an






           
    
   
        
        
 
       
          
       
  
     
         
   
           
       
     
          
     
    
             
       
          
 
          
       
     
          
       
   
          
      
       
            
Sinko, P. J., 2017. Drug delivery systems and drug product design. In: 7th,
ed. Martin's Physical Pharmacy and Pharmaceutical Sciences. Wolters  
Kluwer, pp. 646-647.
Siraj, S., Khurshid, M. & Nazim, S., 2013. Various perspectives of
gastroretentive drug delivery system: A review. Ameri J Adv Drug Deliv, 1(4),
pp. 443-451.
Slavkova, M., Petrovick, G., Breitkreutz, J. & Dimitrov, M., 2016. Systemic  
investigation of the shape evaluation results of solid lipid pellets with diverse
composition employing two different characterization methods.. [Online] 
Available at: https://blog.caleva.com/systematic-investigation-of-the-shape-
evaluation-results-of-solid-lipid-pellets-with-diverse-composition-employing-
two-different-characterization-methods [Accessed 05 04 2019].
Smith, I. et al., 2016. Aston Particle Technologies. [Online] Available at:  
http://www.astonparticletechnologies.com/ [Accessed 2017].
Solanki, D., Patidar, S., Motiwale, M. & Kushwah, L., 2017. Floating Drug
Delivery System – Novel Tool for Delivering H2 Antagonist. Int J Pharmacy  
and Pharm Res, 8(2), pp. 118-133.
Srivastava, S. & Mishra, G., 2010. Review article: fluid bed technology:
overview and parameters for process selection. Inter J Pharm Sci & Drug
Res, 2(4), pp. 236-246.
Staib, AH., Loew, D., Harder, S., Graul, EH., Pfab, R., 1986. Measurement of
theophylline absorption from different regions of the gastro-intestinal tract
using a remote controlled drug delivery device. Eur J Clin Pharmacol. , 30(6),
pp. 691-697.
Streubel, A., Siepmann, J. & Bodmeier, R., 2003. Multiple unit gastroretentive
drug delivery systems: a new preparation method for low density  
microparticles. J Microencapsul., 20(3), pp. 329-347.
Streubel, A., Siepmann, J. & Bodmeier, R., 2006. Drug delivery to the upper  
small intestine window using gastroretentive technologies. Cur Opin
Pharmacol J, 6, pp. 501-608.
Strübing, S., Metz, H. & Mäder, K., 2008. Characterization of poly(vinyl
acetate) based floating matrix tablets. J Cont Rel, 126, pp. 149-155.
Sungthongjeen, S., Paeratakul, O., Limmatvapirat, S. & Puttipipatkhachorn,





         
 
        
        
   
     
 
          
    
     
        
       
         
      
             
       
        
         
           
   
            
        
 
           
     
  
          
        
           
    
           
       
 
delivery system based on gas formation technique. Int J Pharm. , 324(2), pp.
136-143.
Sungthongjeen, S., Sriamornsak, P. & Puttipipatkhachorn, S., 2008. Design
and evaluation of floating multi-layer coated tablets based on gas formation.
Euro J Pharm & Biopharm, 69, pp. 255-263.
TA-Instruments, 2009. TA Instruments Inc. Indium. [Online] 
Available at: http://www.tainstruments.com/pdf/indium.pdf
[Accessed 16 01 2018]. Wagner, K. G., 2015. BioPharma., Webinar on
MUPS tablets [Online] Available at: https://biopharma-asia.com/
webinars/compression-film-coated-pellets-key-parameters-optimal-tablet-
quality/ [Accessed 11 9 2017].
Talukder, R. & Fassihi, R., 2004. Gastroretentive delivery systems: hollow
beads. Drug Dev Ind Pharm., 30(4), pp. 405-412.
Tan, X. & Hu, J., 2015. Investigation for the quality factors on the tablets  
containing medicated pellets review. Saudi Pharm J, pp. 1-8.
Taylor, K., 2018. Particle size analysis. In M. E. Aulton, & K. M. Taylor 
eds., Aulton's Pharmaceutics, The Design and Manufacture of Medicines.
5th ed. London: Churchill Livingstone Elsevier, pp. 143.
Taylor, L. S. & Shamblin, S. L., 2009. Polymorphism in Pharmaceutical
Solids. In: H. G. Brittain, ed. Amorphous Solids. 2nd ed. London: Informa
Healthcare, pp. 615.
Thakral, S., Thakral, N. K., & Majumdar, D. K. (2013). Eudragit®: a
technology evaluation,. J of Expert Opinion on Drug Delivery , 10(1), pp. 131-
149.
Thomas, S., Chong, Y. N. & Chaw, C. S., 2012. Preparation and
characterization of enteric microparticles by coacervation. Drug Dev & Ind
Pharmacy, pp. 1-10.
Thummel, K. E., 2007. Gut instincts: CYP3A4 and intestinal drug metabolism  
Kenneth E. Thummel. J Clin Invest., 117(11), pp. 3173–3176.
Timmermans, J. & Moes, A. J., 1990. How well do floating dosage forms  
float?. Int. J. Pharm., 62, pp. 207-216.
Tongkai, C., Jian, L., Ting, C., Changquan, CS., Ying, Z., 2017. Tablets of






      
        
     
  
    
            
       
    
        
           
        
     
        
        
            
        
      
             
     
        
   
            
      
      
         
     
          
        
 
         
        
      
Treesinchai, S., Puttipipatkhachorn, S., Pitaksuteepong, T. &  
Sungthongjeen., S., 2016. Development of curcumin floating tablets based





[Accessed 04 05 2019].
Tripathi, J., Thapa, P., Maharjan, R. & Jeong, S. H., 2019. Review: Current
State and Future Perspectives on Gastroretentive Drug Delivery Systems.
Pharmaceutics, 193, pp. 11.
USP25, U. S. P., 2002. Theophylline/ Official Monographs.
Vidyadhara, S., Sasidhar, RL., Balakrishna, T., Balaji, B., Amrutha, R., 2015.
Formulation and Evaluation of Controlled Release Floating Microballoons of
Stavudine. Scientia Pharmaceutica J, 83, pp. 671-682.
Vladyka, R. S., Erkoboni, D. F. & Sweriduk, C. A., 2005. microcrystalline  
cellulose cushioning granules. US, Patent No. US 6,858,725 B1.
Vo, AQ., Feng, X., Morott, JT., Pimparade, MB., Tiwari, RV., Zhang, F.,
Repka, MA., 2016. A novel floating controlled release drug delivery system  
prepared by hot-melt extrusion. Euro J Pharm & Biopharm, 98, pp. 108-121.
Vo, AQ., Feng, X., Pimparade, M., Ye, X., Kim, DW., Martin, ST., Repka,
MA., 2017. Dual-mechanism gastroretentive drug delivery system loaded
with an amorphous solid dispersion prepared by hot-melt extrusion. Euro J  
Pharm Sci, 102, pp. 71–84.
Wang, J., Kan, S., Chen, T. & Liu, J., 2015. Application of quality by design
(QbD) to formulation and processing of naproxen pellets by extrusion– $
spheronization. J Pharm Dev & Tech, 20(2), pp. 246-256.
Waterman, K., 2007. A critical review of gastric retentive controlled drug
delivery. J Pharm Dev Technol., 12(1), pp. 1-10.
Weiss, M., Kriangkrai, W. & Sungthongjeen, S., 2014. An empirical model for  
dissolution profile and its application to floating. Euro J Pharm Sci, 56, pp.  
87-91.
Weston, JS., Jentoft, RE., Grady, BP., Resasco, DE., Harwell, JH., 2015.  
Silica nanoparticle wettability: Characterization and effects on the emulsion





            
     
      
 
              
      
  
         
        
      
               
        
       
           
        
        
        
    
           
       
     
   
                 
        
          
             
     
      
           
            
   
           
      
 
Wu, C. & Benet, L., 2005. Predicting drug disposition via application of BCS:
transport/absorption/elimination interplay and development of a
biopharmaceutics drug disposition classification system. Pharm Res., 22(1),
pp. 11-23.
Xu, M., Liew, C. V. & Heng, P. W., 2015. Evaluation of the coat quality of
sustained release pellets by individual pellet dissolution methodology. Inter J  
Pharm, 478, pp. 318-327.
Yang, L., Eshraghi, J. & Fassihi, R., 1990. A new intragastric delivery system
for the treatment of Helicobacter pylori associated gastric ulcer: in vitro
evaluation. J Cont Rel, 57(3), pp. 215-222.
York, P., 2013. Design of Dosage Forms. In: M. E. Aulton & K. M. G. Taylor,
eds. Aulton's Pharmaceutics, The Design and Manufacture of Medicines. 4th  
ed. London: Churchill Livingstone Elsevier, pp. 10-11.
Yu, S., Huang, Z., Gabbott, I., El-Saleh, F., Muehlenfeld, C., Warnke, G.,
Stoyanov, E., de-Matas, M., Salman, AD., 2016. Short Paper: Experimental
study of binder selection using twin screw and batch high-shear wet
granulation. Glasgow, The 10th World Meeting on Pharmaceutics,
Biopharmaceutics, and Pharmaceutical Technology.
Zeeshan, F. & Bukhari, N., 2010. Development and evaluation of a novel
modified-release pellet-based tablet system for the delivery of loratidine and
pseudoephedrine hydrochloride as model drugs. AAPS PharmSciTech,
11(2), pp. 910-916.
Zhang, C., Xu, M., Tao, X., Tang, J., Liu, Z., Zhang, Y., Lin, X., He, H., Tang,
X., 2012. A floating multiparticulate system for ofloxacin based on a
multilayer structure: In vitro and in vivo evaluation. 430, pp. 141-150.
Zhang, J., Wu, C.-Y., Pan, X. & Wu, C., 2017. On Identification of Critical
Material Attributes for Compression Behaviour of Pharmaceutical Diluent
Powders.. J of Materials , 10(7), pp. 1-16.
Zhang, L., Jiang, P. & Liu, J., 2014. Novel sustained-release of propafenone
through pellets: preparation and in vitro/ in vivo evaluation. Int J Mol Sci.,
15(9), p. 15503–15511.
Zhang, L. & Mao, S., 2017. Review: Application of quality by design in the
current drug development. Asian J pharm sci, 12, pp. 1-8.
263
